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 Childhood epileptic encephalopathies (EE) are severe neurodevelopmental diseases that 
manifest in early development. EE is characterized by abnormal electroencephalographic (EEG) 
activity, intractable seizures comprising of various seizure types, as well as cognitive, behavioral 
and neurological defects. Developmental and epileptic encephalopathies (DEEs) are a subclass of 
EEs where the progressive and permanent cognitive and neurophysiological deterioration is not 
caused by seizure activity alone, but is caused by the same underlying etiology. Recent advances 
in whole exome sequencing revealed an important role for synaptic dysregulation in DEE and 
identified multiple new causative variants in synaptic genes. Indeed, mutations in various genes 
associated with neuronal functions like synaptic transmission and recycling, including 
transporters, neurotransmitter receptors, and ion channels, have all been identified as causative of 
DEE. In total, pathogenic DEE-causing variants in over eighty-five genes have been identified and 
more are likely to follow as next-generation sequencing becomes widely available.    
 DEEs comprise a large group of genetically and phenotypically heterogenous diseases that 
have been difficult to treat. While in many cases the etiology is unknown, de novo heterozygous 
missense mutations have often been identified as the underlying cause of DEE. Existing 
pharmacological interventions by way of antiepileptic drugs leave approximately seventy-percent 
of DEE patients with intractable seizures. Moreover, these pharmacological treatments do not 
address the cognitive impairments and associated comorbidities caused by the underlying 
 
 
pathophysiological mechanism. In fact, treatment with antiepileptic drugs may actually worsen 
cognitive comorbidities due to side effects. Additionally, there are no pharmacological treatments 
for these cognitive comorbidities other than mood stabilizers and antipsychotics. Therefore, 
alternative approaches to treatments that address the underlying genetic etiology are necessary. 
Indeed, the recent utilization of gene therapeutic approaches in other genetic disease models such 
as spinal muscular atrophy (SMA) has spurred the investigation of gene therapies to treat DEEs.  
 Here, we executed a molecular, behavioral and functional characterization of three 
preclinical mouse models of DEE involved in synaptic function (Dnm1) and ion channel function 
(Kcnq3). The human orthologs of the Dnm1 and Kcnq3 genes cause some of the most severe DEE 
syndromes. Understanding the pathophysiological mechanisms by which mutations in these genes 
cause disease, is important in identifying and assessing future gene therapeutic interventions.  
 Patients with heterozygous DNM1 pathogenic mutations present with early onset seizures, 
severe intellectual disability, developmental delay, lack of speech and ambulation, and hypotonia. 
For the DNM1 dominant-negative model of DEE, we first characterized the Dnm1Ftfl mouse which 
phenocopies the key disease-defining phenotypes and comorbidities observed in DNM1 patients. 
Further, we modelled a gene therapy approach in Dnm1Ftfl mice using an RNA interference-based, 
virally delivered treatment construct. Dnm1Ftfl homozygous mice showed early onset lethality, 
seizures, growth deficits, hypotonia, and severe ataxia. Molecular analysis of Dnm1Ftfl 
homozygous mice showed gliosis, cellular degeneration, increased neuronal activation and 
aberrant metabolic activity, all indicative of recurrent seizure activity. Importantly, our gene 
therapy treatment significantly rescued all the severe phenotypes associated with DEE, including 
seizures, early-onset lethality, growth deficits, and aberrant neuronal phenotypes. Thus, our gene 
 
 
therapy approach provided a proof-of-principle for the efficacy of gene silencing to treat DEEs 
caused by dominant-negative mutations.  
Second, a DNM1 human variant modelled in mice was generated and characterized. The 
Dnm1G359A mutation, unlike the Dnm1Ftfl mouse-specific mutation has been identified in patients 
suffering from DNM1 DEE. Thus, this model allows for a more clinically relevant assessment of 
the impact of a human DNM1 mutation in mice. In the long run, this model will help validate gene 
therapeutic approaches that may be clinically relevant to DNM1 DEE patients. The Dnm1G359A 
mutation, like the Dnm1Ftfl mutation, led to early onset seizures, growth deficits, and lethality, 
establishing the Dnm1G359A mouse model as a viable model to study DNM1 DEE.  
In the gain-of-function KCNQ3 model of DEE, Kcnq3R231H mice were characterized 
molecularly and behaviorally. Patients with KCNQ3 mutations show electrical status epilepticus 
during sleep (ESES), as well as cognitive and behavioral impairments. The Kcnq3R231H variant led 
to severe spike-wave discharge phenotype on EEG, decreased maximal seizure threshold, and 
anxiety-like behavior. Additionally, Kcnq3R231H led to increased localization of Kcnq3 protein at 
neuronal membranes, suggesting a role for membrane aggregation on disease phenotypes.  
 Altogether, these findings show the viability of preclinical models of both dominant-
negative and gain-of-function mutations in replicating key disease-defining phenotypes associated 
with severe DEEs. Additionally, the results presented here establish a proof-of-principle 
demonstration that gene silencing can rescue severe phenotypes caused by dominant-negative 
mutations in DEE. Future studies on both dominant-negative and gain-of-function models should 
enable an in-depth understanding of mechanistic implications for each mutation, and lead to gene 
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Chapter 1: An Overview of Developmental and Epileptic 
Encephalopathy (DEE) and Potential Therapies 
1.1 Introduction  
 Epileptic encephalopathies (EEs) are a heterogenous group of severe epilepsies 
characterized by early-onset intractable seizures, abundant epileptiform activity on 
electroencephalography (EEG), developmental delay or regression, intellectual disability and early 
death (EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-RES@ua.ac.be et 
al. 2017; Epi4K Consortium and Epilepsy Phenome/Genome Project 2013; McTague et al. 2016a). 
Recent changes to the definition of EE has sought to delineate the contributions of seizure activity 
and underlying pathology on the cognitive and behavioral impairments observed in patients. 
Epileptic encephalopathies (EEs) are conditions whereby frequent seizure activity contributes to 
severe cognitive and developmental deficits and regression beyond those attributable to the 
underlying pathology (Scheffer et al. 2017; Scheffer and Liao 2020; Raga et al. 2021). In contrast, 
developmental and epileptic encephalopathies (DEE) consists of conditions where the underlying 
genetic cause also contributes to  the severe cognitive and developmental impairments (Scheffer 
et al. 2017; Scheffer and Liao 2020; Raga et al. 2021). This redefinition enables the proper 
acknowledgement of EE-causing genes that also negatively impact neurodevelopment through 
different mechanisms (Scheffer and Liao 2020), and influence the treatment approaches and 
expected outcomes for each group. In the case of EE, targeted and aggressive treatment and control 
of seizures with antiepileptic drugs might be sufficient to limit further cognitive impairment and 
even lead to developmental gains (McTague et al. 2016a; Scheffer and Liao 2020). However, for 
DEE, it is not sufficient to stop seizures alone; rather, the developmental impact and accompanying 
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comorbidities of the causative gene mutation must also be addressed; these patients might benefit 
from a precision medicine approach that addresses the underlying pathology (Scheffer and Liao 
2020; Raga et al. 2021; McTague et al. 2016a).  Moving forward, the terms EE and DEE will be 
used when appropriate in discussing these severe epilepsies, specifically in relation to the work 
herein.  
 Although previously considered to be caused by environmental or acquired insults, DEEs 
are now primarily attributed to genetic causes (Happ and Carvill 2020). The first genetic link to 
DEE was established in 2001 in a cohort of children with Dravet syndrome who were shown 
through sequencing to carry de novo mutations in the gene SCN1A (McTague et al. 2016b; Claes 
et al. 2001). The advancements of molecular techniques such as chromosomal microarray, next-
generation sequencing (whole exome and whole genome sequencing), and gene panels have led to 
numerous discoveries of mutations implicated in DEE, including both copy number variants and 
monogenic mutations (Takai et al. 2020). Indeed, between thirty and fifty-four percent of DEEs 
can now be attributed to pathogenic mutations, the majority of which are de novo variants (Epi4K 
Consortium and Epilepsy Phenome/Genome Project 2013; Happ and Carvill 2020; Howell et al. 
2018). Despite this burst in gene identification for DEEs, between fifty and sixty-five percent of 
patients remain without a molecular diagnosis (Happ and Carvill 2020; Steward et al. 2019). This 
lack of diagnosis is likely the result of a combination of factors: i) the presence of DEE-causing 
variants in non-exonic, and unannotated regions of the genome might fail to be detected through 
whole exome sequencing alone (Happ and Carvill 2020); ii) the inaccessibility of brain tissue to 
identify mosaic pathogenic variants which are difficult to detect in blood and cheek samples (Happ 
and Carvill 2020); iii) the role played by epigenetic mechanisms in DEE, including methylation, 
histone modifications, chromatin remodeling, and non-coding RNAs – all of which require 
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different molecular assays that are not as widely used as whole exome sequencing; iv) the presence 
of oligogenic inheritance in which variants exert an effect in a particular genetic background but 
not in another (Happ and Carvill 2020).  
 DEEs are both genetically and phenotypically heterogenous, with an incidence between 
0.27 to 0.54 per 1000 per year, depending on the study (Howell et al. 2018; Ware et al. 2019; Eltze 
et al. 2013). So far, approximately eighty-five EE/DEE-causing genes have been identified that 
impair different components of neuronal function, and more are likely to follow given the 
advancements in, and affordability of, next-generation sequencing (Takai et al. 2020). The 
pathophysiological processes underlying genetic EE/DEE include changes in the structure and 
function of ion channels (channelopathies; SCN1A, KCNQ2,  KCNQ3), synaptic dysfunction 
(DNM1, STXBP1, IQSEC2), neurotransmitter receptor dysfunction (GRIN2A, GRIN2D, 
GABRA1), Transporter defects (SLC12A5, SLC1A2), transcription and translation/post-
translational dysregulation (ARX, MEF2C, FOXG1, CELF4), dysfunction in signal transduction 
(CDKL5, ARFGEF9, SZT2), and epigenetic dysregulation (ACTL6B) (McTague et al. 2016b; 
Takai et al. 2020). DEEs manifest as various age-dependent epilepsy seizure types and syndromes, 
two of which are West syndrome (infantile spasms) and Lennox-Gastaut syndrome, which 
represent classic EE/DEE cases caused by many genes involved in various cellular functions. 
These syndromes are classified based on electroclinical phenotypes that include psychomotor 
impairments, developmental and cognitive impairments, electroencephalographic abnormalities, 
as well as several debilitating seizure types, many of which are refractory to conventional and 
existing anti-epileptic drugs (Takai et al. 2020). Currently, no treatment exists that addresses both 
the seizures and neurodevelopmental impairments for these devastating group of epilepsies. 
Existing treatments that address the seizures alone still leave the majority of DEE patients (about 
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seventy-one percent) with intractable seizures (McTague et al. 2016b; Berg, Levy, and Testa 
2018), highlighting the need for alternative treatments that aim to remedy the underlying pathology 
and key disease-defining phenotypes. Mouse models, some of which recapitulate the key DEE 
phenotypes, have been established to properly characterize and model precision therapies for some 
of the DEE-causing variants (Wang and Frankel 2021).  
 In this chapter, we will: a) further discuss a classic EE seizure type and syndromes as they 
pertain to this dissertation on two genetic mouse models of DEE; b) explore the different 
pathogenic mechanisms of DEE-causing variants; c) hone in on two DEE models (DNM1 and 
KCNQ3) present in the lab; and d) discuss recent pre-clinical therapies for DEE. 
 In the following chapters, we will address the need for alternative treatment approaches for 
this group of devastating epilepsies and provide a proof-of-principle RNAi-based gene therapy for 
DNM1 DEE, a novel approach for DEE treatment in a mouse-specific Dnm1 variant. Finally, we 
will characterize human variants of DNM1 DEE and KCNQ3 DEE modelled in mice.  
Future studies beyond the scope of this dissertation should aim to gain more mechanistic 
insight into the pathogenic variants and identify reproducible phenotypes with which to access 
gene-therapeutic rescue.    
 
1.2 Classical EE/DEE Seizure-type and Syndromes 
West Syndrome (Infantile Spasms) 
 Infantile Spasms (IS) are a seizure type that occurs in early life. They are characterized by 
brief spasms that typically occur in clusters. These spasms involve abrupt contractions followed 
by a less intense but sustained tonic phase (lasting for a couple of seconds) that engages the 
muscles of the neck, trunk, upper and lower limbs (Berg, Levy, and Testa 2018; Cowan and 
 5 
Hudson 1991; Parisi et al. 2011). IS generally consist of flexor, extensor, or mixed types that could 
be symmetric or asymmetric, focal, multifocal or generalized (Wilmshurst, Ibekwe, and 
O’Callaghan 2017). West Syndrome (WS) is an epilepsy syndrome characterized by IS, an 
interictal (between seizures) EEG pattern of hypsarrhythmia, as well as psychomotor retardation 
or regression (Cowan and Hudson 1991). Hypsarrhythmia consists of chaotic high amplitude slow 
waves and multi-focal spikes. (Wilmshurst, Ibekwe, and O’Callaghan 2017; Parisi et al. 2011).  
 IS are relatively rare with an estimated incidence between 0.25 to 0.40 per 1000 births, and 
occur predominantly between two and twelve months of age, with peak onset around six or seven 
months (Osborne et al. 2019; Cowan and Hudson 1991; Gürsoy and Erçal 2016). Genetic analysis 
of unexplained cases of IS has led to the identification of causative mutations in genes such as 
ARX, CDKL5, MAGI2, STXBP1, SCN1A, SCN2A, GABRB3, DNM1 and others (McTague et al. 
2016b; Gürsoy and Erçal 2016). In twenty-three to fifty-four percent of cases, IS has been shown 
to evolve to Lennox-Gastaut Syndrome (LGS), both in the clinical manifestations of seizures and 
the characteristic EEG pattern; and conversely, twenty to thirty-six percent of patients with LGS 
had a prior history of IS, highlighting a shared etiology between these two syndromes which also 
have overlapping genetic variants and are considered age-dependent EE syndromes (McTague et 
al. 2016b; Rantala and Putkonen 1999). Long-term outcomes for patients with IS include: fatality 
in twenty-two to thirty percent of cases (a third of which occurred before the age of three), 
progression to other seizure types in fifty percent of cases, and intellectual disability (ID) recorded 
in approximately seventy to ninety percent of cases (Wilmshurst, Ibekwe, and O’Callaghan 2017; 
Gürsoy and Erçal 2016). IS, like other EE syndromes, are refractory to conventional anti-epileptic 
drugs (Gürsoy and Erçal 2016).  
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 To date, the most effective treatments for IS has been adrenocorticotrophic hormone, 
corticosteroids, and vigabatrin (Wilmshurst, Ibekwe, and O’Callaghan 2017; Mohamed et al. 
2011). Regardless, the outlook is poor, with refractory spasms in about a quarter of treated patients, 
and a majority of patients having seizures with motor and cognitive deficits (Mohamed et al. 2011). 
With the onset of IS, developmental delays often become more evident, making early detection 
and treatment imperative to prevent developmental regression. However, in most cases, early 
intervention and control of spasms does not prevent further developmental impairments because 
the underlying etiology has not been addressed (Raga et al. 2021).  
 
Lennox-Gastaut Syndrome 
 Lennox-Gastaut Syndrome (LGS) is a term used to describe EEs that are always associated 
with developmental delay and intellectual disability, and which are generally diagnosed between 
the ages of two to five years (Raga et al. 2021). Electroencephalographic (EEG) features that are 
most conserved in  LGS patients are, slow background, generalized paroxysmal fast activity and, 
slow spike and wave. Additionally, LGS manifests with multiple intractable seizure types, 
including tonic, myoclonic, atypical absence, atonic, and tonic-clonic seizures (Raga et al. 2021; 
Cowan and Hudson 1991). The incidence of LGS is approximately 0.24 per 1000 live births, or 2 
per 100,000 children between zero and fourteen years of age (Rantala and Putkonen 1999).  
 Treatment for LGS remains a challenge, as seizures are typically resistant to conventional 
antiepileptic drugs, surgery and ketogenic diet (Berg, Levy, and Testa 2018; Douglass and 
Salpekar 2014). In a small subset of cases, corpus callosotomy, vagus nerve stimulation and 
resective surgeries in patients with drug-resistant focal seizures have all proved successful in 
reducing the seizure burden. However, none of these interventions succeeded in completely 
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eliminating seizures (Douglass and Salpekar 2014). Approximately twenty-five percent of LGS 
cases do not have an apparent etiology but are hypothesized to be caused by genetic factors. Indeed, 
advancements in molecular techniques like next-generation sequencing have identified mutations 
in genes such as ALG13, GABRB3, SCN1A, STXBP1, SCN1A, and DNM1, as causative of LGS 
(McTague et al. 2016b; Camfield 2011).  Like genetic IS, and many other DEE syndromes, 
conventional approaches are limiting in their treatment of the seizures and developmental delays. 
Thus, precision gene therapies will be necessary to address both the seizures, developmental 
impairments as well as other associated comorbidities.   
 
1.3 Pathogenic Mechanisms of DEE Causing Variants  
 Most DEE-associated mutations are caused by dominant de novo variants in critical 
neuronal genes (McTague et al. 2016b; Jiang et al. 2019). A de novo variant is considered to be 
DEE-causing when the following criteria are met: a) the variant is rare and has never been reported 
in controls; b) the variant affects highly conserved residues with predicted pathological impact on 
protein structure, function or conformation; and c) when the variant involves a gene whose 
expression is tightly regulated (Jiang et al. 2019). In fact,  pathogenic molecular mechanisms have 
been identified in approximately thirty-five to forty percent of  DEE patients (Jiang et al. 2019). 
These dominant de novo pathogenic variants typically exert either a loss-of-function (LOF)/haplo-
insufficient effect (HI), a gain-of-function (GOF), or a dominant-negative (DN) effect on proper 
gene function.   
 A dominant HI mechanism is observed when a heterozygous mutation in a gene causes 
LOF in the affected allele, leaving only one viable copy. This approximately fifty percent reduction 
in cellular function of the affected gene (haplo-insufficiency) leads to a disruption of normal 
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cellular processes and culminates in disease. Many DEE channelopathies have an underlying 
LOF/HI mechanism. A prime example is SCN1A, which codes for the voltage-gated sodium 
channel alpha subunit 1 (Nav1.1) and is responsible for the flow of sodium ions into the cell and 
the maintenance of electrical balance (Hijikata et al. 2017; Hsiao et al. 2016).  SCN1A LOF/HI 
accounts for the majority of Dravet syndrome cases. In SCN1A LOF/HI, no mutant protein is 
produced and the characteristic Nav1.1 mediated sodium current is not significantly altered in the 
wildtype allele. However, the current amplitude, evoked action potentials, as well as protein and 
mRNA levels are all significantly diminished (Hsiao et al. 2016; Parihar and Ganesh 2013). This 
indicates that, while the existing wildtype copy is functioning normally, it is unable to satisfy the 
electrical demands of the cell on its own and thus results in a diseased state. 
 A GOF mechanism results in the acquisition of a new function by the affected gene product 
which may or may not be associated with a DN effect (Ségalat 2007). Studies suggest that GOF 
mechanisms arise from mutations that compromise the regulatory function accomplished through 
inter-domain interactions within a single protein molecule (Hijikata et al. 2017). An example is 
the KCNQ3R230H GOF DEE which will be the subject of later discussion. Briefly, KCNQ3 encodes 
the voltage-gated potassium channel Kv7.3 which plays an important role in regulating neuronal 
excitability. Specifically, the R230H mutation resides in the voltage sensing domain (VSD) of 
KCNQ3, a domain crucial for stabilizing the resting state of the channel through intricate network 
electrostatic interactions with negatively charged amino acid residues on neighboring domains. 
The R230H mutation destabilizes the resting VSD configuration, thereby causing constitutive 
channel activation – as in most GOF DEE channelopathies (Nappi et al. 2020). In this way, R230H 
causes the channel to “gain” a continuously open conformation.  
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 Finally, DN mechanisms have also been observed in DEEs. DN mutations are those that 
lead to mutant polypeptides that disrupt the activity of the wildtype copy when expressed (Veitia 
2007). In these cases: a) the phenotype of the heterozygous mutant is worse than that of the 
heterozygous null; and b) overexpression of the mutant leads to a stronger phenotype in the 
heterozygote (Veitia 2007).  A study of the functional mechanisms of pathogenic missense 
mutations on three-dimensional macromolecular complex structures identified a significant 
enrichment of protein homooligomerization in genes associated with DN phenotypes compared to 
those with HI and GOF phenotypes. This observation suggests that mutations in homooligomeric 
proteins are highly associated with DN effects (Hijikata et al. 2017). In fact, it was previously 
established that the simplest examples of  DN mutations come from factors that oligomerize, 
wherein the mutant polypeptide “poisons” the complex (Veitia 2007). A key example of DN DEE 
is observed in DNM1 DEE, a focus of further discussing in the following chapters. Briefly, DNM1 
encodes a neuron-specific GTPase involved in synaptic transmission and works by providing the 
mechanical force needed to pinch budding vesicles off the membrane for recycling (Boumil et al. 
2010; von Spiczak et al. 2017). To accomplish this, it forms homooligomeric structures. In silico 
and in vitro analysis of DNM1 variants revealed DN effects caused by an inability of oligomeric 
structures to perform the mechanical action needed for fission (von Spiczak et al. 2017; Dhindsa 
et al. 2015; Marks et al. 2001). Congruent with in silico and in vitro studies, mouse studies showed 
that the presence of a missense Dnm1 mutation in heterozygous mice led to seizures, whereas, 
heterozygous null mice had no overt phenotypes, as expected from an underlying DN mechanism 
(S. K. Asinof et al. 2015). 
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 The different pathogenic mechanisms associated with DEE causing mutations require 
slightly different gene therapeutic approaches. These existing gene therapy approaches will be the 
topic of further discussion in this chapter.  
 
1.4 Conventional Treatments for EE/DEEs  
 Currently, the standard treatment for DEEs consists of steroids, antiepileptic drugs and 
Ketogenic diet. However, these approaches fail to alleviate seizures or developmental impairments 
in most patients suffering from DEE. The most common drugs used to treat DNM1 and KCNQ3 
DEE patients fall into these broad categories: a) sodium channel blockers; b) calcium channel 
blockers; c) GABA receptor agonists; and d) synaptic vesicle protein 2A ligands. Additionally, 
many AEDs have multiple mechanisms of action and can have effects on multiple channel types 
or receptors and thus fall into multiple categories.  
A) Sodium Channel blockers: voltage-gated sodium channels are responsible for the 
depolarization of the neuron and the conduction of action potentials. Drugs like 
lamotrigine, topiramate, oxocarbazepine, zonisamide, rufinamide, lacosamide, and 
eslicarbazepine exert some of their effects through sodium channel blockade. These AEDs 
have the highest affinity for the voltage-gated sodium channel when it is in its inactive state 
and slow down the conformational recycling process that enables the channel to regain its 
resting conformation (Sills 2015). Thus, these drugs reduce channel conductance and limit 
repetitive neuronal firing with little effect on the generation of single action potentials (Sills 
2015). Topiramate, lamotrigine and lacosamide have been implemented to treat patients 
with DNM1 and KCNQ3 DEEs with limited success (Sands et al. 2019; von Spiczak et al. 
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2017). The data available suggests that only one DNM1 DEE patient was able to achieve 
seizure freedom while on lamotrigine (von Spiczak et al. 2017).  
B) Calcium channel blockers: Voltage-gated calcium channels are contributors to neuronal 
excitability and are responsible for the presynaptic release of neurotransmitters at nerve 
terminals. Ethosuximide, zonisamide, lamotrigine, gabapentine, pregabalin, levetiracetam, 
phenobarbital, felbamate and topiramate all block various subtypes of voltage-gated 
calcium channels to varying degrees. Ethosuximide for example, through its inhibition of 
T-type calcium channels, is particularly effective against absence seizures. It was one of 
the AEDs administered to a patient with KCNQ3 GOF DEE to treat ESES (Sands et al. 
2019; Sills 2015).  
C) GABA receptor agonists: GABA is the predominant inhibitory neurotransmitter in the 
mammalian CNS and is released from approximately forty-percent of all synapses in the 
brain. Activation of GABA inhibition by enhancing the GABA receptors response to 
GABA is a major mechanism of AEDs (Sills 2015). AEDs such as phenobarbital, 
diazepam, clobazam, and clonazepam bind to GABA receptors to increase inhibition. 
Meanwhile, vigabatrin and tiagabine alter GABA turnover by preventing catabolism and 
removal of GABA from the synaptic cleft respectively. These actions lead to increased 
GABA concentrations and thus, increased inhibition (Sills 2015). Clobazam and 
Clonazepam have both been used to treat DNM1 patients and have been unsuccessful. It is 
not surprising that these approaches fail given that DN mutations in DNM1 presumably 
cause a depletion of synaptic vesicles needed to package GABA for release (Weston 2016).   
D) Synaptic vesicle protein 2A (SV2A) ligand: Levetiracetam, an AED with broad functions, 
is the only AED that binds synaptic vesicle protein 2A. While the physiological role of 
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SV2A remains to be fully elucidated, strong evidence suggests that binding of 
levetiracetam to SV2A has effective anticonvulsant effects (Sills 2015). Levetiracetam is 
used as an adjunctive therapy for generalized tonic-clonic seizures and myoclonic seizures 
(Sankaraneni and Lachhwani 2015). One DNM1 patient on a combination of levetiracetam 
and lamotrigine was able to achieve seizure freedom.  
These medications may be largely unsuccessful because they do not address the underlying disease 
mechanism and cannot reverse the synaptic reorganization that may underlie both the seizures and 
developmental comorbidities in DEEs. Thus, there is an urgent need for the discovery of more 
targeted therapeutic interventions.  
 
1.5 DNM1 DEE  
 Efficient synaptic vesicle endocytosis and recycling is an important part of synaptic 
transmission, where GTPase Dynamin 1 (DNM1) plays a major role (Ferguson et al. 2007; Park 
et al. 2013). Dynamin 1 is a member of the Dynamin family of GTPases (DNM1, DNM2, and 
DNM3), which share approximately eighty percent overall homology and play partially redundant 
roles physiologically (Park et al. 2013; Hayashi et al. 2008). However, these Dynamins have 
different expression patterns. DNM1 is expressed exclusively in the central nervous system (CNS), 
specifically at presynaptic neuronal nerve terminals where it executes synaptic vesicle endocytosis. 
DNM2 is expressed ubiquitously and is essential for receptor-mediated endocytosis. DNM3 is 
expressed in the testis as well as the dendritic spines of neurons, but at much lower levels than 
DNM1,  suggesting a role in receptor internalization at the postsynapse (Park et al. 2013; Smillie 
and Cousin 2005).  Dynamins have 5 characteristic domains: the GTPase domain is essential for 
synaptic vesicle fission (endocytosis) through mechanochemical force generated by GTP 
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hydrolysis; the middle domain and GTPase effector domain (GED) are involved in self-assembly 
and oligomerization, both of which are necessary for GTPase activity and thus endocytosis; the 
pleckstrin homology domain (PHD) is necessary for membrane binding at clathrin coated pits; and 
the C-terminal proline and arginine rich domain (PRD), which binds Src homology 3 (SH3) 
domains of accessory proteins needed to recruit Dynamins to endocytic sites (Marks et al. 2001; 
Smillie and Cousin 2005; Chappie et al. 2011).  
 The most studied Dynamin thus far is DNM1, which was first identified to cause 
temperature sensitive paralysis in drosophila (shibire mutant) (Marks et al. 2001). The subsequent 
electron micrographic studies of shibire mutants showed large infoldings of membrane with 
electron dense collars (later identified as DNM1) originating from the plasma membrane, and thus 
have implicated DNM1 in the scission of endocytic vesicles (Marks et al. 2001; Smillie and Cousin 
2005). DNM1 can be found both in the cytosol upon phosphorylation (inactive state) by calcium 
dependent kinase 5 (Cdk5) and the depolarized membrane of nerve terminals upon Ca2+ dependent 
dephosphorylation (active state) by Calcineurin (a phosphatase) (Smillie and Cousin 2005).  Both 
Calcineurin and Cdk5 bind to the C-terminal PRD of Dynamin 1 (Smillie and Cousin 2005). 
Dynamin 1 forms tetramers made of two dimers in which the GTPase domain of one molecule 
interacts in trans with the GED of another molecule (Chappie et al. 2011). These tetramers 
oligomerize into ring structures or “collars” around deeply invaginated membranes (or necks of 
clatherin coated pits). Clathrin is a triskelion protein that coats components of the plasma 
membrane in order to carry out selective internalization of cell surface molecules and extracellular 
materials (Smillie and Cousin 2005). Upon oligomerization-dependent GTP hydrolysis, DNM1 
constricts and causes membrane fission (Sever, Damke, and Schmid 2000). 
 14 
 While DNM1 plays a critical role in synaptic vesicle endocytosis, it has proved inessential 
for synaptic transmission, embryonic and early postnatal development (Ferguson et al. 2007; 
Hayashi et al. 2008). However, there is a selective requirement for DNM1 in activity-dependent 
synaptic vesicle recycling needed to sustain synaptic transmission (Ferguson et al. 2007). The 
absence of DNM1 in a knockout (KO) mouse model led to the formation of functional synapses, 
albeit with limited viability. Additionally, these mice appeared normal at birth but failed to thrive 
and died within the first two postnatal weeks. The nerve terminals of Dnm1 KO mice showed 
structural and functional defects. Specifically, spontaneous network activity led to increases in 
deeply invaginated clathrin-coated endocytic pits at nerve terminals, similar to those observed in 
Drosophila Shibire mutants, and silencing activity abolished the defect (Ferguson et al. 2007). 
 DNM1 expression begins during postnatal development, with studies showing steady 
increases concomitant with neurite formation and peaking as synapse formation occurs after the 
first postnatal week (Boumil et al. 2010; Ferguson et al. 2007; M. Li et al. 2010).  Thus, it is not 
surprising that Dnm1 KO mice are born normal, and seem to be able to form synapses initially, but 
are unable to sustain them, and eventually die during the second postnatal week. Finally, there 
appeared to be functional differences between the response of excitatory and inhibitory neurons in 
the absence of DNM1. In inhibitory neurons, the absence of DNM1 at nerve terminals led to a 
significant reduction in inhibitory post-synaptic current amplitude following a single presynaptic 
stimulus. However, no such reduction in excitatory post-synaptic current amplitude was observed 
at excitatory nerve terminals (Ferguson et al. 2007). This demonstrates a more critical dependence 
of inhibitory synapses on readily available synaptic vesicle pools created through clathrin mediated 
dynamin 1 action (Ferguson et al. 2007; Hayashi et al. 2008).  
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 The first documented mammalian DNM1 mutation (G767T) was identified in Labrador 
Retrievers over a decade ago, which caused exercise-induced collapse (Patterson et al. 2008). 
Around the same time, a spontaneous missense mutation (A408T) in mice led to the first direct 
link between DNM1 and severe neurological disease (Boumil et al. 2010). Homozygous “Fitful” 
mice showed tonic-clonic seizures starting the second postnatal week, ataxia, hypotonia, growth 
deficits and eventual lethality by the third postnatal week (Boumil et al. 2010). In 2014, the first 
human variants of DNM1 in the GTPase and middle domains, were identified in patients with 
“unsolved” DEE (EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-
RES@ua.ac.be et al. 2017). Patients with DNM1 mutations presented with infantile spasms (IS) 
that frequently evolved to Lennox-Gastaut syndrome (LGS), severe to profound ID, ataxia, 
hypotonia, lack of speech and ambulation, and in some cases, cerebral atrophy (EuroEPINOMICS-
RES Consortium. Electronic address: euroepinomics-RES@ua.ac.be et al. 2017; von Spiczak et 
al. 2017). These mutations, like the previously identified fitful mutation were shown to cause a 
dominant negative (DN) effect on DNM1 function based on structural modeling analysis (Boumil 
et al. 2010; von Spiczak et al. 2017). Thus far, thirty-four patients have been identified with 21 
different DNM1 mutations from thirty-three different families (H. Li et al. 2019; Kolnikova et al. 
2018) (Fig1/Table 1). Approximately ninety-six percent of patients showed abnormal EEG with 
about ninety percent showing epileptiform discharges that were mostly multifocal, and forty-five 
percent showing hypsarrhythmia. A small percentage of patients also presented with slow spike-
wave complex, and focal epileptiform discharges (H. Li et al. 2019).  
 As of yet, there are no effective treatments for DNM1 DEE and the majority of patients 
show treatment resistant seizures (Table 1) further highlighting the need for alternative therapeutic 
approaches that target the underlying genetic cause of the disease. A novel proof-of-principle gene 
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therapy approach for DNM1 DEE modelled in the fitful mouse (Dnm1Ftfl/Ftfl) will be presented in 
the upcoming chapter. The success of this therapy provides hope for the possible effective 
treatment of DNM1 DEE, and other DN or GOF DEEs, in the near future.  
 
1.6 KCNQ3 DEE 
 Potassium (K+) channels play important regulatory roles in neuronal electrical signaling. 
Mutations in genes that encode members of the voltage gated K+ channel family (KCNQ2, KCNQ3 
and KCNQ5) have been associated with neuronal channelopathies ranging from the early-onset 
inherited autosomal dominant disorder, benign familial neonatal seizures (BFNS), to severe DEEs 
caused by de novo variants (Nappi et al. 2020; Miceli et al. 2015; Schroeder et al. 1998). The 
voltage gated K+ channel family (Kv7) contain six transmembrane segments (S1-S6) as well as 
cytoplasmic N- and C- termini (Nappi et al. 2020; Sands et al. 2019). The transmembrane segment 
between S1 and S4 forms the voltage sensing domain (VSD), of which the S4 segment plays a 
crucial role in channel gating through a series of five positively charged arginines (R1, R2, R4, 
R5, R6) and an uncharged glutamine (Q3) (Nappi et al. 2020). The S5 and S6 segments and their 
interconnecting loop form the pore domain (PD) that coordinates K+ ions flow. The C-terminus 
contains both the subunit interaction domain needed for tetramerization, and the binding and 
transductional activity  domain needed for interactions with critical regulators (Nappi et al. 2020). 
Of the five members of the Kv7 family (Kv7.1, Kv7.2, Kv7.3, Kv7.4, Kv7.5), Kv7.2 (KCNQ2), Kv7.3 
(KCNQ3) and Kv7.5 (KCNQ5) are exclusively or preferentially expressed in neurons in both the 
central and peripheral nervous systems, with Kv7.5 also being expressed in non-neuronal tissues 
like skeletal and smooth muscle (Nappi et al. 2020). Of importance are the Kv7.2 and Kv7.3 channel 
subunits whose heterotetramers predominantly underlie the M-channels responsible for producing 
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the so-called M-current, although, these channels may also contain Kv7.5 (Nappi et al. 2020; 
Schroeder et al. 1998; Peters et al. 2005).  
 M-channels regulates the subthreshold electrical excitability of neurons through the 
hyperpolarizing M-current (Nappi et al. 2020; Watanabe et al. 2000). The M-channel contributes 
to the medium and slow components of the afterhyperpolarization current that proceeds the action 
potential and determines the refractory period. Additionally, the slow component of the M-current 
in the perisomatic region leads to spike-frequency adaptation, a phenomenon where the frequency 
of neuronal firing is reduced in response to sustained stimuli (Nappi et al. 2020; Tzingounis and 
Nicoll 2008). Suppression of the M-current causes depolarization of neurons, thereby increasing 
neuronal excitability. In contrast, activation of the M-current causes hyperpolarization, 
counteracting excitatory inputs, and decreases neuronal excitability (Nappi et al. 2020). In 
neuronal cells, KCNQ2 and KCNQ3 show overlapping expression patterns which are enriched in 
the hippocampus, all layers of the neocortex, cerebellum, thalamus, subiculum, amygdala and 
medulla (Nappi et al. 2020; Schroeder et al. 1998). However, KCNQ3 expression is higher in 
several nuclei including the thalamus and amygdala (Schroeder et al. 1998), indicating an 
alternative independent function for KCNQ3 outside of the KCNQ2/KCNQ3 M-channel complex. 
Indeed, KCNQ3/KCNQ5 heterotetramers have been postulated to contribute to the M-current as 
well (Schroeder et al. 2000). Subcellularly, KCNQ2/KCNQ3 channels localize specifically to the 
axon initial segment (AIS) and the nodes of Ranvier (Rasmussen et al. 2007). Their localization to 
the AIS is due to the C- terminus interaction with Ankyrin-G, an adaptor protein (Rasmussen et 
al. 2007; Pan et al. 2006). Additionally, loss of the Ankyrin-G domain, in KCNQ3 specifically, 
leads to reduction in the enrichment of KCNQ2/KCNQ3 at the AIS (Rasmussen et al. 2007), 
indicating an integral role for KCNQ3 in proper subcellular localization. The localization of 
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KCNQ2/KCNQ3 channels to the AIS, a region where neuronal inputs are summed and action 
potentials are initiated, enables the channels to significantly influence neuronal excitability by 
modulating neurotransmitter release through the  regulation of voltage-gated Ca2+ and Na+ channel 
availability (Nappi et al. 2020). 
 Current reductions of only twenty-five percent have been reported to cause electrical 
hyperexcitability, specifically in the context of BFNS caused by LOF mutations in KCNQ2 and 
KCNQ3 (Schroeder et al. 1998). Suppression of neuronal M-current through DN mutations in mice 
caused spontaneous seizures, behavioral hyperactivity, and morphological changes in the 
hippocampus. Additionally, the developmental time point of expression of M-current suppressing 
DN mutations determined the neurological severity, with mice expressing DN mutations after the 
critical period only showing signs of increased neuronal excitability, and deficits in hippocampal 
dependent spatial memory (Peters et al. 2005). Thus, M-channel activity plays a crucial role in 
proper hippocampal development during the first postnatal weeks (Peters et al. 2005).  
Advances in next-generation sequencing have led to the identification of LOF hereditary 
autosomal dominant mutations in KCNQ2 and KCNQ3 that are associated with BFNS, as well as 
de novo LOF and GOF variants. Of interest are mutations in KCNQ3, which cause a spectrum of  
neurodevelopmental impairments but at a lower incidence compared to KCNQ2 (Nappi et al. 
2020). This decreased incidence could be due to the described ability of KCNQ3 to “tolerate” 
mutations better than KCNQ2, which could be influenced by the temporal differences in 
expression, with KCNQ2 expression beginning at earlier developmental stages compared to 
KCNQ3. Recently identified GOF missense mutations in KCNQ3 cause global developmental 
delay (DD), autism spectrum disorder (ASD), and electrical status epilepticus during sleep (ESES), 
in additional to other comorbidities. ESES is an electroencephalogram (EEG) pattern where 
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interictal focal or multifocal spike-waves occupy at least eighty-five percent of the EEG tracing 
during non-rapid eye movement (NREM) sleep (Gong et al. 2021). Like many other DEEs, 
conventional antiepileptic drugs are not sufficient to properly address the seizures and cognitive 
impairments. Thus, proper modeling of these genetic variants in mice are necessary, with the aim 
of identifying therapeutic strategies to address the seizures and comorbidities. Characterization of 
a preclinical model will be the focus of discussion in an upcoming chapter.  
 
1.7 Limitations of Genetic DEE Mouse Models  
 Laboratory mice (Mus musculus) have long served as model organisms to study human 
physiology and disease because of their phylogenic relatedness and physiological similarity to 
humans. Indeed, mice share a striking genetic homology with humans and are relatively easy to 
maintain and breed, with many inbred strains to choose from, making them the most widely used 
animal model in biomedical research (Perlman 2016; Murillo-Cuesta et al. 2020). Specifically, in 
the context of rare diseases like DEE, mouse models provide much needed information on disease 
mechanisms and therapeutic strategies that cannot be obtained through alternative methods alone 
(Murillo-Cuesta et al. 2020). In fact, animal models reproduce many aspects of the human 
biological and pathological processes, providing key information on disease pathophysiology 
(Murillo-Cuesta et al. 2020). In DEE caused by missense mutations, eighty-eight percent of mouse 
models generated to model the human condition were reported with obvious spontaneous seizures, 
and most had other neurological abnormalities including locomotor, social, cognitive and growth 
deficits (Wang and Frankel 2021).  
 However, some rodent models of disease do not always show a direct correspondence in 
phenotype, and mouse models of monogenic DEEs are no exception (McGraw, Ward, and Samaco 
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2017; Wang and Frankel 2021). An example is the ARFGEF1 mouse model. ARFGEF1 encodes 
the guanine-nucleotide exchange protein-1 involved in intracellular vesicle formation and 
trafficking. A de novo loss-of-function mutation in ARFGEF1 led to haploinsufficiency of the gene 
product in a recently identified patient with Lennox-Gastaut Syndrome (Teoh et al. 2020).  
However, mice harboring the same mutation did not show spontaneous seizures, but had decreased 
threshold to induced seizures, and showed modest developmental delays (Teoh et al. 2020). In 
fact, since some EE/DEE mouse models do not show spontaneous seizures, seizure susceptibility 
and the presence of spike-wave discharges on electroencephalograph (EEG) are often taken as 
indicators of seizure activity (Wang and Frankel 2021).  
 Various factors contribute to the inability of mouse models to fully recapitulate human 
disease phenotypes. One such factor is the eighty-five million years evolutionary divergence 
between mice and humans, which has led to adaptation to different environments and possible 
modifications to gene functions (Perlman 2016). Indeed, gene-by-environment interactions are 
common in disease and may offer some explanation of why direct correlations are not always 
observed even in rodent models of less complex, or monogenic disorders (McGraw, Ward, and 
Samaco 2017). The protracted developmental window in humans, compared to mice, may be 
another factor that contributes to the inability of mouse models to fully replicate the severe 
phenotypes observed in patients. The much quicker development of mice limits their pathogenic 
variant exposure time to a matter of days rather than years, which may lead to milder phenotypes 
in mice.  Regardless of their inherent limitations in modeling human disease, mouse models have 
greatly contributed to the wealth of knowledge on the genetic bases and molecular mechanisms of 
DEE, and other rare diseases. Importantly, these mouse models have accelerated the development 
of new therapeutic options for rare diseases like DEE.   
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1.8 Pre-Clinical Genetic Therapies for DEE in Mouse Models 
1.8.1 Introduction to gene therapy 
 Gene therapy is a therapeutic strategy that involves the introduction of nucleic acids into 
cells to correct mutated genes or execute site-specific modifications in order to treat diseases that 
are not curable with conventional drugs (Gonçalves and Paiva 2017; Kay, Liu, and Hoogerbrugge 
1997; Shahryari et al. 2019). Typically, DNA, mRNA, miRNA, siRNA, and anti-sense 
oligonucleotides are the genetic materials used for therapeutic delivery to  restore a gene’s function 
or to silence toxic gene products (Goswami et al. 2019). Approximately thirty million people in 
the United States, and over three-hundred million people worldwide are affected by genetic 
diseases, and about half of them are estimated to be children (Goswami et al. 2019). Roughly 4000 
diseases (including cancers, AIDS, cystic fibrosis, sickle cell anemia, Parkinson’s and Alzheimer’s 
diseases) have been linked to genetic disorders; however, only 500 human diseases are treatable 
with the estimated ten-thousand available drugs to date (Goswami et al. 2019). This absence of 
viable treatment for the vast majority of genetic diseases underscores the importance of gene 
therapy and the necessity for new therapeutic interventions (Hampson et al. 2018; Goswami et al. 
2019).  
 Gene therapies can be divided into germ-line cell therapies and somatic-cell therapies. The 
former involve the genetic manipulation of germ cells (egg and sperm) to make inheritable changes 
that might prevent the spread of specific disease-causing genetic mutations (Goswami et al. 2019). 
Somatic-cell therapies, which are the only therapies currently being explored in humans, involve 
the therapeutic treatment of all cells in the body except for germ (egg and sperm) cells. The genetic 
effects of such therapies, of course, are not inheritable (Goswami et al. 2019; Gonçalves and Paiva 
2017). Somatic-cell therapies can be delivered in the following three possible ways: ex vivo 
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(outside the body) through the isolation of cells from a patient, therapeutic modification, and 
reintroduction of the manipulated cells into the patient’s body; in situ (in position) through the 
administration of the genetic therapy directly into the affected cells or tissue; or in vivo (in the 
living body) through direct systemic therapy delivery (Goswami et al. 2019).  
 Ex vivo and in vivo delivery methods are the most important and widely used methods of 
gene delivery. There are various challenges involved in the execution and implementation of  these 
approaches for gene therapy (Goswami et al. 2019; Shahryari et al. 2019). One of the most 
significant challenges involves the introduction of genetic constructs (which could be in the form 
of DNA, mRNA, miRNA, or siRNA) into cells in order to achieve an intended effect (Gonçalves 
and Paiva 2017).  
Typically, a vector is utilized for gene delivery. The best vectors are specific and efficient 
at expressing the desired therapeutic construct; they are able to evade the immune system; they 
can be purified in large quantities and high concentrations; they do not illicit an allergic or 
inflammatory response; and most importantly, they are safe and capable of expressing the desired 
genetic construct long-term, preferably over the course of a patient’s entire lifetime (Gonçalves 
and Paiva 2017). The two major vehicles for gene transfer needed for gene therapies are viral and 
non-viral vectors (Kay, Liu, and Hoogerbrugge 1997). Non-viral vectors include both physical and 
chemical methods ranging from DNA microinjections, cationic polymers and liposomes, gene 
guns, electroporation, sonoporation, photoporation, magnetofection, hydroporation, mechanical 
massage, lipid nanoparticles, calcium phosphate, silica, and gold nanoparticles (Goswami et al. 
2019; Gonçalves and Paiva 2017). However, viral vectors remain the most efficient delivery 
systems due to their operational simplicity and ability to deliver genetic materials to target cells 
and tissues (Goswami et al. 2019). 
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 Ideal viral vectors have the capacity to transport large therapeutic cargo; they have a large 
transduction efficiency; they can provide long-term and stable expression; they can target specific 
cells and avoid random insertion of the therapeutic construct into the host genome; finally, they 
should be able to infect both mitotic and non-mitotic cells, while being non-immunogenic and 
noninflammatory (Goswami et al. 2019). Of particular interest are the adeno-associated viral 
(AAV) vectors which are non-pathogenic and replication-defective. They are the only vectors that 
can lead to global systemic transduction at a level that addresses the needs of clinical gene therapy 
in patients (Kay, Liu, and Hoogerbrugge 1997; Goswami et al. 2019; Wasala et al. 2019). AAVs 
are one of the smallest single-stranded DNA viruses and contain a 4.7 kilobase genome made up 
of rep and cap  genes encoding four replication and three capsid proteins respectively (Chakrabarty 
et al. 2013; Kay, Liu, and Hoogerbrugge 1997). These genes are flanked by two inverted terminal 
repeats (ITRs) of approximately one-hundred and forty-five base pairs (Chakrabarty et al. 2013). 
There are thirteen AAV serotypes which are differentiated by their surface antigen expression and 
differences in amino acid sequence. Serotypes AAV1 to AAV9 are the most common (Goswami 
et al. 2019; Pipe et al. 2019). The identification of several hundred naturally occurring AAV 
capsids has spurred the emergence of pseudotyped AAVs bioengineered by combining the ITR of 
one serotype with the capsid from another serotype (Goswami et al. 2019).  
 Capsids are the main determinants of AAV tropism and transduction characteristics, with 
different serotypes and pseudotypes showing preferred tropism for various tissues (Chakrabarty et 
al. 2013).  AAV1 for example displays high tropism for muscles, neurons, heart, and retinal tissue, 
while AAV2 is the only serotype that can transduce the kidneys in addition to its tropism for cancer 
cells, neurons, photoreceptor cells, and the retinal pigment epithelium. AAV4 has a high tropism 
for the retina and AAV5 highly transduces the retina pigment epithelium. AAV6 transduces airway 
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epithelial cells and AAV7 has a high tropism for the liver. AAV8 is the only serotype that 
transduces the pancreas but it also has a tropism for neurons. Finally, AAV9 has a high tropism 
for neurons and is also capable of crossing the blood brain barrier (BBB) (Goswami et al. 2019; 
Steven J. Gray et al. 2011). Regardless, all AAV serotypes have been studied and used for CNS 
applications with various degrees of success. AAV 1 and AAV9 have an almost exclusive neuronal 
tropism when administered directly to the CNS. Thus, they are widely used for different gene 
therapeutic strategies involving the CNS, AAV9 specifically (Steven James Gray 2013).  Indeed, 
coupled with its ability to cross the BBB and transduce both neurons and astrocytes following 
intravenous injection in neonatal mice, adult mice, cats, and nonhuman primates, AAV9 and its 
pseudotypes are the vectors of choice for neuronal therapies (Steven James Gray 2013; Gao et al. 
2020).  
 A caveat to naturally occurring single-stranded (ss) AAVs as therapeutic vectors is the 
temporal delay caused by the formation of double-stranded (ds) DNA from its ssDNA which is 
the rate limiting step in the viral infection, gene delivery, and expression in target cells (Goswami 
et al. 2019). To address this limitation, self-complimentary dsDNA (scAAV) were developed, 
which utilize a mutant AAV2 ITR on one side of the transgene in cis with two complementary 
copies of the transgene flanked by wildtype AAV2 ITR. This modification has led to a decrease in 
packaging capacity of scAAV from 4.7 kilobases to approximately 2.2 kilobases. More 
importantly however,  it has led to a  ten to one-hundred fold increase in  efficiency over traditional 
ssAAV vectors (Steven J. Gray et al. 2011).  
 In recent years, twenty gene therapy products have been approved in the United States and 
Europe, and over two-thousand gene therapy trials were reported worldwide using both viral 
vehicles and non-viral vehicles to treat diseases caused by rare and common genetic disorders, as 
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well as life threatening diseases such as cancers and degenerative diseases (Shahryari et al. 2019). 
In the following subsections, recent advances in therapies for a haplo-insufficient (HI), loss-of-
function (LOF), and gain-of-function (GOF) DEE using preclinical mouse models will be 
discussed. These studies provide hope of possible treatment for patients suffering from this severe 
class of genetic diseases.  
 
1.8.2 Gene therapy for haploinsufficiency DEE in SCN1A models of Dravet Syndrome 
 Dravet syndrome is a DEE syndrome caused predominantly by heterozygous loss of 
function (LOF) mutations in SCN1A, which codes for the alpha1 subunit of the voltage gated 
sodium channel Nav 1.1 (Hsiao et al. 2016).  LOF mutations in this gene lead to a haplo-insufficient 
(HI) phenotype characterized by an approximately fifty percent decrease in SCN1A expression, 
intractable seizures, developmental delay and regression, ataxia, and increased mortality (Han et 
al. 2020; Hsiao et al. 2016).  Like most DEEs, there is no treatment for Dravet syndrome that 
addresses both seizures and developmental impairments. For an HI condition, a potential therapy 
could involve supplementing the wildtype copy of the gene. However, for a large gene like SCN1A 
(which is approximately 6 kilobases), this becomes logistically challenging since a ssAAV can 
only hold about 4.7 kilobases of product (Yamagata et al. 2020). Additionally, most neuronal genes 
are tightly regulated, and increases above wildtype levels are also associated with disease, as is the 
case for SCN1A. Thus, identifying therapy approaches that are carefully tailored to the mutated 
gene and accompanying disease phenotypes is necessary. Over the last few years, various 
therapeutic strategies that aim to increase the expression of SCN1A as a remedy for HI have been 
shown effective in preclinical mouse models of Dravet syndrome. 
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 To address SCN1A HI, antisense-oligos (AntagoNATs) were used to knockdown the long 
non-coding RNA (lncRNA) from the natural antisense transcript (NAT) of SCN1A (SCN1ANAT) 
in order to increase the endogenous expression of SCN1A and remedy disease phenotypes. 
LncRNA are approximately one-hundred kilobases and play an important role as cis and trans-
acting regulators of protein coding genes, specifically through the regulation of  mRNA dynamics 
(Bhat et al. 2016; Hsiao et al. 2016). SCN1ANAT is a lncRNA with multiple exons transcribed 
from the opposite strand of the SCN1A gene that negatively regulates the expression of SCN1A. 
Weekly intrathecal injection of antisense oligonucleotides that target SCN1ANAT (AntagoNAT) 
were administered to seven weeks old Dravet syndrome mice over four weeks. Before treatment, 
these mice showed decreased SCN1A expression, early onset seizures, increased susceptibility to 
heat induced seizures, increased mortality and reduced interneuron excitability – all phenotypes 
associated with Dravet syndrome. However, treatment led to a twenty-five percent increase in 
SCN1A expression, which was sufficient to cause a seventy percent reduction in seizures and 
seizure severity. Additionally, treatment decreased sensitivity to heat induced seizures, and 
increased excitability of hippocampal PV neurons. This study reinforced the notion that increasing 
SCN1A levels in Dravet syndrome HI mice could remedy key disease phenotypes (Hsiao et al. 
2016).  
 Another therapeutic approach to increase endogenous SCN1A levels to remedy severe 
phenotypes in a Dravet syndrome model was the TANGO therapy. Targeted Augmentation of 
Nuclear Gene Output (TANGO) implements antisense oligos (ASOs) to decrease the inclusion of 
an alternatively spliced transcript that contains a nonsense-mediated decay (NMD)-inducing exon, 
and thereby upregulate the expression of the wildtype productive transcript (Han et al. 2020). The 
NMD mechanism is used by eukaryotic cells to degrade mRNA transcripts that contain premature 
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stop codons, and SCN1A harbors an alternatively spliced mRNA transcript destined for NMD. This 
makes SCN1A a viable candidate for the implementation of the TANGO technology. Indeed, 
intracerebroventricular (ICV) injection of Dravet syndrome pups at postnatal day (PND) 2 or PND 
14 led to the restoration of Scn1a mRNA and protein expression back to wildtype levels. 
Additionally, treatment decreased seizures and the incidence of sudden unexpected death in 
epilepsy (SUDEP), a condition for which Dravet syndrome patients high risk. Treatment of 
wildtype mice did not lead to any overt abnormalities indicating the relative safety of this approach 
(Han et al. 2020). While the Dravet mouse model used in this study shows incomplete penetrance 
with approximately fifty percent of mice developing spontaneous seizures and SUDEP, the 
approach has nonetheless proved effective at increasing the expression of wildtype SCN1A 
transcripts, and established a potential avenue through which to remedy HI models of disease.  
 Also of note is the CRSIPR/dCas9 (CRISPR-ON) based gene therapy for SCN1A HI using 
a preclinical mouse model (Yamagata et al. 2020). In this therapy approach, the nuclease-dead 
Cas9 (dCas9) protein fused to the transcriptional activator (VPR; Floxed-dCas9-VPR) was 
directed to the promoter region of the SCN1A gene by four virally delivered guide RNAs (gRNAs; 
AAV-gRNA) to increase expression of SCN1A specifically in inhibitory neurons, a neuronal 
population previously shown to drive the seizure phenotype in the Dravet syndrome model 
(Yamagata et al. 2020). At four weeks, mice expressing dCas9-VPR in inhibitory neurons only, 
were systemically administered the gRNAs packaged into AAV serotype PHP.eB, which is known 
to transduce neurons at high efficiency in adult mice. Treated mice showed an increase in SCN1A 
expression in inhibitory neurons, especially in PV neurons. Treatment also prevented further 
lethality, increased the febrile seizure threshold, decreased single spike discharges, and improved 
behavioral phenotypes (Yamagata et al. 2020). While there are inherent limitations to the study 
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design that include the late onset of treatment at 4 weeks (which is past the peak occurrence of 
lethal spontaneous seizures PND 18 - PND 30 and could have inadvertently led to a survival bias), 
this study shows that therapeutic intervention may be successful in remedying severe disease 
phenotypes even in adulthood. This finding provides hope for patients suffering from these severe 
DEE who are past the developmental stages.  
 
1.8.3 Gene therapy for gain-of-function (GOF) DEE in an SCN8A model  
 SCN8A encodes the neuronal voltage-gated sodium channel Nav1.6. De novo missense 
GOF mutations in SCN8A cause premature channel opening, delayed channel inactivation, or 
elevated persistent current. Patients with SCN8A GOF mutations suffer from early onset refractory 
seizures, cognitive impairments, lack of speech and ambulation (Lenk et al. 2020). For this class 
of DEE caused by GOF mutations, reduction of the mutant transcript is the logical therapeutic 
strategy. To achieve this, ASOs specific to SCN8A were developed and delivered via 
intracerebroventricular (ICV) injection at PND 2 to SCN8A heterozygous mice. Heterozygous 
untreated mice showed early onset seizures that culminated in one-hundred percent lethality by 
PND 16. However, knockdown of SCN8A delayed seizure onset, and extended survival by 
approximately six weeks with the first dose of treatment, and by nine weeks when administered a 
follow-up treatment at PND 30 (Lenk et al. 2020). Even without allele-specific knockdown of the 
SCN8A GOF variant, therapeutic benefits were possible, indicating broad translatability of this 
approach to all SCN8A GOF variants. Ideally, however, the best strategy in this context would be 
a knockdown and replace therapy which would prevent adverse phenotypes associated with HI of 
the affected gene, as is the case with SCN8A.   
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1.8.4 Gene therapy for loss-of-function (LOF) DEE in a CDKL5 model 
 Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene causes DEE that 
is characterized by severe intractable seizures, global developmental delay, motor dysfunction, 
autistic features and sleep disturbances (Gao et al. 2020). CDKL5 disorder predominantly affects 
females through a HI mechanism. However, the null genotype in males causes the more severe 
disease. Like the other DEEs, there is no treatment for CDKL5 disorder. For this group of DEEs 
caused by LOF mutations, the best therapeutic strategy is to replace the affected gene product (Gao 
et al. 2020). Using the male null model as a proof-of-principle, adult CDKL5 knockout mice were 
administered isoform 1 of Cdkl5 packaged in AAV-PHP.B via intrajugular injection. Cdkl5 
knockout mice exhibit motor deficits, autistic-like behaviors, learning and memory deficits, and 
decreased seizure threshold. However, treatment remedied some behavioral abnormalities, 
including motor coordination and autistic-like behaviors, restoring them to intermediate levels 
compared to the wildtype and untreated controls (Gao et al. 2020). Treatment also corrected 
cerebellar structural defects associated with Cdkl5 LOF (Gao et al. 2020). This work further 
establishes the efficacy of gene replacement approaches for LOF mutations and further shows the 
effectiveness of therapies even after the developmental stages.  
 
1.9 FDA Approved Therapies using RNAi or Antisense Oligonucleotide Approaches 
 From 2016 to the present, the FDA has approved four therapies that harness the potential 
of RNA interference (RNAi) and antisense oligonucleotides (ASOs) to improve the clinical 
outcome and lives of patients suffering from rare genetic diseases. Additional therapies are 
currently in advanced stages of clinical trials. As is the case with severe genetic conditions, prior 
traditional therapies proved ineffective at curbing the disease progression and improving the 
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quality of life of affected patients (Zhang et al. 2021). RNAi (siRNA, miRNA) is a regulatory 
mechanism identified over two decades ago that is present in eukaryotic cells to control gene 
expression by targeting specific mRNA sequences destined for suppression. Recent technological 
advances have led to harnessing the therapeutic potential of RNAi to treat diseases. In this vein, 
synthetic ASOs that utilize similar mechanisms have also gained popularity. Beyond gene 
silencing, ASOs can also restore or modify gene expression (Rinaldi and Wood 2018).  
 In 2016, Nusinersen (Spinraza), an ASO, was approved to treat spinal muscular atrophy 
(SMA). SMA is a debilitating motor neuron disease caused predominantly by mutations in the 
survival motor neuron 1 (SMN1) gene. Mutations in SMN1 affect one in ten thousand children, 
representing the most common genetic cause of death in children (Corey 2017). The presence of 
an SMN2 gene, which encodes an unstable protein due to the exclusion of exon 7, created an 
avenue through which to provide an alternative source of SMN protein necessary for proper motor 
neuron function. The ASO therapy Nusinersen, delivered via lumbar puncture, works by targeting 
the critical splice sites at the intron exon junction of exon 7, preventing the recognition of exon 7 
by splicing factors and thus enabling the transcription of an active protein because of the inclusion 
of exon 7 in the mature mRNA transcript (Corey 2017). This treatment led to significant 
improvements in patient health and laid the foundation for a new class of drugs to treat CNS 
diseases.  
 Patisiran (ONPATTRO) was the first commercialized siRNA drug approved by the FDA 
in 2018 to treat transthyretin-mediated amyloidosis (hATTR), a progressive, fatal rare disease 
caused by autosomal dominant mutations in transthyretin (TTR), a hepatocyte derived protein. 
Mutations in TTR cause systemic buildup of amyloid deposits in the PNS, the CNS, the heart, the 
kidney and the gastrointestinal tract, leading to severe neuropathy, cardiomyopathy, and death 
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(Adams et al. 2018; Zhang et al. 2021). Hence, it is of upmost importance to identify viable 
treatment options to extend patient lifespan and quality of life. Patisiran is a hepatically directed 
siRNA molecule which works by targeting the 3’ untranslated region of the TTR mRNA. Thus, it 
decreases production of TTR protein in amyloid deposits. Moreover, the 2’ OH group of the siRNA 
molecule, which is inessential for siRNAs silencing, was replaced with 2’-O-methyl group on all 
pyrimidines in the sense strand and uridines in the antisense strand. This modification has multiple 
beneficial effects: it enhances stability; it protects from endonuclease degradation; it decreases 
immunogenicity and other immune-mediated off-target effects after administration (Zhang et al. 
2021). This modified siRNA was then packaged into a lipid nanoparticle to enable increases in 
stability, circulation time and uptake by cells. Treatment with Patisiran resulted in rapid and robust 
reduction in serum TTR levels sustained over the study duration, and improved secondary 
endpoints which included motor strength, mobility, body mass index, and autonomic symptoms 
(Adams et al. 2018; Zhang et al. 2021).  
 The second commercialized siRNA therapeutic drug, Givosiran (GIVLAARI) was 
approved in 2019 to treat acute hepatic porphyria (AHP) (Zhang et al. 2021). AHP is a rare genetic 
disease caused by mutations in heme biosynthesis enzymes which result in feedback upregulation 
of aminolevulinate synthase 1 (ALAS1), the first enzyme in the heme biosynthetic pathway (Zhang 
et al. 2021). Acute intermittent porphyria is the most common subtype of AHP representing eighty 
percent of symptomatic cases (Balwani et al. 2020). In patients with hepatic intermittent porphyria, 
induction of ALAS1 results in the accumulation of neurotoxic heme intermediates aminolevulinic 
acid (ALA) and porphobilinogen (PBG), which cause debilitating and often life-threatening 
symptoms including seizures, mental status changes, muscle weakness, paralysis, vomiting, 
hypertension and tachycardia (Zhang et al. 2021; Balwani et al. 2020). Givosiran is an siRNA 
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modified at the 2’OH with 2’-OMe and 2’-fluoro (2’F). These modifications increase the nuclease 
resistance while maintaining the gene-silencing activity of the siRNA. To enable delivery into 
cells, the modified siRNA is conjugated to a glycoprotein terminating in N-acetylgalactosamine 
(GalNAc), a sugar with a high binding affinity and specificity to a receptor abundantly expressed 
in hepatocytes (Zhang et al. 2021). This construct binds to ALAS1 mRNA, mediating knockdown 
and thereby reducing the production of ALA and PBG, which are the pathogenic metabolites that 
cause dysfunction. Monthly injections of Givosiran significantly reduced ALAS1 mRNA, ALA, 
and PBG levels, decreasing the rates of disease attacks (Balwani et al. 2020; Zhang et al. 2021). 
 Lumasiran (OXLUMO) was the third FDA approved siRNA drug to treat primary 
hyperoxaluria type 1 (PH1) in 2020. PH1 is a rare disease characterized by mutations in the AGT 
gene that encodes an enzyme needed for the metabolization of glyoxylate to pyruvate and glycine, 
preventing proper functioning and culminating in the accumulation the toxic metabolite oxalate. 
This accumulation and overproduction of oxalate triggers crystallization of calcium oxalate which 
deposits as kidney and urinary tract stones leading to sustained kidney damage and renal disease. 
The decline of renal function leads to the accumulation of oxalate in other tissues too, resulting in 
often-fatal systemic oxalosis (Zhang et al. 2021). Lumasiran works by targeting glyoxalate oxidase 
(GO) which synthesizes glyoxylate, the precursor of toxic oxalate, and thereby decreases the 
pathogenicity of oxalate. The siRNA modifications and delivery approaches of Lumasiran are 
similar to those of  Givosiran (Zhang et al. 2021). Like the other siRNA therapies, Lumasiran led 
to significant decreases in urinary oxalate levels to the normal range in patients that were 
administered the drug monthly or quarterly via subcutaneous injections (Zhang et al. 2021).  
 Presently, there are seven additional RNAi-based therapies in late-stage clinical trials. The 
successes of these therapies, specifically those that treat PNS and CNS conditions, bode well for 
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the delivery of RNAi-based therapies to treat DEEs in the near future. Indeed, our novel application 
of this therapeutic approach to DEE, and its success in a mouse model further reinforces the 
widespread use of RNAi therapies for rare intractable diseases. 
 
Concluding Remarks 
 The ongoing efforts to identify gene therapeutic approaches for the treatment of various 
DEE preclinical models, and the established efficacy of a few recently implemented techniques, 
together, create an optimistic outlook for future DEE treatments that are tailored to the specific 
disease mechanisms, and which address seizures as well as associated comorbidities. Furthermore, 
the success of some therapies in adult mouse models provides hope that treatments implemented 
even in adulthood can still benefit patients significantly. In the next chapter, we will discuss a 



















Figure 1.1. Pathogenic variants identified in DNM1 patients. List of DNM1 variants and the 
domains the affected domains. In red are the A408T (fitful mutation) and the G359A mutation, 
both of which affect the middle domain of DNM1 and also represent the two Dnm1 models 






















44% (15 of 34) 
32% (12 0f 34) 
12% (4 of 34) 
 9% (3 of 34)  
Seizure type at onset 
Infantile Spasms/Epileptic Spasms 
Other seizure type 
 
62% (19 of 31) 
39% (12 of 31) 




90% (28 of 31) 
10% (3 of 31) 
Severe to Profound ID 82% (28 of 34) 
Non-verbal and/or Non-ambulatory 82% (28 of 34) 
Hypotonia 85% (29 of 34) 
 
 
Table 1.1. Severe phenotypes associated with DNM1 pathogenic variants (H. Li et al. 2019; 
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Figure 1.2. KCNQ3 GOF mutations. Mutations in the outermost two arginines of the S4 domain 
(red “+”). The R2H mutation will be discussed further in later chapters (Sands et al. 2019).  
















 18% (2 of 11) 
Abnormal EEG 
ESES 
Other EEG phenotypes 
90% (10 of 11) 
55% (6 of 11) 
36% (4 of 11) 
ID 27% (3 of 11) 
ASD/autistic features 63% (7 of 11) 
Hypotonia 63% (7 of 11) 
Ataxia/walking delay 100% (11 of 11) 
 
 
Table 1.2. EEG and neurodevelopmental phenotypes associated with KCNQ3 R2 GOF 
















Chapter 2: RNAi-Based Gene Therapy Rescues Developmental and 
Epileptic Encephalopathy in a Genetic Mouse Model1 
2.1 Introduction  
 DNM1 encodes a critical multimeric brain-specific GTPase, dynamin-1, that localizes to 
the presynapse where it mediates endocytosis (Ferguson et al. 2007; Marks et al. 2001; Powell and 
Robinson 1995; Dhindsa et al. 2015). Individuals with pathogenic DNM1 variants suffer from two 
of the most severe developmental and epileptic encephalopathy (DEE) syndromes, Lennox-
Gastaut Syndrome and Infantile Spasms, with at least 20 heterozygous de novo variants identified 
in 33 patients predominantly in the critical GTPase and the middle domains of the protein 
(EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-RES@ua.ac.be et al. 
2017; S. K. Asinof et al. 2015; von Spiczak et al. 2017; Brereton et al. 2018; Kolnikova et al. 2018; 
H. Li et al. 2019).(EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-
RES@ua.ac.be et al. 2017; S. K. Asinof et al. 2015; von Spiczak et al. 2017; Brereton et al. 2018; 
Kolnikova et al. 2018)(EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-
RES@ua.ac.be et al. 2017; S. K. Asinof et al. 2015; von Spiczak et al. 2017; Brereton et al. 2018; 
Kolnikova et al. 2018) The identification of affected individuals is likely to increase as DNM1 is 
now included on screening panels for severe childhood epilepsy. Children with DNM1 mutations 
suffer from intractable conditions manifesting as early-onset seizures, global developmental delay, 
profound intellectual disability, lack of speech, muscular hypotonia, dystonia and spasticity (von 
                                               
1 This chapter is adapted from: Aimiuwu, Osasumwen V., Allison M. Fowler, Megha Sah, Jia Jie Teoh, Ayla Kanber, 
Nettie K. Pyne, Sabrina Petri, Chana Rosenthal-weiss, Mu Yang, Scott Q. Harper and Wayne N. Frankel. 2020. 
“RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model.” 




Spiczak et al. 2017; Brereton et al. 2018; Kolnikova et al. 2018). Affected individuals do not 
respond well to anti-epileptic drugs, leaving >80% of patients with seizures (von Spiczak et al. 
2017; Brereton et al. 2018), as is the case with many DEEs.  
Prior to the identification of pathogenic human variants, the first direct link between DNM1 
and severe epilepsy was a spontaneous missense mutation in the mouse orthologue, termed “fitful” 
(gene symbol: Dnm1Ftfl) (Boumil et al. 2010). This mutation occurs in a mutually-exclusive 
alternate exon in the middle domain of Dnm1 that defines Dnm1a – which along with Dnm1b 
comprises two functionally semi-redundant isoforms of Dnm1. Peptides encoded by these very 
highly conserved exons form part of the assembly domain that is critical for oligomerization of 
dynamin monomers into ring structures that carry out endocytosis (von Spiczak et al. 2017; Boumil 
et al. 2010).  
Whereas Dnm1Ftfl/+ heterozygous mice show only mild spontaneous and handling-induced 
seizures from 2 to 3 months of age and have a normal lifespan (Boumil et al. 2010), Dnm1Ftfl/Ftfl 
homozygotes show a DEE-like phenotype with severe ataxia, developmental delay, and fully 
penetrant lethal seizures by the end of the third postnatal week (Dhindsa et al. 2015; S. K. Asinof 
et al. 2015; Boumil et al. 2010; S. Asinof et al. 2016). While Dnm1b is expressed predominantly 
during gestation and expression wanes during early postnatal development, Dnm1a expression 
increases during early postnatal development and peaks during the second postnatal week, 
becoming the predominant isoform of adulthood (Boumil et al. 2010). However, neither Dnm1a 
nor Dnm1b isoform-specific homozygous knockout mice (Dnm1∆a/∆a or Dnm1∆b/∆b) show seizures 
or other overt phenotypic characteristics associated with the Dnm1Ftfl allele (S. K. Asinof et al. 
2015; S. Asinof et al. 2016). These and other in vivo and in vitro studies suggest that Dnm1Ftfl 
exerts a dominant-negative effect on protein function, as was modeled or predicted for all DNM1 
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pathogenic variants (Dhindsa et al. 2015; S. K. Asinof et al. 2015; von Spiczak et al. 2017). The 
emerging successes of gene silencing therapies directed at specific variants or isoforms in animal 
models embolden the application of genetic-based therapies for this class of genetic diseases 
(Adams et al. 2018; Morelli et al. 2019; Wallace et al. 2012). 
Similar to the approach taken recently in a mouse model of peripheral neuropathy where a 
virally delivered RNAi successfully prevented deleterious phenotypes associated with Charcot-
Marie-Tooth type 2D (CMT2D) (Morelli et al. 2019), we developed a therapeutic miRNA that 
targets Dnm1a, the isoform which houses Dnm1Ftfl, and cloned it into self-complementary adeno-
associated virus 9 (scAAV9) for in vivo delivery to neonatal mice. While the efficacy of AAV-
mediated RNAi treatments has been established in other toxic genetic disease models, (Daya and 
Berns 2008) such treatments have not been previously applied to intractable DEE.  
Here we determined that a one-time bilateral intracerebroventricular injection of neonatal 
Dnm1Ftfl/Ftfl mouse pups reduced seizure severity, extended lifespan, improved growth and 
abolished various developmental impairments. Treatment also greatly reduced or eliminated 
underlying cellular pathology. This study provides proof of principle for postnatal gene silencing 
to curb fundamental features of DNM1 DEE, with implied application to other early 




scAAV9-miDnm1a selectively inhibits Dnm1a 
 To knock down Dnm1Ftfl, we identified a microRNA that specifically and efficiently targets 
the Dnm1a isoform that harbors the fitful mutation (S. K. Asinof et al. 2015; Boumil et al. 2010; 
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S. Asinof et al. 2016). We first designed four different microRNA constructs (miDnm1a-1 through 
miDnm1a-4) and tested their efficacy in vitro using a dual luciferase reporter assay (Fig. 2.1A). 
miDnm1a-4 was the most effective at reducing the amount of Dnm1a mRNA (Fig. 2.1A). We then 
packaged miDnm1a-4 into a scAAV9 virus vector (scAAV9-miDnm1a) for in vivo validation 
(Fig.2.1B). Mice were either administered the treatment (scAAV9-miDnm1a) or control 
(scAAV9-eGFP) via a one-time bilateral intracerebroventricular (ICV) injection at postnatal day 
zero (PND 0; see Methods; Fig. 2.1B-C). miDnm1a treated mice showed significant reduction of 
Dnm1a mRNA two weeks post-delivery compared to scAAV9-eGFP mice (p<0.0001), assessed 
by using RT-qPCR (Fig. 2.1C). Expression of the other Dnm1 isoform, Dnm1b, was unaltered, 
reflecting the specificity of miDnm1a for the Dnm1a isoform and fitful silencing (p=0.783; Fig. 
2.1C). Because all viral constructs express GFP, viral expression was verified histologically using 
an anti-GFP antibody (see Methods). GFP expression was detected in the brains of scAAV9-
miDnm1a and scAAV9-eGFP injected mice (Fig. 2.1D). 
 
scAAV9-miDnm1a treatment improves developmental and seizure behaviors 
 To assess the efficacy of scAAV9-miDnm1a in extending survival and to identify and 
address any logistical constraints in the use of the construct, including viral delivery, we undertook 
a pilot study in the C57BL/6J (B6J) mouse strain background. Dnm1Ftfl/Ftfl mice experience severe 
and fully-penetrant tonic-clonic seizures and comorbidities resulting in lethality by the third 
postnatal week, irrespective of mouse strain background (Boumil et al. 2010). B6J-Dnm1Ftfl/Ftfl 
mice were treated with three doses of miDnm1a: 1x1010, 1.85x1011, 3.25x1011 vector genomes 
(vg). Treatment of Dnm1Ftfl/Ftfl mutants, extended survival in a dose-dependent manner: 30% 
(p=0.0001) and 50% (p=0.01) of mice treated with the latter two doses respectively, survived to 
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PND 30 and showed growth improvements (p=0.003; Supplemental Fig. 2.1B-C). The highest 
dose at 3.25x1011 vg did not produce overt adverse effects, suggesting that similar or higher doses 
could be used in a full experiment.  
 To further evaluate the effectiveness of miDnm1a, we employed (B6J x FVB/NJ)F2 hybrid 
background mice because of their large litter size, animal size and good maternal care. Dnm1Ftfl/Ftfl 
and Dnm1+/+ F2 hybrids were either treated (scAAV9-miDnm1a) or control-injected (i.e., scAAV9-
eGFP or saline; see Methods; Fig. 2.2A) at PND 0. Mice were observed for survival, seizure 
activity and weight until PND 30, the chosen endpoint for this study (Fig. 2.2A). While control-
injected Dnm1Ftfl/Ftfl mice, similar to prior observation,(Boumil et al. 2010) did not survive past 
PND 19 (n=27; Fig. 2.2B), 88% of treated mice lived past PND 20 and 75% (n=25) survived until 
PND 30 (p=7.5 x 10-10; Fig. 2.2B). These data show the effectiveness of miDnm1a at extending 
survival of Dnm1Ftfl/Ftfl mice considerably.  
 As shown from prior studies (Boumil et al. 2010), control-injected Dnm1Ftfl/Ftfl mice started 
showing growth deficits from PND 8 until moribundity, due to failure to thrive, or a terminal 
seizure event by PND 18-19 (Fig. 2.2B, C). In contrast, treated Dnm1Ftfl/Ftfl mice grew steadily 
until PND 30, although they lagged behind treated and control-injected Dnm1+/+ mice starting at 
PND 8 and PND 18, respectively (Fig. 2.2C). Overall, there was a significant growth improvement 
in treated Dnm1Ftfl/Ftfl mice compared to control-injected Dnm1Ftfl/Ftfl by PND 18 (repeated 
measures ANOVA; p=3.3x10-13). We also note that even treated Dnm1+/+ mice showed some 
growth delay starting at PND 8 compared to control-injected Dnm1+/+ (p=0.004; Fig. 2.2C). 
Although germline Dnm1a null mice were previously reported to lack any overt impairments (S. 
K. Asinof et al. 2015; S. Asinof et al. 2016), it is plausible that modest growth delay as seen in 
treated Dnm1+/+ is a feature of postnatal Dnm1a elimination. Alternatively, the growth deficits 
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observed in treated Dnm1+/+ mice could be due to unpredictable off-target effects of miDnm1a. 
Regardless, these data reinforce the effectiveness of miDnm1a in improving growth outcomes of 
Dnm1Ftfl/Ftfl mice.  
To determine the effect of miDnm1a on seizure phenotypes, treated and control-injected 
Dnm1Ftfl/Ftfl homozygotes were assessed for overt seizure and seizure-associated activity, including 
wild runs, Straub tail, continuous vertical jumping lasting for more than 10 seconds with 
subsequent facial grooming, continuous jerking of the limbs and full-blown tonic-clonic seizures. 
These assessments were done on alternate days, starting at PND 14 during weight examination 
sessions. While both treated and control-injected Dnm1Ftfl/Ftfl mice exhibited seizure behaviors, 
treated mice had fewer overall observed events between PND 14-18 (Fig. 2D, Table 2.1). By PND 
18, all control-injected Dnm1Ftfl/Ftfl mice were moribund and incapable of staying upright. Treated 
Dnm1Ftfl/Ftfl mice showed handling seizures between PND 14-24 (Table 2.1). After this period, the 
number and intensity of their observed seizure and seizure-like events decreased (Fig. 2.2D, Table 
2.1). These data suggest that miDnm1a treatment decreased seizures and seizure-associated 
activity in Dnm1Ftfl/Ftfl mice. 
 Patients with pathogenic heterozygous missense mutations in DNM1 present with 
neurodevelopmental phenotypes like hypotonia and psychomotor impairments; thus, we selected 
and developed assays that could elucidate such phenotypes in pups. To determine the outcome of 
miDnm1a treatment on neurodevelopmental phenotypes, strength, sensorimotor development, and 
gait were assayed (see Methods). Treated and control-injected Dnm1Ftfl/Ftfl homozygotes were 
tested for grip strength, an assay whereby mouse pups at PND 9 and PND 11 were placed on a 
vertical screen mesh and latency to fall recorded. Treated Dnm1Ftfl/Ftfl mice (n=30) showed 
improved grip strength compared to control-injected Dnm1Ftfl/Ftfl mice (n=28) at PND 11 
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(p=0.0009; Fig. 3A). However, treated Dnm1Ftfl/Ftfl mice did not differ in grip strength from treated 
(n=24) or control-injected (n=19) Dnm1+/+ at PND 9 and PND 11 (p>0.05; Fig. 2.3A). We then 
evaluated possible sensorimotor impairment using the negative geotaxis assay, which challenges 
the innate behavior in mice to utilize vestibular cues for motor coordination (Feather-Schussler 
and Ferguson 2016; Yang et al. 2012). Mice were placed on a 45° incline with heads pointing 
downwards and latencies to turn 90o and 180o were recorded. Unlike control-injected Dnm1Ftfl/Ftfl 
mice, treated Dnm1Ftfl/Ftfl mice like wildtype controls, tended to exhibit a shorter latency to turn 
90˚ and 180˚ at PND 11, but only the more challenging 180˚ turn was statistically significant 
compared with control-injected Dnm1Ftfl/Ftfl mice (p=0.0004; Fig. 2.3B, C). We further assessed 
gait impairments since ataxia is a prominent phenotype of Dnm1Ftfl/Ftfl mice (Boumil et al. 2010). 
We recorded PND 14 treated and control-injected Dnm1Ftfl/Ftfl and Dnm1+/+ mice for 10-minute 
intervals using automated software and counted the number of falls and wobbles (see Methods). 
As expected, control-injected Dnm1Ftfl/Ftfl mice had numerous ataxic events (overtly wobbly gait 
and falls), but miDnm1a treatment completely abolished this ataxic phenotype observed in the 
control-injected Dnm1Ftfl/Ftfl mice (p<0.0001; Fig. 2.3D). We also quantified ambulation during 
this time but found no difference in either distance traveled or velocity between groups (p>0.05; 
Fig. 2.3E, F). These results show that miDnm1a treatment improved the developmental outcomes 
of Dnm1Ftfl/Ftfl mice. 
 In conclusion, treated Dnm1Ftfl/Ftfl mice showed extended survival, improved growth, 
decreased lethal seizures, improved developmental outcomes, and an absence of ataxia. These data 
together show the effectiveness of miDnm1a at curbing or eliminating the most severe fitful 
behavioral phenotypes including seizures, growth deficits and ataxia, culminating in an overall 
improvement in their quality of life and survival to the endpoint.  
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miDnm1a treatment improves cellular pathology 
 The significant mitigating effect of Dnm1Ftfl mRNA silencing on severe seizures and 
impaired neurodevelopment prompted us to examine the extent to which treatment impacts 
underlying cellular pathology. Gliosis and neuronal cell death are hallmarks of neuronal insults 
and recurrent seizure activity (Pollen and Trachtenberg 1970; Wilcox 1909), features not 
previously examined in the published studies on Dnm1Ftfl mouse model. Here we investigated the 
presence of gliosis and cell degeneration via immunolabeling using glial fibrillary acidic protein 
(GFAP) and Fluoro-Jade C (FJC). At PND 18, control-injected Dnm1Ftfl/Ftfl mice showed intense 
fibrillary gliosis (GFAP) in the hippocampus, specifically around CA1, compared to treated 
Dnm1Ftfl/Ftfl mice (p=0.018), indicative of a hippocampus under stress (Fig. 2.4A). In contrast, 
treated Dnm1Ftfl/Ftfl mice did not show gliosis and their hippocampi did not differ from wildtype 
controls (p>0.05; Fig. 2.4A, Supplemental Fig. 2.2A). By the study endpoint at PND 30, surviving 
treated Dnm1Ftfl/Ftfl mice showed an increase in GFAP intensity in the hippocampus compared to 
treated and control-injected Dnm1+/+ mice (p=0.0059 and p=0.0072 respectively; Fig. 2.4B, 
Supplemental Fig. 2.2A). FJC labeling of control-injected Dnm1Ftfl/Ftfl mice revealed striking 
cellular degeneration in the hippocampus, and more so in the CA1 region compared to treated 
Dnm1Ftfl/Ftfl mice (p=0.015; Fig. 2.4C, Supplemental Fig. 2.2B). This cell death phenotype was 
significantly diminished in treated Dnm1Ftfl/Ftfl mice but not in control-injected Dnm1Ftfl/Ftfl mice 
(Fig. 2.4C). By the PND 30 endpoint, treated Dnm1Ftfl/Ftfl mice showed some cell death; however, 
not significantly more compared to treated and control-injected Dnm1+/+ mice (Fig. 2.4D, 
Supplemental Fig. 2.2B). These results revealed a susceptibility of the hippocampal neurons to 
Dnm1Ftfl. Additionally, these results showed that miDnm1a treatment was successful at curbing or 
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delaying gliosis and cellular degeneration in the hippocampus of Dnm1Ftfl/Ftfl mice at PND 18 and 
PND 30. (Fig. 2.4A-D, Supplemental Fig. 2.2A-B).  
 Given the increased gliosis and cellular degeneration observed in the hippocampus of 
control-injected Dnm1Ftfl/Ftfl mice, we examined hippocampal involvement further by using cellular 
footprints of metabolic activity typically associated with recurrent limbic seizure behavior. We 
examined neuropeptide Y (NPY), as upregulation of NPY in the hippocampus is a known method 
of evidencing hyperexcitability in rodent models of epilepsy (Manno et al. 2011; Sørensen et al. 
2009). We observed aberrant cellular NPY expression in the hippocampal cornu ammonis areas, 
specifically in CA3, of control-injected Dnm1Ftfl/Ftfl mice compared to treated Dnm1Ftfl/Ftfl mice at 
PND 18 (p=0.0012; Fig. 2.5A, Supplemental Fig. 2.3A). Treated Dnm1Ftfl/Ftfl mice, however, 
showed NPY expression similar to treated and control-injected Dnm1+/+ mice at PND 18 (p>0.05; 
Fig. 2.5A, Supplemental Fig. 2.3A). By PND 30, treated Dnm1Ftfl/Ftfl mice still did not differ from 
treated and control-injected Dnm1+/+ mice, although treated Dnm1Ftfl/Ftfl mice tended to have more 
aberrant NPY+ cells in the CA3 (p>0.05; Fig. 2.5B, Supplemental Fig. 2.3A). Additionally, we 
immunostained for the immediate early gene marker of neuronal activity, c-Fos (Kadiyala et al. 
2015). We observed a significant increase in c-Fos+ cells in the hippocampus, specifically in the 
CA3 of control-injected Dnm1Ftfl/Ftfl mice (Fig. 2.5C; Supplemental Fig. 2.3B). In contrast, this 
increased neuronal activity was abated in treated Dnm1Ftfl/Ftfl mice at PND 18 (p<0.00001) and 
persisted until PND 30 (Fig. 2.5C-D, Supplemental Fig. 2.3B). Moreover, treated Dnm1Ftfl/Ftfl mice 
did not differ from treated and control-injected Dnm1+/+ mice at PND 18 or PND 30 (p>0.05; Fig. 
2.5C-D, Supplemental Fig. 2.3B). These results suggest that miDnm1a treatment decreased the 
abnormal cellular metabolic activity of Dnm1Ftfl/Ftfl mice.  
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 Overall, unlike control-injected Dnm1Ftfl/Ftfl mice, treated Dnm1Ftfl/Ftfl mice showed a 
decrease in gliosis, cell death, and aberrant neuronal activity at PND 18 which persisted and led to 
their survival until the PND 30 endpoint. These results together show that miDnm1a treatment 
















Figure 2.1. scAAV9-miDnm1a selectively inhibits Dnm1a. A) Knockdown efficacy of Dnm1a 
in vitro by 4 different miRNA constructs. miDnm1a-4 was the most effective with 95% knockdown. 
B) Experimental and control constructs delivered via ICV injection at PND 0. The black boxes 
indicate the viral inverted terminal repeats, and pA indicates an SV40 polyadenylation signal. C) 
Validation of Dnm1a knockdown efficacy in vivo by scAAV9-miDnm1a (n=8) compared to 
scAAV9-eGFP control (n=6) shows significant decrease of Dnm1a but not Dnm1b in whole brain 
extracts from scAAV9-miDnm1a treated mice (p<0.0001; ns, respectively; 2-way ANOVA with 
Sidak’s correction for multiple comparisons). D) Broad viral transduction of both Dnm1Ftfl/Ftfl and 
Dnm1+/+ scAAV9-miDnm1a treated mice 30 days after ICV injection. Images were taken at 10X 
magnification. Data reported as mean±SEM. Scale bar on whole brain represents 500 µm, and 















Figure 2.2. scAAV9-miDnm1a treatment improves survival, growth and seizure outcomes. 
A) Experimental design with ICV injection administered at PND 0, developmental phenotyping 
executed between PND 4 - PND 11, survival, seizure and growth measurement assessed from PND 
4 - PND 30 (the endpoint of the study) and cellular phenotyping performed at PND 18 and PND 
30. B) Treatment with miDnm1a led to 75% survival of Dnm1Ftfl/Ftfl mice (n=25) to PND 30 
compared to control-injected mice (eGFP or saline, n=27) which were 100% lethal before PND 20 
(p<0.0001, log-rank Mantel-Cox test). Treated Dnm1Ftfl/Ftfl mice differed from treated Dnm1+/+ 
(n=24) or control-injected Dnm1+/+ (n=19) mice (p=0.0239; p=0.0097, respectively; log-rank 
Mantel-Cox test). C) Although treated and control-injected Dnm1Ftfl/Ftfl mice were notably smaller 
as early as PND 8, miDnm1a treated Dnm1Ftfl/Ftfl showed growth improvement beginning at PND 
12. Repeated measures ANOVA was performed until PND 18 when control-injected Dnm1Ftfl/Ftfl 
mice exited the study, including genotype-treatment effects (combining the two control treatments, 
eGFP and saline), plus other independent variables including sex, virus dose and litter size. For 
treated vs. control-injected Dnm1Ftfl/Ftfl, the effect of treatment was highly significant (p=3.3 x 10-
13), despite a significant effect of litter size (p=1.4 x 10-7) but no significant impact of virus dose 
or sex. Growth differences at the PND 30 study endpoint between treated Dnm1Ftfl/Ftfl and treated 
wildtype were significant (p=0.004), with a modest effect of litter size (p=0.048). Using similar 
analysis, treated wildtype mice also showed growth delay compared to control wildtype (p=0.004), 
with a modest effect of sex (p=0.01) and litter size (p=0.033). D) Both miDnm1a treated and 
control-injected Dnm1Ftfl/Ftfl mice show seizure-like behavior, however, control-injected 
Dnm1Ftfl/Ftfl mice had significantly more seizures at PND 14 and PND 18. Seizure-behaviors of 
treated mice decreased over time. See Table 1 for sample numbers and analysis. Data reported as 






Figure 2.3. scAAV9-miDnm1a treatment improves developmental outcomes. A) Treatment 
significantly improved the grip strength at PND 11 of Dnm1Ftfl/Ftfl mice (n=30) compared to 
control-injected (n=28) mice (p=0.0009, least squares regression using rank- and normal-quantile 
transformed data), with no effect of litter size, sex or virus dose. Treated Dnm1Ftfl/Ftfl mice did not 
differ from treated (n=24) or control-injected (n=19) Dnm1+/+ mice (same test as above with 
Tukey’s HSD post-hoc test, p>0.05). B,C) In an assay for sensorimotor development, at PND 9 
and PND 11, control-injected Dnm1Ftfl/Ftfl mice had a higher latency, albeit not significant for the 
easier 90˚ turn (p>0.05, least squares regression using rank- and normal-quantile transformed data, 
Dunnett’s post-hoc test). However, for the more difficult 180˚ turn, control-injected Dnm1Ftfl/Ftfl 
mice showed a significantly higher latency at PND 11 compared to the other 3 groups (p<0.001, 
Dunnet’s post-hoc test). D) Control-injected Dnm1Ftfl/Ftfl mice (n=24) show severe ataxia, 
importantly, treatment with miDnm1a (n=17) eliminates this phenotype (p=6.9 x 10-17, log-Poisson 
test) and restores Dnm1Ftfl/Ftfl motor coordination back to the level of treated (n=16) and control-
injected (n=23) Dnm1+/+ mice (p=0.19 mixed model log-Poisson test). E,F) Using locomotion and 
velocity as a proxy for possible hyperactivity, we observed that there was no significant difference 












Figure 2.4.  miDnm1a treatment diminishes gliosis and cellular degeneration at PND 18 until 
PND 30. A) Control-injected Dnm1Ftfl/Ftfl mice showed strikingly increased gliosis specifically in 
the hippocampal CA1 as identified with the marker GFAP compared to treated Dnm1Ftfl/Ftfl mice 
(p=0.018). Treated Dnm1Ftfl/Ftfl mice did not differ from treated and control-injected Dnm1+/+ mice 
(p>0.05) at PND 18. B) By PND 30, treated Dnm1Ftfl/Ftfl showed significantly more GFAP intensity 
compared to treated and control-injected Dnm1+/+ mice (p=0.0052 and p=0.0072 respectively). 
Images (A-B) were taken at 10X magnification and analysis was done using an Ordinary one-way 
ANOVA followed by Tukey’s multiple comparisons test. Scale bar of entire hippocampus 
represents 200 µm and region of interest (ROI) scale bar represents 20 µm.  C, D) FJC labeling at 
PND 18 showed significant cell death in the hippocampus of control-injected Dnm1Ftfl/Ftfl mice, 
specifically along the CA1, unlike treated Dnm1Ftfl/Ftfl mice (p=0.015). Treated Dnm1Ftfl/Ftfl mice 
did not differ from treated and control-injected Dnm1+/+ mice (p>0.05). By PND 30, treated 
Dnm1Ftfl/Ftfl mice had little apparent cell death as identified by FJC labeling. However, they did not 
differ from treated and control-injected Dnm1+/+ mice (p>0.05). Images were taken at 10X 
magnification and scale bars correspond to 100 µm. Analyses were executed using  the Poisson 
overdispersion option in the GMLJ module of Jamovi’s software. 3-5 mice were used in these 










Figure 2.5.  miDnm1a treatment improves metabolic cellular activity at PND 18 until PND 
30. A) Aberrant NPY expression was observed in the hippocampus and specifically in the CA3 of 
control-injected Dnm1Ftfl/Ftfl mice at PND 18; treatment with miDnm1a reverted this phenotype 
(p=0.0012). Treated Dnm1Ftfl/Ftfl mice did not differ from treated and control-injected Dnm1+/+ 
mice (p>0.05). B) NPY expression varied amongst treated Dnm1Ftfl/Ftfl mice at PND 30. However, 
treated Dnm1Ftfl/Ftfl mice trended toward significance compared to treated Dnm1+/+ mice (p=0.057) 
and control-injected Dnm1+/+ mice (p=0.074). C) At PND18 c-Fos staining showed increased 
neuronal activation in the hippocampal CA3 of control-injected Dnm1Ftfl/Ftfl mice which was 
significantly diminished in treated Dnm1Ftfl/Ftfl mice (p<0.00001). Treated Dnm1Ftfl/Ftfl mice did not 
differ from Dnm1+/+ controls (p>0.05). D) By PND 30, there was a modest increase in neuronal 
activation in the hippocampus, specifically in the CA3 region, of treated Dnm1Ftfl/Ftfl mice 
compared to Dnm1+/+controls, but this increase was not significant (p>0.05). All images (A-D) 
were taken at 10X magnification. Scale bar of entire hippocampus represents 200 µm and ROI 
scale bar represents 20 µm. Analyses were executed using the Poisson overdispersion option in 
the GMLJ module of Jamovi’s software. 3-5 mice were used in these analysis and data are reported 

















Postnatal day Group Positive Negative total % positive p-valuea 
14 
 
Control 25 19 44 56.8% 0.017 
miDnm1a 8 21 29 27.6% 
16 Control 24 19 43 55.8% 0.156 
miDnm1a 11 18 29 37.9% 
18 Control 39 3 42 92.9% 2x10-6 
miDnm1a 12 17 29 41.4% 
20 miDnm1a 5 19 24 20.8% n.a. 
22 miDnm1a 9 12 21 20.8% n.a. 
24 miDnm1a 7 13 20 35.0% n.a. 
26 miDnm1a 3 17 20 15.0% n.a. 
28 miDnm1a 1 19 20 5.0% n.a. 
30 miDnm1a 1 19 20 5.0% n.a. 
 
Table 2.1. Observed seizure or seizure associated behaviors in treated or control-injected 
Dnm1Ftfl/Ftfl mice. aFisher exact test, 2-tail, 2 x 2 contingency analysis. Treated Dnm1Ftfl/Ftfl mice 
show fewer seizures compared to untreated Dnm1Ftfl/Ftfl mice and this is statistically significant at 
PND 14 and PND 18. At PND 18, four treated mice were removed from the study for histological 







Supplemental Figure 2.1.  miDnm1a improves survival in a dose dependent manner 
(C57BL/6J strain background pilot experiment; related to Figure 2A-C). A) Experimental 
plan for pilot studies. Three miDnm1a doses were administered to neonates and examined for 
survival and growth. B) The survival curve for treated Dnm1Ftfl/Ftfl mice is significantly different 
from untreated Dnm1Ftfl/Ftfl mice only for the 1.85x1011 (n=10) and 3.2x1011 (n=6) doses 
(p=0.0001, p =0.01, respectively, log-rank Mantel-Cox test). C) For these doses, treated 















Supplemental Figure 2.2. PND 18 and PND 30 cellular phenotypes images (GFAP and FJC; 
2 other representative replicate sets; related to Figure 4). A) Control-injected Dnm1Ftfl/Ftfl mice 
show increased hippocampal GFAP  which is absent from treated Dnm1Ftfl/Ftfl mice and Dnm1+/+ 
controls at PND 18. At PND 30, treated Dnm1Ftfl/Ftfl mice show a significant  increase in GFAP 
compared to Dnm1+/+ controls. Scale bar correspond to 200 µm. B) Control-injected Dnm1Ftfl/Ftfl 
mice show cell death in the hippocampal CA1. This phenotype is absent from treated Dnm1Ftfl/Ftfl 
mice and Dnm1+/+ controls at PND 18. However, by PND 30 there is some noticeable cell death in 










Supplemental Figure 2.3. PND 18 and PND 30 cellular phenotypes images (NPY and c-Fos; 
2 other representative replicate sets; Related to Figure 5)  A) Dnm1Ftfl/Ftfl treated  mice show a 
decrease of  NPY+ cells in the hippocampus at PND 18 and PND 30 compared to control-injected 
Dnm1Ftfl/Ftfl mice. By PND 30 treated mice start to show increased NPY compared to  Dnm1+/+ 
controls in the CA3. B) Treated Dnm1Ftfl/Ftfl mice show decrease in c-Fos compared to control-
injected Dnm1Ftfl/Ftfl mice at PND 18. By PND 30 treated mice show variable increase in 





2.3 Discussion  
 Here, we examined an RNAi-based gene therapy approach in an animal model of severe 
childhood epilepsy. The preclinical features of Dnm1 fitful mice are representative of many genetic 
gain-of-function or dominant negative DEE which represent the most severe forms (McTague et 
al. 2016c). Similar to a recently described approach in the Gars model of a genetic peripheral 
neuropathy (Morelli et al. 2019), we used a microRNA that specifically targets the pathogenic 
Dnm1Ftfl isoform, packaged it into a self-complementary AAV9 vector and delivered it via 
intracerebroventricular injection of neonatal mice. We determined that a single treatment 
eliminated ataxia, improved growth and development, and decreased lethal seizures, thus 
improving survival at least to the endpoint of our study at postnatal day 30. We also observed 
significant accompanying improvements in cellular pathology. 
 Although treatment rendered the seizures survivable, eliminated the ataxia, greatly reduced 
underlying cellular pathology, and improved animal growth, miDnm1a treatment did not 
completely eliminate seizures as mutants still had observable seizures prior to weaning age, nor 
was 100% survival achieved. Nevertheless, compared with most other DEE models, it is critical 
to note that the Dnm1 model is exceptionally debilitating, culminating in 100% moribundity or 
lethality before the third postnatal week, and yet the RNAi approach led to 75% survival until at 
least PND 30.  Though a 30-day study endpoint was set to mark the end of the developmental stage 
and without expectations of the kind of success observed, the apparent vigor of treated mutants 
suggests even longer survival - a focus of future experiments. The lethality associated with surgical 
electrode implantation of Dnm1Ftfl homozygous mice prevented electroencephalographic (EEG) 
assessment of seizure activity. EEG assessments would have provided the opportunity to observe 
milder epileptiform activity that did not culminate in a visually detectable generalized tonic-clonic 
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seizure event. Future studies will aim to assess seizures, specially seizure onset during the more 
clinically relevant early developmental window, through intracranial electroencephalographic 
recordings of mutant pups. Regardless, our results highlight the significant potential of RNAi 
therapy at rescuing the developmental phenotypes and decreasing the early-onset seizure 
occurrence associated with DEE. It is possible that a higher viral dose might have led to a more 
complete rescue, but experimental logistics precluded this. However, our hypothesis is that AAV9 
delivery even as early as the first postnatal day for mice was unable to fully compete against 
disease pathogenesis already in rapid progress. That is, gene expression from self-complementary 
AAV9 is not instantaneous – gene expression begins 4 days after transduction and peaks at 14 days 
(Zincarelli et al. 2008), lagging behind Dnm1a peak expression - but Dnm1Ftfl/Ftfl associated 
symptoms are already evident by the end of the first postnatal week. Overall, despite limitations 
intrinsic to an initial study of this type, the results demonstrate the potential effectiveness of virally 
delivered RNAi as a strategy for treating DEE where it is necessary to block or eliminate, rather 
than reintroduce, the abnormal gene product. 
 RNAi therapy presents a promising, and perhaps necessary avenue for treating such 
debilitating diseases. Indeed, this approach is currently being used to treat various other diseases 
caused by dominant negative or gain of function mutations in both mouse models, and  humans 
with success (Adams et al. 2018; Morelli et al. 2019; Wallace et al. 2012). Very recently, the RNAi 
therapy Patisiran was approved for treating hereditary transthyretin amyloidosis, and more similar 
therapies are likely to follow (Adams et al. 2018). Such advances together with our results and 
recent success in using AAV as a delivery system for treating various neurological diseases 
(Morelli et al. 2019; 2019; Daya and Berns 2008), suggest that RNAi therapy for treatment of 
DEEs caused by dominant negative or gain-of-function mutations is directly translationally 
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feasible. Although the lag in AAV9 gene expression may be a limitation for treating this early 
severe DEE in mice, one would expect that the larger therapeutic window of human postnatal 
development compared to mouse would facilitate a more complete therapeutic response. 
Furthermore, given that human mutations are heterozygous, for some mutations, RNAi would 
allow for allele-specific silencing, leaving the wildtype copy intact as was the case in the Gars 
model (Morelli et al. 2019). There are also alternative albeit more transient therapy vehicles, such 
as antisense oligos (ASOs) (Rinaldi and Wood 2018), that may be more suited for instantaneous 
results, better control of dosage, and the potential for stopping treatment if side effects manifest. 
This, however, means that patients will require multiple “booster” applications, whereas AAV9 is 
expected to be more robust and longer-term as vector expression is persistent (Rinaldi and Wood 
2018; Steven James Gray 2013). 
In summary, this study serves as a strong proof-of-principle of the efficacy of RNAi 
therapy for the treatment of DNM1 DEE with potential broad application to other dominant 
negative or gain-of-function DEEs. Indeed, even conversion of a severely debilitating, untreatable 
disease to a more manageable form of epilepsy would immensely improve the quality of life and 
be transformative for patients and their families. 
 
2.4 Materials and Methods 
Study design  
 Experiments were performed blinded to genotype and treatment, and randomized as 
appropriate. Postnatal day (PND) 30 was selected prospectively as the adult endpoint because pups 
are typically weaned between PND 22 and PND 28, marking the end of the developmental period. 
To conform with institutional compliance data collection from live Dnm1Ftfl/Ftfl mice was stopped 
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upon moribundity. For 95% confidence in detecting improvement from inhibition of mutant 
Dnm1a, at least 12 animals per group (genotype x treatment, sexes combined) was necessary to 
detect an effect with 80% power. For the primary study, to assess a possible dose effect two 
experiments were executed in the F2 hybrid background, representing two viral doses: ~5.2x1011 
vg; ~6.0x1011 vg. Mice were randomly assigned to either miDnm1a treatment or control condition 
which included eGFP or saline administration; in analysis for simplicity the two control conditions 
were combined since they did not differ in effect. Thus, for analysis when modeling treated vs. 
control-injected groups we combined as covariates the two dose-experiments and sexes (using 
categorical indicator variables for each) and litter size. Cellular analysis was executed at PND 18, 
because that is the timepoint by which almost all untreated or control-injected mice become 
moribund, and PND 30, the endpoint of the study. For this study, we show three representative 
replicates for the cellular characterization of the effect of miDnm1a treatment.  
 
Animals and genotyping 
 C57BL/6J-Dnm1Ftfl-flox mice used for these studies (hereafter termed B6J-Dnm1Ftfl) were 
generated in Dnm1∆1a/∆1a mice by The Jackson Laboratory’s Genetic Engineering Technology core, 
introducing the Dnm1Ftfl mutation using CRISPR/Cas9. To generate interstrain F2 hybrid mice, 
B6J-Dnm1Ftfl/+ mice were mated to FVB/NJ females (JAX, Bar Harbor, ME, stock 004624), and 
F1 hybrid mice mated inter se. Mice were genotyped with a PCR protocol designed to detect the 
presence of loxP sites in the fitful allele. The genotyping primers (5’- 
CCTCTCTGTCCACTTGTAGCCATT -3’ and 3’- ACTGGGTGATGCTCACTAGAACCT – 5’) 
produce a 321 bp mutant allele and a 215 bp wildtype allele. Mice for this study were between 0 
and 30 days old. To identify individual pups, they were tattooed at PND 0 according to the AIMS 
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pup tattoo identification system (Budd Lake, NJ) using Ketchum Animal Tattoo Ink (Cat# 
329AA). Mice were also ear notched at PND 10. Post weaning at PND 21, mice had access to food 
and water in their home cages ad libitum. Pups were never separated from their home cage for 
more than 10 mins at a time. Lights were maintained on a 12 h light/dark cycle with behavioral 
testing occurring during the light portion of the cycle. All procedures were approved by Columbia 
University’s Institutional Animal Care and Use Committee and were performed in accordance with 
the National Institute of Health Guide for the care and use of laboratory animals.  
 
Dnm1a microRNA production and viral packaging 
 Four microRNA sequences potentially targeting Dnm1a were designed and cloned into a 
mir-30 based construct with expression driven by the U6 promoter, as previously 
described.(Wallace et al. 2012)(Wallace et al. 2012)(Wallace et al. 2012)(Wallace et al. 2012) 
Qualifying miRNAs had to be 22 nt long, with the first four and last four nucleotides  being at least 
75% GC rich and AU rich respectively. Additionally, the string of 22 nucleotides had to be 40% 
AU rich. miRNA specific targeting of Dnm1a capitalizes on the 42 nt difference between Dnm1a 
and Dnm1b. The full miRNA sequence is: 5’-
cucgagugagcgaaccaucagaaaguguagugaacuguaaagccacagauggguucacuacacuuucugauggugugccuac
uaga-3’. The antisense strand of the mature miRNA (red) binds Dnm1a mRNA. After in vitro 
testing, the lead candidate U6 miRNA was cloned into a self-complementary adeno associated 
viral vector and packaged as serotype 9 (scAAV9). Vectors contained a CMV driven eGFP 
reporter. scAAV9 vectors were generated and titered by the Harper lab and the Viral Vector Core 
at Nationwide Children’s Hospital.  
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Intracerebroventricular (ICV) injection of scAAV9-miDnm1a 
 For ICV delivery of scAAV9-miDnm1a, PND 0 mice were anesthetized using hypothermia 
by being placed on a chilled metal block until properly anesthetized.(Kim et al. 2014) The injection 
site was approximately 2/5th the distance from the lambda suture to each eye (Kim et al. 2014). All 
injections were executed free hand using a point style 4, 33-gauge needle and a 10µL or 25µL 
Hamilton syringe (Cat# 65460-06 and Cat# 65460-10) for escalating doses of scAAV9-miDnm1a. 
F2 mice were treated with ~ 5.2x1011 vg to 6.0x1011 vg per mouse based on the titers acquired. B6J 
mice were treated with varying doses (1x1010, 1.85x1011 and 3.25x1011 vg) which correspond to 
volumes of ~ 6-13µLs in an effort to establish possible dosage effects. Control scAAV9-eGFP 
injections were matched to miDnm1a dosage, and saline controls were matched to the volume of 
virus injected.  
 
In vivo quantification of transduction and Dnm1a knockdown 
 Dnm1+/+ mice were treated with miDnm1a or eGFP at PND 0. Whole brain was isolated 
from 6 eGFP and 8 miDnm1a injected mice at PND 14. The tissues were flash frozen with 2-
Methylbutane and stored at -80°C. Samples were homogenized using a dounce and RNA was 
isolated using TRIzol Reagent (ThermoFisher, Waltham, MA, Cat# 15596018). RNA was 
converted to cDNA using Invitrogen SuperScript III First-Strand Synthesis System (Carlsbad, CA, 
Cat# 18080051). Dnm1a knock down was assessed using the primers (5’-
CTCGCTTTTGAAGCCACAGT- 3’ and 3’-TTTCTGATGGTGGACGTGAG - 5’). Dnm1b 
expression was evaluated using the primers (5’- GGCCTTTGAAACCATTGTGA -3’, and 3’- 
GCACTGTCTAACCGTGCTGA - 5’). SYBRTM Select Master Mix (Applied Biosystems, 
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Waltham, MA, Cat# 4472903) was used for qPCR which was run using Applied Biosystems-Quant 
Studio 5.  
Pup developmental milestones and behaviors  
 Developmental milestones in pups are important readouts of developmental delays. To 
begin the test, each pup was gently removed from the nest and placed on a clean piece of bench 
protector. The cage lid was immediately and gently placed back, to reduce agitation in the nest. 
All assessment was completed by a deft experimenter within 3 min. At the end of the session, the 
pup was quickly returned to the nest. For all behaviors, mice from both groups (genotype x 
treatment) were handled every day from PND 4-12. On all even days (PND 4 to PND 12) they 
were weighed and on odd days (PND 5 to PND 11), they were assessed for strength and 
sensorimotor development. From PND 14 to PND 30 mice were weighed on every other day on 
even days. Testing was executed blind.  
Negative geotaxis 
 Mice are placed head down on a mesh screen set at a 45° angle. The latency for the pups 
to turn 90° (sideways) and 180° (heads up) from a downward facing start position was recorded 
(Feather-Schussler and Ferguson 2016; Yang et al. 2012; Hill, Lim, and Stone 2008). Mice were 
given 30 sec to perform the task and were allowed two attempts. Both attempts were averaged for 
the analysis.  
Vertical screen hold 
 To evaluate strength, mice were placed on a vertical mesh screen and their latency to fall 
off the screen was recorded. Mice were observed for 30 sec and were allowed two attempts to 
complete the task. The scores from both trials were averaged. Mice were tested at PND 9 and PND 
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11 because the average age of a rodent to perform this task is PND 8 (Feather-Schussler and 
Ferguson 2016). 
Open field 
 To quantify the ataxic phenotype, we observed PND 14 pups in the open field using the 
EthoVision XT video tracking software (Noldus). Mice were tested in a 28.5 cm arena with 
luminescence of 100 lux. Mice were recorded for 10 minutes. Videos were subsequently scored 
blind by counting the number of times each mouse wobbled or fell during movement over a 10-
min window. Mice that moved less than 100 cm were excluded. Additionally, distance travelled 
and velocity of each mouse was quantified.  
Growth and survival monitoring 
 Between PND 4 and PND 30, mice were weighed every other day. In addition, general 
health and survival were monitored every day from PND 0 to PND 30 (study endpoint).  
Seizure quantification 
 Each litter of pups were monitored for approximately 5 mins during weighing. Seizure 
activity was characterized by wild runs, Straub tail, vertical jumps that lasted more than 10 sec 
with subsequent facial grooming, continuous jerking of the forelimbs and hindlimbs and tonic-
clonic seizures. All seizures within the observation window were counted as one event. 
 
Histology 
 At least 3-5 mice from each group (genotype: Dnm1Ftfl/Ftfl and Dnm1+/+ X treatment: 
miDnm1a and eGFP) were perfused with 4% PFA for immunohistochemical assessment at PND 
18. We also evaluated Dnm1Ftfl/Ftfl miDnm1a mice surviving until PND 30 and Dnm1+/+ controls. 
All animals were handled in the same way prior to euthanasia. Brains were dissected from the skull 
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and postfixed in 4% PFA overnight at 4°C. Brains were transferred to gradient concentrations of 
sucrose (15% and 30%) overnight at 4°C. Once saturated, the brains were embedded in OCT 
(Fisher Healthcare Cat# 4585) and frozen. Free floating 40µm sections were collected using a 
cryostat (Leica CM3050S). The sections were permeabilized with 0.1% Triton X in PBS for 30 
minutes and blocked with 5% normal goat serum in PBS (blocking buffer) for 1 h at room 
temperature. Slices were incubated with either anti-NPY (1:500, ImmunoStar, Hudson, WI Cat# 
22940), anti-c-Fos (1:250, Abcam, Cambridge, UK, Cat# ab190289), anti-GFP (1:250, Invitrogen, 
Carlsbad, CA, Cat# A11120) or anti-GFAP (1:750, Sigma, Saint Louis, MO, Cat. # M4403) in 
blocking buffer overnight at 4°C. Afterwards, sections were washed in PBST for 10 min and 
incubated in AlexaFluor secondary 555 (1:1000, Thermo Fisher Scientific, Waltham, MA, Ref# 
A31428 and Ref# A32727) for 2 h at room temperature. Sections were incubated in DAPI for 5 
mins before washing with PBS. Sections were finally mounted on slides and cover slipped with 
Fluoromount-G (Southern Biotech, Birmingham, AL, Cat# 0100-01).  
 For FJC labeling, 3-5 PND 18 and PND 30 mice (genotype x treatment) were euthanized, 
and their brains dissected and flash frozen. 20µm thick sections were collected with a cryostat and 
mounted on gelatin coated slides (FD NeuroTechnologies, Inc. Columbia, MD, Cat# PO101). 
Sections were post fixed with 2% PFA and washed in PBS. Slides were air dried on a 50°C heating 
block for 20-30 mins and subsequently placed in 80% ethanol solution consisting of 1% NAOH 
for 5 mins. Slides were moved to 70% ethanol for 2 mins, rinsed in deionized water for 2 mins, 
incubated in 0.06% potassium permanganate in deionized water for 10 mins, rinsed for 2 mins in 
deionized water, and finally incubated in FJC working solution consisting of 0.0001% FJC in 0.1% 
acetic acid for 10 mins. Finally, slides were washed 3 times for 2 mins each in deionized water, 
air dried completely and cleared in xylene for at least 1 min before they were cover slipped with 
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mounting media (DPX, Saint Louis, MO, Cat# 06522) (Schmued et al. 2005). Slides were imaged 
using a Zeiss LSM-800 confocal microscope and Zen v2.3. Tiled images of 10X magnification 
were acquired of the hippocampus for each section keeping the laser and gain settings constant. 
For FJC, the Axio X-Cite series 120 Q epifluorescence microscope was used and images of 10X 
magnification were acquired. Post processing of images was carried out with Adobe Photoshop. 
All image processing was kept consistent.  
 
Quantification  
 IHC images were quantified blind using ImageJ (Fiji; nih.gov). Images were converted to 
8-bit and brightness and contrast keep constant. The cell counter plugin was used to count aberrant 
NPY and c-Fos positive cells in the whole hippocampal CA3 and to count FJC positive cells in the 
hippocampal CA1. GFAP fluorescence intensity was determined using the measure tool with the 
region of interest (ROI) in the CA1. Measurements were set to include area, min and max gray 
value and integrated density. For fluorescence intensity measurement, background intensity was 
collected. Relative fluorescence was calculated by first subtracting the integrated intensity of the 
background from the integrated intensity of the CA1 ROI to yield a background corrected intensity. 
Area was kept constant across all intensity measures. The corrected intensities of the wildtype 
control group was then averaged. Each corrected intensity was divided by the average of the 
wildtype control corrected intensity and multiplied by 100.  
 
Statistical analysis 
 Statistical analysis was done using either Prism 8 software (GraphPad, Inc), JMP 14 
software (JMP, Inc), depending on the test. qPCR data (Fig. 2.1) were analyzed using 2-way 
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ANOVA (Prism 8). Survival analysis for the pilot study (Supplemental Fig. 2.1) was analyzed 
using the log-rank Mantel-Cox test (Prism 8), and for the primary study (Fig. 2.2) the Proportional 
Hazards test with risk ratios was used to accommodate covariates (JMP 14). Growth 
(Supplemental Fig. 2.1, Fig. 2.2) was analyzed using repeated measures MANOVA (JMP). 
Seizure-like behaviors (Fig. 2.2) were analyzed using 2 x 2 Fisher Exact Test (JMP 14). Grip 
strength and negative geotaxis (Fig. 2.3) were analyzed using least squares regression after rank- 
and normal-quantile transformation of the data (JMP). Ataxia (counts of falls and wobbles) was 
analyzed using the log-Poisson test and contrast modeling to compare specific groups (JMP 14). 
IHC quantifications were analyzed using Poisson overdispersion option in the Generalized 















Chapter 3: Characterization of a Human DNM1 Middle Domain 
Variant Modelled in Mice 
3.1 Introduction  
 Until recently, the Dnm1Ftfl was the only published mouse model of DN DNM1 DEE. 
Although the fitful mutation rests in the functionally relevant middle domain that also houses 
various pathogenic human variants, it is a mouse-specific mutation with no human correlate. 
Indeed, there is a paucity of viable preclinical mouse models for missense DEE-causing mutations 
compared to the amount of known DEE causing genes (Wang and Frankel 2021). To address this 
need, and further our understanding of DNM1 DEE, and to perform more clinically relevant 
therapy approaches, we have generated the first mouse model which harbors a middle DNM1 
human variant (Dnm1G359A/+). To date, in the literature there are two patients with the G359 
mutations, eight patients with middle domain mutations, and thirty-four patients with DNM1 
mutations (H. Li et al. 2019). It is clear that the majority of patients with DNM1 mutations, have 
intractable seizures, severe to profound ID, are nonverbal and non-ambulatory, and show various 
abnormal EEG phenotypes, emphasizing the need for preclinical modeling and precision therapies 
(von Spiczak et al. 2017; H. Li et al. 2019; Kolnikova et al. 2018). The efficacy of RNAi-based 
therapeutic intervention at remedying both seizure and severe psychomotor impairments in the 
Dnm1Ftfl mouse model bodes well for the success of a similar therapeutic approach in Dnm1G359A/+ 
model.  Indeed, the success of this approach in the preclinical Dnm1G359A/+ human variant model 
would be of clinical significance, not just for DNM1 DEE but for other GOF and DN DEEs. 
 Prior studies in the Dnm1Ftfl mouse model had shown that the seizures, behavioral and 
neurological comorbidities caused by DNM1 may have different cellular etiology. Depletion of 
wildtype Dnm1 from GABAergic neurons in Dnm1Ftfl/+ mice led to one-hundred percent lethal 
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seizures by the fourth postnatal week. Additionally, eliminating wildtype Dnm1 and expressing 
only the Dnm1Ftfl mutation in parvalbumin (PV) positive inhibitory neurons, which make up forty 
percent of GABAergic neurons and include fast-spiking interneurons that play a major role in 
perisomatic inhibition of pyramidal (excitatory) neurons, led to early onset seizures that 
culminated in lethality by PND 50 (S. K. Asinof et al. 2015). In contrast, depletion of wildtype 
Dnm1 and expression of Dnm1Ftfl in forebrain excitatory neurons led to growth deficits, 
hyperactivity, altered posture, and repetitive behaviors. However, these mice were viable and 
fertile with normal lifespans (S. K. Asinof et al. 2015). These findings highlight the notion that 
addressing seizures alone may not be sufficient to prevent severe developmental impairments in 
DEEs, since both the seizures and developmental comorbidities are likely driven by the  effects of 
the pathogenic variants on different neuronal subpopulations.  Moreover, the severe seizure 
associated lethality beginning within the first two weeks of life in mice expressing the Dnm1Ftfl 
mutation, specifically in inhibitory neurons, is likely due to the importance of DNM1 at inhibitory 
synapses (Ferguson et al. 2007; Boumil et al. 2010). Indeed, while all neurons expressing the 
Dnm1Ftfl mutation at their synapses had larger and less frequent miniature and spontaneous 
excitatory and inhibitory post synaptic currents, evoked transmission was reduced only at 
inhibitory synapses onto excitatory neurons (McCabe et al. 2021). This data shows that a decrease 
in available synaptic vesicle pools could impair inhibition of excitatory neurons, and lead to 
seizures.  
 Using the Dnm1G359A-cKI  model of DNM1 DEE, our preliminary data show that global 
neuronal expression of G359A led to decreased birth weight, overall growth deficits, and early 
onset lethality in approximately forty-eight percent of mice. However, expression of G359A in 
GABAergic neurons using (Gad2Cre) led to significant growth deficits by PND 10, and early onset 
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lethal seizures. Finally, mice expressing G359A in excitatory neurons (Emx1Cre) did not show 
any overt behavioral phenotypes. These results are congruent with previously published data on 
the Dnm1Ftfl mouse specific mutant model, showing differential impact of Dnm1Ftfl on both 
neuronal subgroups (S. K. Asinof et al. 2015). Additionally, unlike the Dnm1Ftfl/Ftfl   mice which 
showed striking molecular phenotypes associated with seizure activity, the Dnm1G359A/+ mice did 
not have the same prominent molecular impact on neuronal integrity. This work lays the 
foundation for further exploration into the pathophysiology of DNM1 DEE and identifies 
physiological, and behavioral phenotypes with which to model future gene therapy approaches 
that address both seizure and developmental impairments.   
 
3.2 Results 
Dnm1G359A causes early onset lethality and growth deficits when expressed globally and in 
inhibitory neurons. 
 The Dnm1G359A conditional knock-in mice (cKI) were generated using a knockout first 
approach. First, wildtype exon six to eight were deleted. They were then replaced with a stop 
cassette between exon six and seven flanked by lox p sites immediately preceding the mutant exon 
eight, which harbors the G359A mutation. The stop cassette creates a null allele that is then deleted 
upon Cre administration to allow expression of mutant exon eight (Fig. 3.1A). Heterozygous 
conditional mice harboring one null allele and one wildtype allele were then crossed to mice 
expressing different Cre driver genes: Sox2Cre for global expression of G359A; Nestin Cre for 
neuron specific expression of G359A; Gad2Cre for inhibitory neuron specific expression of 
G359A; and Emx1Cre for excitatory neuron specific expression of G359A (Fig. 3.1A).  
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 To examine the effect of global expression of G359A (Sox2Cre: Dnm1G359A/+) mice were 
weighed and observed for overt behavioral abnormalities, seizures and survival. Sox2Cre: 
Dnm1G359A/+ mice showed significant growth deficits by PND 5 (p<0.0001; n=14) compared to 
control mice (n=20). However, surviving mice show growth improvement over time (Fig. 3.1B). 
This apparent difference early in postnatal development prompted us to determine the onset of 
these growth deficits. Subsequent weighing of pups at PND 1 identified the presence of significant 
growth deficits in Sox2Cre: Dnm1G359A/+ (n=9; p=0.016) compared to control mice (n=17; Fig. 
3.1C and Fig. 3.1D). This prompted the conclusion that early global expression of G359A caused 
decreased birth weight and growth deficits. Additionally, Sox2Cre: Dnm1G359A/+ expression led to 
early onset lethality starting at PND 11 in approximately forty-eight percent of mice (n=19; Fig. 
3.1H) and no overt seizure behavior was observed.  
 The incomplete penetrance of early onset lethality in Sox2Cre: Dnm1G359A/+ mice prompted 
the hypothesis that the Sox2Cre transgene might not be leading to complete recombination. Thus, 
we crossed heterozygous female mice to homozygous male Nestin-Cre mice. Unlike Sox2Cre 
which is expressed globally during development, Nestin-Cre is expressed specifically in neural 
progenitor cells that give rise to neurons and glia (Dahlstrand, Lardelli, and Lendahl 1995; 
Hendrickson et al. 2011). Mice expressing Nestin-Cre: Dnm1G359A/+ did not show the same early 
onset growth deficits observed in Sox2Cre: Dnm1G359A/+ mice (Fig. 3.1E). However, expression of 
Nestin-Cre: Dnm1G359A/+ led to significant growth deficits starting at PND 8 (n=10; p=0.010) 
compared to controls (n=6). Interestingly, expression of Nestin-Cre: Dnm1G359A/+ did not cause 
early onset lethality. Taken together, these data suggest that Nestin-Cre: Dnm1G359A/+ may not be 
causing early onset expression of G359A in key neuronal populations and Sox2Cre: Dnm1G359A/+ 
might better represent the expected outcomes for this model.  
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 Next, we sought to elucidate the contributions of neuronal subpopulations expressing 
G359A on disease phenotypes. Previous work in the fitful model showed that restriction of fitful 
to inhibitory neurons drove the lethal seizures, while restriction of fitful to excitatory neurons 
drove the associated comorbidities (S. K. Asinof et al. 2015). To explore this, we crossed female 
heterozygous conditional G359A mice to Gad2Cre (inhibitory neurons) and Emx1Cre (excitatory 
neurons; Fig. 3.1A) mice. Gad2Cre: Dnm1G359A/+ led to growth deficits that were significant at 
PND 10 (p=0.0052; n=16), and subsequent growth regression that coincided with the onset of 
lethal seizures by PND 11 (Fig. 3.1G, I). Gad2Cre: Dnm1G359A/+ also led to one hundred percent 
seizure lethality by PND 21 (n=16; n=30 control mice; Fig. 3.1H, I).  In contrast, Emx1Cre: 
Dnm1G359A/+ mice showed late onset growth deficits (p=0.0004) but did not show lethality, or any 
overt seizure activity (Fig. 3.1F, H). However, Emx1Cre: Dnm1G359A/+ mice showed significant 
weight differences at PND 28 (p=0.023), PND 40 (p=0.033), and PND 55 (p=0.0041). These data 
show that, as expected, inhibitory neurons drive the seizures and lethality in the DNM1 model of 
DEE.  
 Overall, expression of Sox2Cre: Dnm1G359A/+ and Gad2Cre: Dnm1G359A/+ had the most 
debilitating effect on growth and survival outcomes. 
 
 
scAAV9-miDnm1a is unsuccessful at rescuing severe phenotypes in Gad2Cre: Dnm1G359A/+ mice. 
 The success of scAAV9-miDnm1a at rescuing the severe disease phenotypes associated 
with the Dnm1Ftfl model presented in the previous chapter (Chapter 2), spurred the exploration of 
the efficacy of the same therapy, using the same constructs on a G359A model. Initial assessment 
of the Sox2Cre: Dnm1G359A/+ mice suggested early onset lethality at PND 11, which takes place 
before full viral expression at PND 14, eliminating the Sox2Cre: Dnm1G359A/+ model as a viable 
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option to assess the possible gene therapeutic benefits of scAAV9-miDnm1a. Of course, it is now 
clear, based on more data, that the lethality phenotype is not fully penetrant in the Sox2Cre: 
Dnm1G359A/+ mice, for reasons that we are still exploring. On the opposite spectrum, the Emx1Cre: 
Dnm1G359A/+ mice did not show any overt deficits with which to assess the possible benefits of 
gene therapy. Thus, we opted to test RNAi therapy in the Gad2Cre: Dnm1G359A/+ model. Postnatal 
intracerebroventricular (ICV) injection of scAAV9-miDnm1a at PND 0 in Gad2Cre: Dnm1G359A/+ 
did not significantly improve growth or survival outcomes (n=11; p>0.05) compared to untreated 
Gad2Cre: Dnm1G359A/+ controls (Fig. 3.2B, C). Of the eleven mice treated, only one mouse 
survived past PND 40 (Fig. 3.2C). With only mouse surviving past PND 40, it is difficult to 
determine if this was a true rescue, or a mutant mouse that naturally survives longer than most - a 
phenomenon that was observed, albeit very rarely in Dnm1Ftfl/Ftfl mice (W. Frankel, personal 
communication). To ensure that ineffectiveness of treatment was not due to an inactive virus, 
Gad2Cre: Dnm1G359A/+ mice were treated with scAAV9-miDnm1a and scAAV9-eGFP via ICV at 
PND 0, and then euthanized at PND 14. Between six and eight mice were injected in each group, 
and only four remained in each group at PND 14 for RNA analysis. Treated mice (n=4) showed 
significant knockdown of Dnm1a (p=0.0032) expression and no difference in Dnm1b expression 
(p>0.05) compared to eGFP controls (n=4; Fig. 3.2A). Taken together, these data suggest that 
Dnm1a-isoform specific knockdown will likely be of no effect in remedying disease phenotypes 
in the more severe G359A models.   
 
G359A may not cause overt structural abnormalities. 
 
 Molecular characterization of Dnm1Ftfl/Ftfl mice showed hippocampal cell death, gliosis, 
abnormal neuronal activation and aberrant neuronal metabolic activity, phenotypes consistent with 
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recurrent seizures (Aimiuwu et al. 2020). Thus, we sought to determine if G359A expression, both 
globally and in inhibitory neurons, led to similar molecular phenotypes. Here, we investigated the 
presence of gliosis via immunolabeling with glial fibrillary acidic protein (GFAP), and 
Neuropeptide Y (NPY) dysregulation in the hippocampi of Sox2Cre: Dnm1G359A/+ and Gad2Cre: 
Dnm1G359A/+ mice. Aberrant GFAP and NPY expression are known markers of seizures in epilepsy 
models. PND 10 was chosen as a timepoint to perform molecular assessments because lethality in 
the Sox2Cre: Dnm1G359A/+ and Gad2Cre: Dnm1G359A/+ models began at PND 11. At PND 10, there 
was no difference in GFAP or NPY expression in Sox2Cre: Dnm1G359A/+ (n=3) and Gad2Cre: 
Dnm1G359A/+ (n=3) mice compared to controls (n=3; Fig. 3.3A). Thus, hypothesizing that a later 
time point, especially in the Gad2Cre: Dnm1G359A/+ mice which showed seizures starting at PND 
11, would show more striking molecular phenotypes, we assessed Gad2Cre: Dnm1G359A/+ at PND 
18. Similar to the results observed at PND 11, there were no significant differences in GFAP and 
NPY expression in mutant mice at PND 18 (Fig. 3.3B).  Additionally, cell death and aberrant 
neuronal activation were not observed in brain slices from both Gad2Cre: Dnm1G359A/+ and 
Sox2Cre: Dnm1G359A/+ mice (data not shown). These data suggest that seizures caused by 















Figure 3.1. Dnm1G359A causes early onset lethality and growth deficits when expressed 
globally and in inhibitory neurons. A) Dnm1G359A conditional knock-in mouse construct and 
schematic showing the transgene cassette. Conditional mice were crossed to mice Cre recombinase 
in all cells (Sox2Cre), inhibitory neurons (Gad2Cre) and excitatory neurons (Emx1Cre). B) 
Sox2Cre: Dnm1G359A/+ mice (n=29) show growth impairments that is significant starting at PND 5 
compared to wildtype mice (n=51; overall p<0.0001; mixed-effects analysis). C) Sox2Cre: 
Dnm1G359A/+ mice (n=9) show significant differences (p=0.016; Mann-Whitney test) in growth as 
early as PND 1 compared to control mice (n=21). D) An image showing the significant growth 
impairment in Sox2Cre: Dnm1G359A/+ at PND 9, compared to wildtype mice. E) Nestin-Cre: 
Dnm1G359A/+ mice (n=10) significantly differ in growth compared wildtype (n=6) controls starting 
at PND 8  (p=0.010; overall p<0.0001; mixed-effects analysis with Geisser-Greenhouse correction 
followed by Šidák’s multiple comparisons test). F) Emx1Cre: Dnm1G359A/+ mice (n=22) show 
significant early onset growth deficits compared to controls (n=20) during the first month of life. 
However, they show a significant difference in weight at PND 28 (p=0.023), PND 40 (p=0.033), 
and PND 55 (p= 0.0041; overall p=0.0004; mixed-effects analysis with Geisser-Greenhouse 
correction followed by Šidák’s multiple comparisons test). G) Gad2Cre: Dnm1G359A/+ mice (n=16) 
show significant growth defects starting at PND 10 (p=0.0052) compared to wildtype mice (n=31; 
overall p<0.0001; mixed-effects analysis with Geisser-Greenhouse correction followed by Šidák’s 
multiple comparisons test). H) Survival curve comparing G359A heterozygous mice to wildtype 
control. Sox2Cre: Dnm1G359A/+ (n=9 dead; n=10 alive; p<0.0001; Log-rank (Mantel-Cox) test); 
Gad2Cre: Dnm1G359A/+ (n=16 dead; p<0.0001; Log-rank (Mantel-Cox) test); Emx1Cre: 
Dnm1G359A/+ (n=21 alive; p>0.99); Dnm1+/+ (n=30 alive). I) Representative image showing lethal 























Figure 3.2. scAAV9-miDnm1a is unsuccessful at rescuing severe phenotypes in Gad2Cre: 
Dnm1G359A/+ mice A) Revalidation of scAAV9-miDnm1a post PND 0 ICV injection shows 
significant knockdown of Dnm1a at PND 14 (p=0.0032) compared to eGFP control. miDnm1a did 
not affect Dnm1b expression (p=0.91; 2-way ANOVA followed by Šidák’s multiple comparisons 
test). B) Growth of G359A/+ miDnm1a treated mice did not significantly differ from G359A/+ 
untreated controls (p>0.05; mixed-effects model with Geisser-Greenhous correction followed by 
Tukey’s multiple comparisons test). C) miDnm1a treatment did not significantly improve survival 










Figure 3.3. G359A did not lead to overt neuronal structural abnormalities A) Sox2Cre: 
Dnm1G359A/+ (n=3) and Gad2Cre: Dnm1G359A/+ (n=3) mice do not show aberrant NPY of GFAP 
expression in the hippocampus of PND 10 mice compared to wildtype controls in preliminary 
molecular assessment. B) At PND 18, Gad2Cre: Dnm1G359A/+ still do not show molecular evidence 
of seizure activity based on GFAP and NPY expression compared to wildtype. Scale bars 




Here, we performed preliminary examination of the first DNM1 DN human variant 
modelled in mice (Dnm1G359A). The G359A variant rests in the middle the middle domain of 
DNM1, and causes severe DEE associated with intractable seizures, severe to profound DD, ID, 
lack of speech and hypotonia (von Spiczak et al. 2017). We showed that expressing G359A in all 
neuronal cells led to early onset lethality and growth deficits. Additionally, while inhibitory neuron 
specific expression of G359A culminated in growth deficits, and lethal seizures, mice expressing 
G359A in excitatory neuron did not show any overt phenotypes. Also, G359A did not visibly 
impact neuronal integrity based on the markers assessed, but might decrease neuronal response to 
stimulation. Finally, scAAV9-miDnm1a proved ineffective at remedying growth deficits and 
extending survival in Gad2Cre: Dnm1G359A/+ mice.  
 The incomplete lethality phenotype observed in Sox2Cre: Dnm1G359A/+ mice poses a 
conundrum. For one, based on the work on the fitful model, we hypothesized that pan neuronal 
expression of G359A would be even more severe. However, this was not observed. Additionally, 
driving pan neuronal expression of G359A with a different Cre driver (Nestin-Cre), showed an 
even less severe phenotype and failed to help us ascertain and validate the Sox2Cre model. Indeed, 
the Nestin-Cre mice used in this experiment were previously shown to be insufficient for directing 
recombination in early embryonic  neural progenitor cells since Nestin-Cre expression only 
reaches sufficiently high levels during late embryonic and early postnatal periods (Liang, 
Hippenmeyer, and Ghashghaei 2012). This lag in Nestin-Cre driven expression of G359A could 
be responsible for the later onset growth deficits and the absence of lethality observed. Although 
Sox2Cre: Dnm1G359A/+ show variable lethality, all mice in this model show significant early onset 
growth deficits, and lethality thus far, has not been observed to correlate with weight, which 
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possibly serves as an indication that the observed lethality phenotype is not due to insufficient 
recombination. 
 If the incomplete lethality phenotype observed in Sox2Cre: Dnm1G359A/+ is later validated, 
it will suggest that G359A present in all neurons, and neuronal subtypes alters the mechanism of 
pathogenesis.  To this end, to understand the molecular impact of each model, future studies could 
assess the transcriptomic changes caused by global neuronal, and subtype specific expression of 
G359A. Additionally, these models will benefit from more behavioral and seizure characterization. 
While seizures were observed in Gad2Cre: Dnm1G359A/+ mice, they were not observed in Sox2Cre: 
Dnm1G359A/+ mice. Given that these mice live past PND 40, electroencephalographic recordings 
could be performed to assess seizure activity, providing another means through which to evaluate 
future therapeutic interventions.  
 The difference in the severity of observed phenotypes between Gad2Cre: Dnm1G359A/+ and 
Emx1Cre: Dnm1G359A/+ further reinforce previously established data and show that the human 
DNM1 variants work in a similar mechanism as the Dnm1Ftfl mouse specific variant (S. K. Asinof 
et al. 2015). However, the observed late onset growth deficits in the Emx1Cre: Dnm1G359A/+ mice 
indicates an effect of G359A on growth later in life and is in line with prior data on the fitful model 
which suggests that excitatory neuron expression of fitful leads to some behavioral abnormalities 
(S. K. Asinof et al. 2015). Thus, continuing growth assessments, and performing behavioral 
assessments could enable better understanding of the Emx1Cre: Dnm1G359A/+ mice. 
 The absence of gliosis and aberrant NPY expression in G359A mice suggests that 
Dnm1G359A/+ might not cause the molecular phenotypes previously characterized in the Dnm1Ftfl/Ftfl 
model. This could be explained by the presence of a wildtype copy of Dnm1 in the G359A 
heterozygous model. The presence of Dnm1Ftfl mutation in both alleles of the Dnm1a isoform, the 
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predominant postnatal isoform, is likely the reason such severe neuronal phenotypes were 
observed. Thus, the difference in molecular phenotypes between the two models comes down to 
“mutant gene dosage.” Indeed, previous molecular assessment of Dnm1Ftfl/+ heterozygous mice 
brain slices did not show the hippocampal cell death phenotype characteristic of homozygous 
Dnm1Ftfl/Ftfl mice. However, this phenotype may take longer to develop in the G359A model and 
the surviving Sox2Cre: Dnm1G359A/+ mice provide an avenue with which to access the long-term 
effect of G359A on neuronal stability. While we observed some preliminary qualitative differences 
between G359A heterozygotes and wildtype mice in LFP recordings, these results need further 
validation. Future work could focus on the quantitative analysis of the acquired data, as well as 
increasing the sample sizes of each group. The absence of severe molecular impairments in the 
hippocampus would enable a better assessment of the physiological impact of G359A. However, 
we established that LFP analysis could serve as a viable physiological correlate for future 
therapeutic rescue.  
  In conclusion, Dnm1G359A/+ represents a viable model of DNM1 DEE, that 
replicates key disease defining phenotypes. This model provides an avenue for assessing future 
therapeutic approaches that aim to improve the quality of life of patients with dominant negative 
DEEs.  
3.4 Materials and Methods 
Animals and genotyping  
 Dnm1G359A-cKI mice were generated by Leveragen, Inc (Boston, MA) Mice were created by 
inserting a floxed gene trap cassette in front of the target exon, while replacing the target exon 
with the engineered mutant exon. This approach creates a knockout allele prior to Cre mediated 
deletion of the gene trap cassette and expression of the mutated exon. Dnm1G359A/cKI mice where 
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then crossed to various Cre strains (Sox2Cre, Gad2Cre, Emx1Cre, Nestin-Cre, JAX, Bar Harbor, 
ME) to generate Dnm1G359A/+ mice which were used for the experiments. Mice were genotyped 
using primers designed to detect the neomycin = resistance sequence in the gene trap cassette and 
to assess for Cre-mediated recombination. The genotyping primers were: (forward: 5’- 
ACCGCTTCCTCGTGCTTTAC-3’ and reverse: 5’- TTCTGACAGGAGCCAGGAAT-3’ 
producing an 826 bp product only present in the conditional animals) and (forward: 5’- 
TCTGCGACACCACTCTATGAAAA -3’ and reverse: 5’- 
CCGAATCAATATGCCATAGCTCA- 3’ producing a 282 bp wildtype product, a 2549 bp mutant 
product, and a 337 bp product after recombination). Mice for this study were between 0 and 60 
days old. To identify individual pups, they were tattooed at PND 0 according to the AIMS pup 
tattoo identification system (Budd Lake, NJ) using Ketchum Animal Tattoo Ink (Cat# 329AA). 
Mice were also ear notched at PND 10. Post weaning at PND 21, mice had access to food and 
water in their home cages ad libitum. Pups were never separated from their home cage for more 
than 10 mins at a time. Lights were maintained on a 12 h light/dark cycle with behavioral testing 
occurring during the light portion of the cycle. All procedures were approved by Columbia 
University’s Institutional Animal Care and Use Committee and were performed in accordance with 
the National Institute of Health Guide for the care and use of laboratory animals. 
Intracerebroventricular (ICV) injection of scAAV9-miDnm1a 
 For ICV delivery of scAAV9-miDnm1a, PND 0 mice were anesthetized using hypothermia 
by being placed on a chilled metal block until properly anesthetized.(Kim et al. 2014) The injection 
site was approximately 2/5th the distance from the lambda suture to each eye.(Kim et al. 2014) All 
injections were executed free hand using a point style 4, 33-gauge needle and a 10 L or 25 L 
Hamilton syringe (Cat# 65460-06 and Cat# 65460-10) for escalating doses of scAAV9-miDnm1a. 
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F2 mice were treated with ~ 5.2x1011 vg to 6.0x1011 vg per mouse based on the titers acquired. B6J 
mice were treated with varying doses (1x1010, 1.85x1011 and 3.25x1011 vg) which correspond to 
volumes of ~ 6-13µLs in an effort to establish possible dosage effects. Control scAAV9-eGFP 
injections were matched to miDnm1a dosage, and saline controls were matched to the volume of 
virus injected.  
In vivo quantification of transduction and Dnm1a knockdown 
 Dnm1+/+ mice were treated with miDnm1a or eGFP at PND 0. Whole brain was isolated 
from 6 eGFP and 8 miDnm1a injected mice at PND 14. The tissues were flash frozen with 2-
Methylbutane and stored at -80 C. Samples were homogenized using a dounce and RNA was 
isolated using TRIzol Reagent (ThermoFisher, Waltham, MA, Cat# 15596018). RNA was 
converted to cDNA using Invitrogen SuperScript III First-Strand Synthesis System (Carlsbad, CA, 
Cat# 18080051). Dnm1a knock down was assessed using the primers (5’-
CTCGCTTTTGAAGCCACAGT- 3’ and 3’-TTTCTGATGGTGGACGTGAG - 5’). Dnm1b 
expression was evaluated using the primers (5’- GGCCTTTGAAACCATTGTGA -3’, and 3’- 
GCACTGTCTAACCGTGCTGA - 5’). SYBRTM Select Master Mix (Applied Biosystems, 
Waltham, MA, Cat# 4472903) was used for qPCR which was run using Applied Biosystems-Quant 
Studio 5.  
Growth and survival assessments 
 Between PND 5 and PND 60, mice were weighed frequently. In addition, general health 
and survival were monitored every other day from PND 0 to PND 60 (study endpoint).  
Histology  
 Three mice per group (Sox2Cre: Dnm1G359A/+, Gad2Cre: Dnm1G359A/+ and Dnm1+/+) were 
perfused with 4% PFA for immunohistochemical assessment at PND 10 and PND 18 (Gad2Cre: 
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Dnm1G359A/+ and Dnm1+/+ only). All animals were handled in the same way prior to euthanasia. 
Brains were dissected from the skull and postfixed in 4% PFA overnight at 4 C. Brains were 
transferred to gradient concentrations of sucrose (15% and 30%) overnight at 4 C. Once saturated, 
the brains were embedded in OCT (Fisher Healthcare Cat# 4585) and frozen. Free floating 40 m 
sections were collected using a cryostat (Leica CM3050S). The sections were permeabilized with 
0.1% Triton X in PBS for 30 minutes and blocked with 5% normal goat serum in PBS (blocking 
buffer) for 1 h at room temperature. Slices were incubated with either anti-NPY (1:500, 
ImmunoStar, Hudson, WI Cat# 22940), anti-c-Fos (1:250, Abcam, Cambridge, UK, Cat# 
ab190289), anti-GFP (1:250, Invitrogen, Carlsbad, CA, Cat# A11120) or anti-GFAP (1:750, 
Sigma, Saint Louis, MO, Cat. # M4403) in blocking buffer overnight at 4 C. Afterwards, sections 
were washed in PBST for 10 min and incubated in AlexaFluor secondary 555 (1:1000, Thermo 
Fisher Scientific, Waltham, MA, Ref# A31428 and Ref# A32727) for 2 h at room temperature. 
Sections were incubated in DAPI for 5 mins before washing with PBS. Sections were finally 
mounted on slides and cover slipped with Fluoromount-G (Southern Biotech, Birmingham, AL, 
Cat# 0100-01).  
Statistical analysis 
 Statistical analysis was done using Prism 9 software (GraphPad, Inc).  Growth was 
analyzed using mixed-effects analysis with Geisser-Greenhouse correction followed by Šidák’s 
multiple comparisons test (Fig. 3.1 and Fig. 3.2). Survival analysis was performed using the Log-
rank (Mantel-Cox) test (Fig. 3.1 and Fig. 3.2). PND 1 growth of Sox2Cre: Dnm1G359A/+  mice were 
analyzed using the Mann-Whitney test (Fig. 3.1). qPCR data (Fig. 1) were analyzed using 2-way 
ANOVA. 
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Chapter 4: Kcnq3 Gain-of-Function Mouse Model: Molecular, 
Seizure and Behavioral Phenotypes 
4.1 Introduction 
 KCNQ3 encodes the voltage-gated potassium channel Kv7.3. Along with its heteromeric 
partner KCNQ2 (Kv.7.2), underlies the M-current which regulates neuronal excitability and is 
critical for postnatal brain development and cognitive performance (Nappi et al. 2020; Peters et al. 
2005). KCNQ3 contains six transmembrane segments (S1-S6), and cytoplasmic N- and C- termini. 
The first four segments (S1-S4) serve as the voltage sensing domain (VSD), with the S4 segment 
containing a series of arginines that regulate channel gating (Nappi et al. 2020; Sands et al. 2019). 
Missense mutations in KCNQ3 cause a spectrum of neurodevelopmental impairments ranging 
from severe LOF to severe GOF, with inherited LOF variants causing benign familial neonatal 
seizures (BFNS), a self-limiting epilepsy with normal psychomotor development in most cases 
(Nappi et al. 2020; Sands et al. 2019). In contrast, de novo GOF missense mutations – specifically 
in the outermost two arginines of the S4 segment (R1: R227Q; R2: R230C/S/H) – cause severe 
neurodevelopmental diseases which have been described in eleven patients to date (Nappi et al. 
2020; Sands et al. 2019). Patients with the R1 and R2 variants were identified by epilepsy gene 
panel or whole exome sequencing, and all patients had some degree of intellectual disability (ID) 
and developmental delay (DD) reported between the ages of four and eighteen months of age 
(Sands et al. 2019). Additionally, all patients showed a delay in speaking, that often occurred 
concurrently or preceding gross motor delays (Sands et al. 2019).  Forty-five percent of the patients 
were diagnosed with autism-spectrum disorder (ASD); sixty-four percent with hypotonia and 
strabismus; seventy-three percent had focal or multifocal spikes during sleep, of which sixty-seven 
percent had electrical status epilepticus during sleep (ESES) – an EEG pattern characterized by 
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focal and multifocal spike waves that frequently occurs during non-rapid eye movement (NREM) 
sleep (Sands et al. 2019; Gong et al. 2021). Additionally, approximately sixty-four percent (6 of 
11) of patients did not show clinical seizures; twenty seven percent (3 of 11) were reported to have 
staring spells; and eighteen percent (2 of 11) presented with generalized-tonic clonic, atonic and 
absence seizures (Sands et al. 2019).  
 KCNQ3 GOF mutations stabilize the resting VSD configuration by forming electrostatic 
interactions with neighboring negatively charged residues thereby causing constitutive channel 
activation (Nappi et al. 2020). Specifically, the substitution of R2 with mostly uncharged histidine 
(H) and cysteine (C) residues preferentially weaken the stability of the resting, fully deactivated 
VSD state in favor of the activated state (Miceli et al. 2015). Functional analysis of the R1 and R2 
mutants in vitro showed increased current density and loss of voltage dependence, consistent with 
a constitutively activated channel (Sands et al. 2019). It is accepted that suppression of M-currents 
increases neuronal excitability, and activation of M-currents reduces neuronal excitability (Nappi 
et al. 2020). Indeed, most patients with GOF KCNQ3 mutations, unlike those with LOF mutations, 
do not have seizures (only two out of the eleven patients in the cohort were diagnosed with 
generalized tonic-clonic seizures, atonic seizures and absence seizures). However, most patients 
do show ESES (an EEG phenotype), implicating an alternative mechanism through which GOF 
mutations lead to hyperexcitability and cognitive impairments (Sands et al. 2019). Recently, 
increased excitability was found in pyramidal neurons with KCNQ3 GOF mutations, indicating 
the contribution of complex alternative network properties on the neuronal hyperexcitability 
observed in KCNQ3 GOF mutations (Miceli et al. 2015). Therefore, suppressing or enhancing M-
current can trigger epileptogenesis by a distinct pathophysiological mechanism that involves the 
subcellular locations of the M-channels (Miceli et al. 2015). Regardless, GOF mutations cause 
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neurodevelopment impairments with a severe clinical course. Due to the rarity of KCNQ3 GOF 
mutations (eleven patients reported thus far), and the severe clinical course of the disease, there is 
a need to fully characterize and identify precision therapies for this rare but severe DEE.  
 To address this need, we have generated a Kcnq3 GOF mouse model harboring the R231H 
mutation in the C57BL6/J background. The R231H mutation is orthologous to the R230H GOF 
human variant. In this mouse model of KCNQ3 GOF disorder, we observe that mice harboring the 
R231H variant show spike-wave discharges, decreased maximal seizure threshold, and a trend 
towards increased anxiety-like behaviors. Finally, on a molecular level, R231H significantly 
increases the membrane expression of Kcnq3. These data establish the first steps towards 
replicable phenotypes with which to access rescue. More work beyond the scope of this 
dissertation is underway, exploring the physiological impact of R231H and piloting an RNAi-
based gene therapy. 
 
4.2 Results 
R231H causes seizure activity and increases Kcnq3 expression at neuronal membranes 
 Gain-of-function (GOF) mutations in KCNQ3 cause focal and multi-focal spikes during 
sleep in a majority of patients (Gong et al. 2021; Sands et al. 2019). To determine the seizure 
phenotype in the Kcnq3R231H/+ mouse model of KCNQ3 DEE, electroencephalographic (EEG) 
recordings and electroconvulsive seizure threshold (ECT) testing were performed. Kcnq3R231H/+ 
mice showed significant spike wave discharges (SWDs) that were absent in Kcnq3+/+ mice (n=3-
4) both in the F1 hybrid (FVB 1800 X C57BL6/J-Kcnq3R231H/+; p=0.016; n=7) and original 
C57BL6/J (p=0.023; n=6) backgrounds (Fig. 4.1A, Supplemental Fig. 4.1A). Additionally, while 
there was an insignificant difference in the number of SWD events in Kcnq3R231H/+ from the F1 
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hybrid background (n=6-7) during the day time compared to night time (p>0.05), there was, 
however, a significant difference in the C57BL6/J background, with both heterozygous and 
homozygous R231H mice showing significantly more SWDs at night, based on an examination of 
EEG recordings alone (Supplemental Fg.4.1B, C). Interestingly, Kcnq3R231H/R231H mice in the 
C57BL6/J background (n=6) showed significantly more SWDs than Kcnq3R231H/+ (p=0.0061) and 
Kcnq3+/+ (p<0.0001) mice (Supplemental Fig. 4.1A). ECT testing of FI hybrid mice showed a 
significant decrease in maximal seizure threshold (model for generalized tonic-clonic seizures) in 
Kcnq3R231H/+ male (n=10; p=0.033) and female (n=6; p<0.0001) mice compared to Kcnq3+/+ male 
(n=8) and female (n=9) controls (Fig 4.1B).  However, there were no significant differences 
between Kcnq3R231H/+ and Kcnq3+/+ in the psychomotor limbic seizure 6 Hz test and the minimal 
seizure (clonic jaw and forelimb seizures) ECT tests (Supplemental Fig 4.1D, E). Together, these 
data suggest that the Kcnq3R231H/+ GOF mutation causes neuronal imbalances that lead to seizure 
activity.  
 Given the impact of the R231H mutation on seizure activity and susceptibility, we 
investigated the molecular effect of the R231H GOF mutation on the RNA and protein expression 
of Kcnq3 and its heteromeric partner Kcnq2, through reverse-transcription quantitative-PCR (RT-
qPCR) and western blotting of whole brain tissue. RNA analysis showed no significant differences 
(p>0.05) in Kcnq3 or Kcnq2 expression between Kcnq3R231H/+ (n=9) and Kcnq3+/+ (n=9) mice (Fig 
4.1C). Congruently, there was also no difference in total protein expression of Kcnq3 (Kv7.3) or 
Kcnq2 (Kv7.2) between both groups (n=5-9 mice; p>0.05; Fig.4.1D, E). However, there was a 
significant difference in Kcnq3 (p=0.025) but not Kcnq2 (p>0.05) expression in crude membrane 
extracts from Kcnq3R231H/+ mice compared to Kcnq3+/+ mice (Fig. 4.1F, G). These results suggest 
that R231H mutation alters the membrane expression of Kcnq3.  
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 Overall, R231H caused SWDs, decreased maximal seizure threshold and resulted in 
aberrant membrane expression of Kcnq3.  These results establish the R231H mouse model of 
KCNQ3 DEE as a viable model to understand the electroclinical and molecular impact of KCNQ3 
GOF mutations.  
 
R231H does not significantly impair developmental outcomes but may increase anxiety-like 
behavior observed in adult mice 
 Given the importance of KCNQ3 in postnatal brain development and cognitive 
performance, it is not surprising that GOF mutations cause DD, ID, speech delays, motor deficits 
and ASD in patients (Sands et al. 2019; Nappi et al. 2020; Peters et al. 2005). To identify the 
possible behavioral correlates in the R231H mouse model, pup developmental milestones and adult 
behavioral assays were executed. To determine if R231H altered pup neurodevelopment, growth 
and ultrasonic vocalizations were assessed. Growth monitoring on alternate days from PND 4 to 
PND 10 showed no differences (p>0.05) in growth between Kcnq3R231H/+ (n=17) mice compared 
to Kcnq3+/+ (n=15) mice (Fig. 4.2A). The USV assay measures the innate ability in pups to 
communicate with their mothers in order to elicit retrieval and maternal care. As such, it can be 
used to assess abnormal neurodevelopmental phenotypes in mice that are loosely akin to ASD and 
speech deficits (Premoli et al. 2019). USVs were recorded on alternated days from PND 4 to PND 
10. There was no overall significant difference (p>0.05) between the total number of vocalization 
over a three-minute recording interval between Kcnq3R231H/+ (n=17) and Kcnq3+/+ (n=15) mice 
from PND 4 to PND 10 (Fig. 4.2B).  However, Kcnq3R231H/+ mice showed a nominal (p=0.03) 
decrease in vocalizations at PND 4 (corrected p-value=0.06), indicating possible delay in 
vocalizations. Additionally, further qualitative in-depth analysis of vocalizations were performed 
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to assess vocalization duration, interval, peak frequency and peak amplitude. There were no overall 
significant differences (p>0.05) observed in these parameters between Kcnq3R231H/+ (n=17) and 
Kcnq3+/+ (n=15) mice. An exception: Kcnq3R231H/+ mice showed significantly decreased 
vocalization duration at PND 4 (p=0.03; Fig. 4.2C), and significantly increased peak amplitude 
(p=0.03) at PND 10 compared to Kcnq3+/+ mice (Fig. 4.2F). Taken together, these results indicate 
that R231H may not significantly impact neurodevelopmental milestones associated with innate 
vocalizations and growth.  
 To examine the impact of R231H on adult behavioral phenotypes, the open-field, elevated-
plus maze (EPM), fear conditioning, Y-maze and catwalk assays were performed. The open field, 
EPM, and fear conditioning assays were conducted using two different cohorts of mice, to assess 
replicability and to increase power. In the open field assay which measures ambulatory, 
exploratory and anxiety-like behaviors in mice, we observed no overall significant differences in 
ambulatory distance travelled (p>0.05), and rearing (exploratory) behavior, between Kcnq3R231H/+ 
(n=26) mice compared to Kcnq3+/+ (n=25) mice (Fig. 4.3A, B), when both cohorts were combined. 
However, initial assessment of ambulatory distance travelled in the first cohort of mice showed 
significant overall differences (p=0.0038) between Kcnq3R231H/+ (n=15) and Kcnq3+/+ (n=15) mice 
(Supplemental Fig. 4.2A).  This significantly decreased ambulatory distance was not observed in 
the second cohort of mice (p>0.05) and in fact, Kcnq3R231H/+ mice (n=11) tended to ambulate more 
than Kcnq3+/+ (n=10) mice (Supplemental Fig. 4.2B). Additionally, Kcnq3R231H/+ (n=26) mice 
spent significantly less time at the center of the open field box (p=0.024) compared to Kcnq3+/+ 
(n=25) mice when both cohorts were combined (Fig. 4.3C, D). Specifically, Kcnq3R231H/+ mice 
spent significantly less time at the center of the open field box during the first twenty minutes 
(p=0.0020 and p=0.0044 respectively) of the hour-long assay, indicating an increase in anxiety-
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like behavior, likely caused by the novel environment. While the decrease in center time observed 
in Kcnq3R231H/+ mice did not reach significance levels in the second cohort of mice (p>0.05; 
Supplemental Fig. 4.2A, B), as was observed in the first cohort of mice, combining both cohorts 
yielded a stronger significance value and reinforced initial observations.  
Next, in the EPM assay which assesses anxiety-like behavior, Kcnq3R231H/+ mice (n=26) 
did not significantly (p>0.05) differ from Kcnq3+/+ mice (n=24) in the amount of time spent in the 
open arms or the amount of time spent in the closed arms or the apparatus. Although, Kcnq3R231H/+ 
mice showed a trend towards increased time spent in the closed arm (p=0.1), an indication of 
possible anxiety-like behavior (Fig. 4.3E). Like the open field ambulatory distance travelled 
assessment, both cohorts of mice in the EPM assay showed conflicting results. In the first 
experimental cohort, Kcnq3R231H/+ mice (n=15) spent significantly more time (p=0.0023) in the 
closed arms and significantly less time (p=0.0069) in the open arms of the apparatus compared to 
Kcnq3+/+ mice (n=14; Supplemental Fig. 4.2C). However, data from the second experimental 
cohort did not show significant differences (p>0.05) between the groups; in fact, Kcnq3R231H/+ mice 
tended to spend more time in the open arms of the apparatus compared to Kcnq3+/+ mice (n=10; 
Supplemental Fig. 4.2D). 
 To determine the impact of R231H on associative learning and memory, the delay fear 
conditioning assay was utilized. Before the fear conditioning assay, the acoustic startle response 
(ASR) assay was performed which measures the reflexive muscular activity mice elicit in response 
to sudden loud sounds. In the ASR assay, Kcnq3R231H/+ mice did not significantly differ (p>0.05) 
from Kcnq3+/+  mice in startle amplitude.  Additionally, the ability of Kcnq3R231H/+ mice to produce 
stronger startle amplitudes in response to higher sound intensities, meant that Kcnq3R231H/+ mice 
had no gross hearing defects that might confound the fear conditioning data (Fig. 4.3G). During 
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the fear conditioning assay, Kcnq3R231H/+ mice (n=26) froze significantly more than Kcnq3+/+ mice 
(n=25) during the post-training (p<0.0001), contextual (p=0.0042), and cued (p=0.010) portions 
of the fear conditioning assessment (Fig. 4.3F; Supplemental Fig. 4.2E, F). However, like the open 
field and EPM assays, these data were pooled from two different cohorts of mice. While 
Kcnq3R231H/+ (n=15) mice from the first cohort froze significantly more than Kcnq3+/+ mice (n=15) 
during the post-training (p<0.0001), contextual (p=0.0008), and cued (p=0.023) portions of the 
fear conditioning assessment, the second cohort of mice only showed similar trends (Supplemental 
Fig. 4.2E, F).  Further tests of memory processes in R231H mice, through the Y-Maze spontaneous 
alternations (spatial working memory/short term memory) and Y-Maze novel arm (recognition 
memory) assays showed no significant differences (p>0.05) between Kcnq3R231H/+ (n=10) and 
Kcnq3+/+ (n=7) mice (Fig. 4.3H, I). Interestingly, in the novel arm assay, Kcnq3R231H/+ mice spent 
significantly less time (p=0.008) than their Kcnq3+/+ counterparts in the center of the Y-Maze 
apparatus, a similar occurrence to what was previously observed during the first twenty minutes 
of the open field assay. Finally, given that KCNQ3 GOF patients show motor deficits (Sands et al. 
2019), we explored the impact of R231H on motor function using the Catwalk assay (Supplemental 
Fig. 4.3). Some of the parameters assessed included print area, stride length, print position, 
cadence, step cycle and percent maximum variation. Only the percent maximum variation 
(maximum change in speed) readout was significant (p=0.025). In general, Kcnq3R231H/+ (n=10) 
mice did not strikingly differ from Kcnq3+/+ (n=7), indicating an absence of gross motor deficits 
in Kcnq3R231H/+ mice based on this preliminary assessment. 
 Overall, R231H mutation did not cause significant neurodevelopmental deficits, nor did it 
severely alter adult behavioral phenotypes. However, Kcnq3R231H/+ mice showed a trend towards 
increased anxiety-like behavior and a heighted fear response based on the assays examined.  
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Fig. 4.1. R231H causes seizure activity and increases Kcnq3 expression at neuronal 
membranes. A) SWD quantification in F1 hybrid mice over a 24-hour recording period during 
the windows 9 pm-3 am and 9 am-3 pm show significant differences at PND 46 (p=0.016; Mann-
Whitney test) between Kcnq3R231H/+ (n=7) and Kcnq3+/+ (n=3). B) Maximal ECT in F1 hybrid mice 
showing significant differences between males and females from both genotypes (p=0.033 and 
p<0.0001 respectively; Šidák’s multiple comparisons test).  C) QPCR analysis of Kcnq3 and 
Kcnq2 RNA expression show no differences (p>0.05; Šidák’s multiple comparisons test) between 
Kcnq3R231H/+ (n=9) and Kcnq3+/+ (n=9). D) Representative image of SWDs seen in Kcnq3R231H/+ 
mice. E, F) Representative blots showing the total protein expression of Kcnq3 and Kcnq2 
between both genotypes (p>0.05; Šidák’s multiple comparisons test). G, H) Representative blots 
and quantification showing a significant increase (p=0.025; Šidák’s multiple comparisons test) in 
Kcnq3 membrane protein between Kcnq3R231H/+ (n=7) and Kcnq3+/+ (n=7), but no difference in 




Fig. 4.2. R231H does not significantly impair developmental behaviors A) Kcnq3R231H/+ (n=17) 
and Kcnq3+/+ (n=15) do not significantly differ in growth from PND 4 to PND 10 (p>0.05; Šidák’s 
multiple comparisons test). B) There is no overall significant difference (p>0.05; 2-way ANOVA 
followed by Tukey’s multiple comparisons test) between Kcnq3R231H/+ (n=17) and Kcnq3+/+ (n=15) 
in the number of vocalizations emitted during the three-minute recording period.  C) There is a 
significant decrease in the duration of vocalizations emitted by Kcnq3R231H/+ compared to Kcnq3+/+ 
mice at PND 4 (p= 0.039; Tukey’s multiple comparisons test), however, there are no significant 
differences in duration overall (2-way ANOVA). Kcnq3R231H/+ and Kcnq3+/+ do not show 
significant differences in vocalization interval (D) or peak frequency (E) during the testing period 
(p>0.05; 2-way ANOVA). F) Kcnq3R231H/+ mice show a significant difference in peak amplitude 
at PND 10 (p= 0.036; Tukey’s multiple comparisons test), however, there is no overall significant 













Fig. 4.3. Kcnq3R231H/+ mice show a trend towards increased anxiety-like behavior and fear 
response. In the open field assay, Kcnq3R231H/+ mice (n=26) showed no significant difference in 
(p>0.05) ambulatory distance (A), no difference (p>0.05) in rearing or exploratory behavior (B), 
and spent significantly less time (p=0.024; Proportional Hazards test with risk ratios to 
accommodate covariates (JMP 14)) in the center of the apparatus with no significant impact of 
cohort (C) compared to Kcnq3+/+ (n=25) controls (2-way ANOVA followed by Šidák’s multiple 
comparisons test). D) Representative open field traces from both genotypes. E) Kcnq3R231H/+ mice 
(n=26) did not significantly differ from Kcnq3+/+ (n=25) mice in the amount of time spent in the 
open arms (p>0.05) of the EPM apparatus, or the amount of time spent in the closed arms (p>0.05). 
Additionally, there was no difference in time spent at the junction (p>0.05; 2-way ANOVA 
followed by Šidák’s multiple comparisons test) of the arms compared to Kcnq3+/+ mice (n=24). F) 
Increased freezing behavior in Kcnq3R231H/+ mice (n=26) during post-training (p<0.0001), 
contextual (0.0042), and cued fear conditioning (p=0.010), with no difference in pre-cued fear 
conditioning (p>0.05; 2-way ANOVA followed by Šidák’s multiple comparisons test) compared 
to Kcnq3+/+ mice (n=24). G) Acoustic startle response assay shows no gross deficits in audition in 
Kcnq3R231H/+ mice and no significant difference (p>0.05; 2-way ANOVA with Šidák’s multiple 
comparisons test) between both groups. H) Kcnq3R231H/+ mice (n=10) do not significantly differ 
(p>0.05) from Kcnq3+/+ (n=7) in the spontaneous alternations assay. Additionally, both groups do 
not significantly differ in movement around the apparatus (p>0.05; 2-way ANOVA followed by 
Šidák’s multiple comparisons test). In the Y-maze novel arm assay, Kcnq3R231H/+ mice (n=10) did 
not significantly differ (p>0.05; Mann-Whitney test) from Kcnq3+/+ (n=7) controls in time spent 
in the novel arm (I), and did not differ in the amount of time spent moving (J), but significantly 
differed in the amount of time spent in the center of the apparatus (p=0.008; 2-way ANOVA 
















Supplemental Fig. 4.1. R231H mutation causes SWD but does not alter 6 Hz or minimal 
electroconvulsive threshold. A) C57BL6/J Kcnq3R231H/+ (n=6) and Kcnq3R231H/R231H (n=6) mice 
show significantly more SWD (p=0.023 and p<0.0001, respectively) compared to Kcnq3+/+ (n=4) 
mice. Additionally, Kcnq3R231H/R231H mice show significantly more SWDs (p=0.0061; ordinary 
one-way ANOVA with Tukey’s multiple comparisons test) than Kcnq3R231H/+ mice. EEG 
performed on mice between PND 55 and PND 62.  B) F1 hybrid Kcnq3R231H/+ mice (PND 46) do 
not show a difference in SWD (p=0.73; Mann-Whitney test) occurrence based on the time of day. 
C) Both Kcnq3R231H/+ and Kcnq3R231H/R231H mice show significantly increased SWD events during 
night time (p=0.010 and p=0.0014 respectively; 2-way ANOVA with Šidák’s multiple 
comparisons test). ECT assessment showed no differences between the sexes from both genotypes 
in the 6Hz. D) and minimal. E) tests (p>0.05; 2-way ANOVA followed by Tukey’s multiple 






Supplemental Fig. 4.2. Differences in outcomes of adult behavioral experiments in 
Kcnq3R231H/+ mice. A) In the first cohort of mice used for the open field assessment, Kcnq3R231H/+ 
mice (n=15) showed significantly decreased (p=0.0038) ambulatory distance, no difference 
(p>0.05) in rearing or exploratory behavior, and spent significantly less time (p= 0.042) in the 
center of the apparatus compared to Kcnq3+/+ (n=15) controls (2-way ANOVA followed by 
Šidák’s multiple comparisons test). B) The second cohort of mice did not show any significant 
differences in ambulatory distance, rearing, or center time between Kcnq3R231H/+ mice (n=11) and 
Kcnq3+/+ (n=10) controls (p>0.05; 2-way ANOVA followed by Šidák’s multiple comparisons 
test). C) First cohort EPM: Kcnq3R231H/+ mice (n=15) spent significantly less time in the open arms 
(p=0.0069) of the EPM apparatus, and significantly more time in the closed arms (p=0.0023), with 
no difference in time spent at the junction (p>0.05; 2-way ANOVA followed by Šidák’s multiple 
comparisons test) of the arms compared to Kcnq3+/+ mice (n=15). D) Second cohort EPM: no 
significant differences are observed in the amout of time spent in the open arms or closed arms of 
the EPM apparatus between Kcnq3R231H/+ mice (n=11) and Kcnq3+/+ (n=10) controls (p>0.05; 2-
way ANOVA followed by Šidák’s multiple comparisons test). E) The first cohort of the fear 
conditioning assay showed increased freezing behavior in Kcnq3R231H/+ mice (n=15) during post-
training (p<0.0001), contextual (0.0008), and cued fear conditioning (p=0.023), with no difference 
in pre-cued fear conditioning (p>0.05; 2way ANOVA followed by Šidák’s multiple comparisons 
test) compared to Kcnq3+/+ mice (n=15). F) Cohort 1: initial fear conditioning assessment showed 
significant differences between Kcnq3R231H/+ (n=15) and Kcnq3+/+  (n=15) during post-training 
(p<0.0001), contextual (p=0.0008) and cued (p=0.023) fear conditioning assessments. Cohort 2: 
reassessment of Kcnq3R231H/+ (n=11) and Kcnq3+/+ (n=10) in the fear conditioning assay does not 
shows significant differences in freezing between groups (p<0.05; 2-way ANOVA with Šidák’s 

















Supplemental Fig. 4.3. R231H mutation does not cause significant motor deficits in F1 hybrid 
mice based on catwalk assay. A-J, L, M) Various software generated readouts comparing motor 
coordination of Kcnq3R231H/+ (n=10) mice to Kcnq3+/+ (n=7) mice do not show any significant 
differences between the groups (p>0.05; 2-way ANOVA followed by Šidák’s multiple 
comparisons test and Mann-Whitney tests). K) Maximum variation is the only parameter that 
shows a significant difference (p=0.025; Mann-Whitney test) between both genotypes and 
represents a maximum change in speed where a high value represents large change in speed and a 





 De novo missense gain-of-function mutations in KCNQ3, which encodes a voltage gated 
K+ channel, are associated with DEE characterized by DD, ID, ASD, speech delays, gross motor 
delays and electrical status epilepticus during sleep (ESES) on EEG (Sands et al. 2019; Nappi et 
al. 2020). Using a GOF mouse model of KCNQ3 DEE, Kcnq3R231H, we observed spike-wave 
discharges (SWD), decreased maximal seizure threshold,  a trend towards increased anxiety-like 
behaviors, and a heighted fear response in an associated learning task in heterozygous mice 
harboring the R231H mutation. Additionally, the R231H mutation did not cause severe deficits in 
pup developmental milestones, motor coordination, spatial working memory and novel memory 
based on the assays tested. Interestingly, while there were no significant differences in Kcnq3 and 
Kcnq2 RNA nor in total protein between Kcnq3R231H/+ and Kcnq3+/+ mice, Kcnq3R231H/+ mice 
showed increased Kcnq3 expression in crude membrane protein extracts. 
 The increase in Kcnq3 at neuronal membranes in Kcnq3R231H/+ mice is reminiscent of 
increases observed in KCNQ1 R231 mutants at the plasma membrane. Indeed, like Kcnq3R231H, 
human KCNQ1R231H expressed in HEK293 cells showed significantly higher membrane 
expression compared to wildtype. This increased membrane expression was shown to be a result 
of  both enhanced efficiency of membrane integration caused by the R231H mutation, and the 
ineffectiveness of wildtype R231 membrane integration (Huang et al. 2021). These results 
observed in KCNQ1 R231 mutants suggests that a similar mechanism could be at play in the 
Kcnq3R231H/+ mice. Further evaluation to identify the precise subcellular membrane localization 
(plasma membrane or ER membrane) of Kcnq3 in Kcnq3R231H/+ mice were unsuccessful and are 
the basis of future investigation. Such a study will determine if the increased expression observed 
is due solely to aggregation at the ER membrane, which could indicate impaired trafficking caused 
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by the R231H mutation, or at the plasma membrane, which would support the super-trafficking 
hypothesis of R231H posited by Huang et al.  
 Most patients with KCNQ3 GOF mutations do not show a clinical seizure phenotype, 
but do show ESES on EEG with characteristic focal and multifocal spikes, and in a minority of 
cases, show absence seizures. Similarly, Kcnq3R231H/+ mice do not show overt seizures, but do 
show a consistent, replicable spike-wave discharge phenotype. Additionally, R231H decreases the 
maximal seizure threshold in heterozygous mice, indicating an increased propensity for 
generalized tonic-clonic seizures and epileptic activity. Interestingly, Kcnq3R231H/R231H 
homozygous mice showed significantly more SWDs than Kcnq3R231H/+ mice, suggesting a dose-
dependent effect of the R231H GOF mutation. Based on this finding, it is not surprising that 
homozygous GOF mutations in KCNQ3 have not been reported in humans; they are likely 
embryonic lethal. Crude assessment of SWD events showed significant increases in SWDs at night 
in heterozygous mice from the C57BL6/J background, but not in the F1 hybrid background. This 
difference could be due to the difference in the amount of time spent recording each group and the 
age difference. For the C57BL6/J mice, recording was over a forty eight-hour period in mice 
between PND 55 and PND 62 and quantification was performed on the second day to allow 
sufficient acclimation. However, for the F1 Hybrid mice, recording was over a twenty four-hour 
period in PND 46 mice with quantification beginning after eight hours of acclimation. Regardless, 
efforts are underway to properly assess the state dependence of SWDs using EEG and 
electromyography (EMG). Performing behavioral analysis and seizure threshold testing in 
homozygous mice might show more severe impairments; however, such model would not 
accurately represent the human disease mechanism. Hence, we have focused on heterozygous mice 
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in a genetically heterogenous hybrid background for more accurate representation of the human 
condition.  
 A major caveat of the behavioral analyses was the inability to replicate previously 
identified behavioral phenotypes. Indeed, behavior is a challenging experimental readout due to 
the inter- and intra-subject variability. This variability leads to a requirement for larger sample 
sizes to discern significant differences and replication assess phenotypic robustness. The inability 
to replicate the EPM data suggests that this assay is not a viable assay with which to assess the 
effects of R231H on behavioral outcomes. In the open field apparatus, we were able to replicate 
the effect of genotype on field center time, suggesting it  may be a more robust phenotype in this 
model.  Of note was the heighted fear response observed in the Kcnq3R231H/+ mice in almost all 
portions of the fear conditioning associative learning assay. This significantly elevated freezing 
observed is likely not a depiction of enhanced learning capabilities caused by the R231H mutation. 
Rather, it may be due to increased anxiety-like behavior which was validated across multiple 
assays. Follow-up delay fear conditioning assessment in the second cohort of mice did not show 
such stark differences in freezing between wildtype and heterozygotes, however, heterozygous 
mice did show a similar trend towards increased freezing. The unremarkable results of the spatial 
and novel memory assays in Kcnq3R231H/+ mice further support the hypothesis that anxiety might 
play a likely role in the elevated freezing response observed in Kcnq3R231H/+ mice. Interestingly, 
anxiety and  specifically defensive behaviors (like freezing)  associated with anxiety have been 
shown to be mediated by the dorsal periaqueductal gray and amygdala circuit (Camplesi et al. 
2012; Fanselow 1991).  Additionally, in the contextual portion of the delay fear conditioning assay, 
Kcnq3+/+ mice showed diminished freezing beyond that expected in wildtype mice, which might 
also confound the overall data. However, this decreased contextual-freezing was not observed in 
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wildtype mice from the second fear conditioning cohort. Overall, differences in behavioral 
outcomes between both cohorts could be due to the time of year these tests were run, the difference 
in breeders, and handling variation between experimentalists. Regardless, the fear conditioning 
and the EPM assays appear to be unreliable assays with which to assess the impact of R231H on 
behavioral outcomes in this model, and thus are not robust enough to evaluate the effect of future 
therapies on curbing disease phenotypes.  
 In summary, this study serves to establish the Kcnq3R231H/+ model as a model for 
studying the behavioral, functional, and molecular pathogenicity of KCNQ3 DEE. While it may 
be impossible to replicate all observable human phenotypes caused by pathogenic mutations in 
mice, our Kcnq3R231H/+ mouse model has been successful in mimicking some key disease 
phenotypes. Furthermore, it has elucidated molecular phenotypes previously unexplored in 
KCNQ3 models of disease. Future studies will explore more directly the physiological impacts of 
R231H, the onset of seizure activity, and the state-dependence of the SWDs more accurately. In 
combination with the existing behavioral and molecular phenotypes herein, such studies will serve 
as potential readouts with which to assess future gene therapeutic interventions that aim to decrease 
the expression of the KCNQ3 GOF variant.   
 
4.4 Materials and Methods 
Study Design 
 Experiments were performed blinded to genotype when necessary, specifically for 
behavioral assays and included both sexes. The FVB 1800 KCNQ3+/+ female mice were crossed 
to C57BL6/J KCNQ3R231H/+ or KCNQ3R231H/R231H mice to generate the first filial generation (FI 
hybrid) mice which were used for SWD analysis, ECT testing, and behavior. F1 hybrid mice were 
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used to maximize fecundity and maternal care which significantly sped up the various experiments. 
Additionally, the F1 hybrid background represents a heterogenous background similar to that 
observed in the general human population enabling proper assessment of the R231H mutation in 
a more heterogeneous background. Mice from the original C57BL6/J background were used to 
assess molecular phenotypes. Molecular studies were initiated in C57BL6/J background and where 
not changed with the introduction of the F1 hybrid background given that there should be no 
significant molecular differences between them. 
Animals and genotyping 
 The C57BL6/J- KCNQ3R231H/+ mice used for this study were generated by the Columbia 
University Genetically Modified Mouse Models Shared Resource (GMMMSR) core, through 
CRISPR/Cas9 using guide sgRNA-Kcnq3-49rev: GCAGGATCTGCAGGAAGCGA. The 
C57BL6/J- KCNQ3R231H/+ mice were mated to FVB 1800 females (Jax, Bar Harbor, ME, stock 
001800). Both B6J and F1 hybrid mice were genotyped using primers (Forward: 5’- 
GCAGTTGACATCACCCTCAA- 3’ and Reverse: 5’- GGTTCTGTAGAAAGCAGGAGTG- 3’) 
meant to detect Kcnq3 and then subsequently digested for thirty minutes using the PstI restriction 
enzyme to differentiate the R231H allele from the wildtype allele based on the presence of the an 
additional PstI restriction site on the R231H allele. To identify pups for developmental behavioral 
assays, they were tattooed at PND 0 according to the AIMS pup tattoo identification system (Budd 
Lake, NJ) using Ketchum Animal Tattoo Ink (Cat# 329AA) and subsequently ear notched at PND 
10. Pups were never separated from their home cages for more than five minutes at a time. Breeders 
and weanlings had access to food and water ad libitum and were kept on a 12 h light/dark cycle 
with behavioral testing occurring during the light phase. All procedures were approved by 
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Columbia University’s Institutional Animal Care and Use Committee and were performed in 
accordance with the National Institute of Health Guide for the care and use of laboratory animals. 
Molecular assessment of Kcnq3 RNA and protein 
 Whole brains were isolated from nine KCNQ3R231H/+ and nice KCNQ3+/+ mice that were 
approximately 2-3 months old, and were split down the midline with each hemisphere going 
towards RNA isolation and protein extraction. To assess Kcnq3 and Kcnq2 RNA expression levels, 
the tissue was homogenized using a dounce homogenizer and RNA was subsequently isolated 
using TRIzol Reagent (ThermoFisher, Waltham, MA, Cat# 15596018). RNA was converted to 
cDNA using Invitrogen SuperScript III First-Strand Synthesis System (Carlsbad, CA, Cat# 
18080051). Kcnq3 expression was detected using the primers (Forward: 5’- 
CACCGTCAGAAGCACTTTGAG- 3’ and Reverse:  5’- CCTTTAGTATTGCTACCACGAGG- 
3’) and Kcnq2 expression was detected using the primers (Forward: 5’- 
AGTCCAAGAGCAGCATCGGCAA- 3’ and Reverse: 5’- CAGTGACTGTCCGCTCGTAGTA- 
3’). SYBRTM Select Master Mix (Applied Biosystems, Waltham, MA, Cat# 4472903) was used 
for qPCR which was run using Applied Biosystems-Quant Studio 5.  
 To evaluate Kcnq3 and Kcnq2 protein levels protein extracts were prepared as previously 
described from forebrain samples  (Murphy, Jensen, and Walikonis 2006). Crude membrane 
extracts were isolated via further centrifugation at 16,000 x g for fourty-five minutes at 4oC. The 
pellet was resuspended in five percent SDS RIPA buffer (Sigma-Aldrich) and the protein 
concentration was determined using the BCA assay (Thermo Fisher Scientific). A total of 50µg of 
protein per lane was separated on a 7.5- 10 % SDS-polyacrylamide gels and transferred to PVDF 
membranes before incubating in anti-KCNQ3 (1:500, synaptic systems, Cat# 368003), anti-
KCNQ2 (1:500, ThermoFisher Scientific, Cat# PA1-929), and anti-tubulin primary antibodies 
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(1:1000, Abcam, Cat# ab4047) over night. Blots were then incubated for two hours at room 
temperature with the corresponding HRP-conjugated secondary antibodies (1:500, Invitrogen). 
Signal was detected using high sensitivity chemiluminescent HRP substrate (BioRad).  
Video EEG and Electroconvulsive Seizure Threshold Testing 
 Adult mice of both sexes and genotypes between six and twelve weeks were used for EEG 
and ECT testing. To assess the presence of abnormal electroencephalographic activity, EEG 
surgery was performed as previously described (Teoh et al. 2020). Recordings were performed 
over twenty-four to forty-eight hours and were analyzed using interactive Assyst 3.1 software 
(Kaoskey, Inc.). Twenty-four hour recordings (F1 Hybrid; KCNQ3R231H/+ and KCNQ3+/+ mice of 
both sexes), were analyzed from 9pm to 3am and from 9am to 3pm. For forty-eight hour recordings 
(C57BL6/J; KCNQ3R231H/+ , KCNQ3R231H/R231H and  KCNQ3+/+), quantification began on day 2 of 
recordings from 9am-3pm and 9pm-3am. ECT testing was performed in F1 Hybrid KCNQ3R231H/+ 
and KCNQ3+/+ mice of both sexes between seven to ten weeks of age based on a previously 
established protocol in the lab with minor modification (Frankel et al. 2001). Minimal seizures 
(clonic jaw and forelimb), Maximal seizures (generalized tonic-clonic seizures, hindlimb 
extension) and 6Hz (psychomotor partial) seizures were performed.  
Developmental Milestones 
 Pup growth (weight) and ultrasonic vocalizations were assessed every other day starting at 
PND 4 through PND 10. Mice were evaluated for USVs around the same time of day during each 
test to avoid circadian-rhythm induced variability. To assess USVs, pups were gently placed in a 
small plastic container containing fresh bedding and placed in the USV chamber. USV were 
recorded for three minutes using UltraSoundGate Condenser Microphone CM 16 (Avisoft 
Bioacoustics, Berlin, Germany). The number of calls (quantitative) and the vocalization 
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characteristics (qualitative) were then assessed blind to genotype using Avisoft-SASLab pro 
bioacoustics sound analysis software.  
Adult Behavior 
 Open field, elevated plus maze, acoustic startle, fear conditioning, Y-maze and Catwalk 
assays were performed in F1 hybrid KCNQ3R231H/+ and KCNQ3+/+ mice between seven weeks and 
twelve weeks. For the open field assay, mice were placed in an acryliopen-field box (27.31cm x 
27.31 cm x 20.32 cm) and allowed to freely explore the environment for sixty minutes under light 
conditions of 10 lux. Infrared beams on the X, Y, and Z planes of the arena automatically tracked 
movement using Ethovision XT software (Noldus). Chambers were cleaned between each trial 
with 70% ethanol.  
  Elevated plus maze was performed using the system created by Med Associates Inc 
(Fairfax, VT), with light conditions set at 5 lux. The EPM apparatus consists of two open arms 
(30cm x 5cm) and two closed arms (30cm x 5 cm x 15cm) extending from a central 5cm x 5cm 
square. Mice were introduced to the center region of the EPM apparatus and allowed to freely 
explore for five minutes and photobeams embedded at the entrances registered movement. 
Chambers were cleaned between each trial with 70% ethanol.  
 Acoustic startle response was tested using the SR-Laboratory System (San Diego 
Instruments, San Diego, CA). Mice were placed in plexiglass cylinder for five minutes to acclimate 
and subsequently tested for an eight-minute period. Over the eight-minute period, mice were 
presented with thirty-six trials of pseudorandom sound burst intensities (80, 90, 100, 110, and 120 
dB) and the force with which they responded to the intensities were recorded based on their contact 
with the plexiglass cylinder. Chambers were cleaned between each trial with 70% ethanol.  
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 Fear conditioning assay, an associative learning test was performed over a three-day 
period. On the first day, mice were placed in two identical chambers that were 30cm x 24cm x 
21cm with an attached camera (Med Associates, Fairfield VT) calibrated to administer 0.5 mA 
foot shock. The chambers were scented with vanilla extract before mice were introduced. Mice 
were allowed a two-minute acclimation period before training began. During the subsequent three-
minute training, a 90dB tone (conditioned stimulus) is played for thirty seconds before the foot 
shock (unconditioned stimulus) was administered during the last two seconds. This was repeated 
five times, separated by ninety seconds interval. Freezing behavior after training was then 
quantified. On day two of training, mice were placed in the original training chambers, with the 
same olfactory cues (vanilla scent), but without foot shock and freezing behavior was assessed. 
On day three, the chamber environment and olfactory cues (lemon scent) were changed. For the 
first three minutes, there was no tone played. The CS tone was played in the subsequent three-
minute testing period and freezing behavior was once again assessed. The chambers were cleaned 
between each trial with 70% ethanol.    
 Y-maze, spontaneous alternations and novel arm both tests working and novel memory 
respectively. Both tests were performed on the Y-maze apparatus (Maze Engineer) which consists 
of three arms of equal dimensions (35 x 5cm x 10cm). During the spontaneous alternations portion 
of the test, mice were allowed to freely explore each arm for a five-minute period and their 
movement across the arms were recorded. Visitation of each arm during one movement period 
indicates a successful spontaneous alternation. Repeatedly visiting the same arm indicates a failure 
and a deficit in spatial working memory. For the Novel arm assay, mice were first trained in two 
arms with the third arm blocked off. One arm had a start sign velcroed to the wall and the second 
arm had a bus or a plane velcroed to the wall. Mice were placed in the arm with the start signal 
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and allowed to explore both arms for five minutes. They were then subsequently taken out of the 
apparatus for a ten-minute resting period. Mice were then reintroduced into the apparatus as before, 
but this time with the third arm accessible and a different image (bus or plane) velcroed to the wall. 
The propensity for the mice to spend more time in the novel arm over a five-minute period was 
then accessed via video recording (Ethovision software by Noldus).  
 Motor coordination was assessed using the Catwalk XT system (Noldus). Mice were placed 
on an illuminated walled glass walkway (130cm x 10cm) with a highspeed camera underneath the 
walkway. Reflected light illuminates the footprint when pressure is applied. Mice were placed one 
at a time on the walk way until they completed three compliant runs. Various parameter such as 
stride length, width, maximum variation, cadence, print area, speed measures were automatically 
scored by the software. Automatic scoring was then inspected, and prints that were miscalled by 
the software were manually reclassified.   
Statistics 
 Statistical analysis was done using either Prism 9 software (GraphPad, Inc).  EEG data, Y-
maze spontaneous alternation and the novel arm discrimination index were analyzed using the 
Mann Whitney test (Fig. 4.1, Fig. 4.3). ECT, protein, open field, EPM, and Y-maze data were 
analyzed using 2-way ANOVA with Sidak’s multiple comparisons test (Fig. 4.1). USV data was 
analyzed using 2-way ANOVA followed by Tukey’s multiple comparisons test (Fig. 4.2). 
Supplemental EEG (Supplementary Fig. 4.1) data were analyzed using ordinary one-way ANOVA 
followed by Tukey’s multiple comparisons test, the Mann-Whitney test, and 2-way ANOVA with 
Šidák’s multiple comparisons test. Catwalk data (Supplemental Fig. 4.2) was analyzed using 2-
way ANOVA with Šidák’s multiple comparisons test and the Mann-Whitney test. 
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Conclusions 
 Developmental and epileptic encephalopathies are devastating neurodevelopmental 
diseases often caused by de novo missense mutations. Next-generation sequencing has led to the 
identification of more than eight-five EE/DEE causing genes thus far. EEs/DEEs are rare 
genetically and phenotypically heterogenous diseases with an incidence of roughly 0.44 per 1000 
births (Symonds et al. 2019; Ware et al. 2019). In comparison, the incidence of epilepsy is 
approximately 68 per 100,000 (Fiest et al. 2017). EE/DEEs are often caused by mutations in genes 
that perform a wide variety of critical neuronal functions. Some of the most common EE/DEE 
causing mutations occur in the genes KCNQ2, SCN1A, SLC2A1, STXBP1, and CDKL5 with an 
incidence ranging from two to seven per one-hundred thousand (López-Rivera et al. 2020; 
McTague et al. 2016a; Symonds et al. 2019). In contrast, the two genes that are the focus of this 
dissertation, DNM1 and KCNQ3 are even rarer, with just thirty-four and eleven cases, respectively, 
reported to date (Choi et al. 2021; H. Li et al. 2019; Sands et al. 2019). Regardless of the low 
incidence of disease-causing mutations in these genes, viable models can be developed using 
DNM1 and KCNQ3 in order to study genetic mechanisms of DEE. Of course, the hope is that 
therapeutic treatments developed for such specific models may be applied to other DEE-causing 
genes with similar mechanisms. Modeling these diseases in rodent models enables flexibility to 
perform various manipulations that aim to provide more mechanistic insight into disease 
pathogenesis and viable treatment options.  
This dissertation was focused on modeling two DEE-causing mutations with the aim of 
identifying diseases phenotypes with which to assess future therapeutic treatments. Importantly, 
in Chapter 2, we also successfully implemented an RNAi-based gene therapy for treating DNM1 
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DEE. The success of our therapy in the Fitful model and, more generally, our efforts to characterize 
multiple mouse models of DEE could, one day, pave the way for future therapies in humans.  
 
DNM1 model of dominant negative  DEE: Conclusions and future directions 
 DNM1 is a mechanochemical brain-specific GTPase involved in fission of synaptic 
vesicles and maintenance of synaptic transmission. Mutations in DNM1 cause DEE associated 
with intractable seizures, severe to profound ID, DD, and lack of speech and ambulation.  
Studies performed over the past five years focused on further elucidating the pathogenic 
effects of DN mutations in DNM1 using a mouse model. In this work, we implemented a novel 
gene therapy approach (scAAV9-miDnm1a) to treat DEE, and we successfully remedied key 
disease phenotypes. Our work was performed in mice harboring the mouse-specific “fitful” 
mutation (Dnm1Ftfl) in the middle domain of Dnm1. Mutations in the middle and GTPase domains 
of DNM1 cause severe disease in the vast majority of cases, making our fitful mouse model an 
appropriate tool to assess disease pathogenesis and therapeutic interventions. Recently, we 
modelled the middle domain, human specific G359A variant (Dnm1G359A) in mice to further 
explore DNM1 pathogenesis, and to create a more accurate depiction of the human condition. 
Indeed, the biggest caveat of the fitful mouse model was that the fitful mutation was uniquely 
linked to Dnm1a, one of two middle domain isoforms of Dnm1. Additionally, severe disease that 
phenocopied the human condition was only observed in homozygous mice, with heterozygotes 
showing adult-onset spontaneous seizures. In contrast, the human condition is a heterozygous 
condition that affects both isoforms of DNM1 (DNM1A and DNM1B). It is likely that the earlier 
expression onset of DNM1B contributes to the early onset seizures observed in patients, whereas, 
fitful mice do not begin to show overt phenotypes until the second week of life. In fact, global 
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expression of G359A, the human variant, in mice led to significantly reduced birth weight 
observed at PND 1 and overall growth deficits. Mice expressing G359A also showed earlier 
lethality onset compared to fitful mice.  
 The homozygous Dnm1Ftfl mutation causes one hundred percent lethality before PND 25; 
however, the heterozygous Dnm1G359A, does not show the same lethality. Global conditional 
expression of G359A (Sox2Cre) in all cells, specifically all neuronal cells, only caused lethality in 
approximately forty-eight percent of mice by PND 40. Expecting a more severe survival outcome, 
especially given that these mice showed significant growth deficits, and suspecting an inefficient 
recombination of the G359A construct in Sox2cre: Dnm1G359A/+ mice, we utilized the Nestin Cre 
recombinase driver. Nestin is an intermediate filament expressed in neural progenitor cells of the 
developing CNS (Hendrickson et al. 2011). While this experiment is still in progress, preliminary 
data already acquired suggests that conditional expression of G359A using Nestin-Cre causes 
growth deficits, but has had no effect on survival within the first four weeks of life. This is not 
surprising given that the Nestin-Cre mice used for this experiment had previously been shown to 
be inefficient at driving recombination of neural progenitor cells in early embryonic development 
(Liang, Hippenmeyer, and Ghashghaei 2012). Thus, there is the possibility that the decreased 
severity in this model is due to decreased overall expression of G359A in neurons during the earlier 
developmental stages. To make matters more interesting, expression of G359A in inhibitory 
neurons alone, using Gad2Cre recombinase, led to early onset observable seizures, growth deficits 
and a hundred percent lethality by PND 21. This difference in severity between pan-neuronal 
expression and inhibitory neuron expression may be due to network level interactions of both 
neuronal populations. The pan-neuronal expression of G359A decreases the overall firing of both 
excitatory and inhibitory neurons, potentially decreasing runaway excitation. However, expression 
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of G359A in inhibitory neurons alone, decreases the firing rate of inhibitory neurons, which are 
then unable to properly inhibit unaffected excitatory neurons. This dynamic potentially leads to 
more runaway excitation, and might explain the lethal seizures observed in the Gad2Cre: 
Dnm1G359A/+ model. The phenotypic heterogeneity observed, specifically in the Sox2Cre: 
Dnm1G359A/+  mice may be a more accurate depiction of the human condition. Indeed, there are at 
least three patients with DNM1 mutations in the GTPase and middle domains that either didn’t 
show a seizure phenotype, or are seizure free (H. Li et al. 2019). Of note is the recent identification 
of a patient (age 4 years) with a GTPase domain mutation who is seizure-free without the use of 
antiepileptic drugs, ambulates independently and can speak in two-word phrases (Choi et al. 2021). 
This case presents the possibility that there may be more phenotypic heterogeneity in DNM1 
GTPase and middle domain mutations, and that not all patients will present with intractable 
seizures, severe to profound developmental delays, and lack of speech and ambulation. With more 
access to next generation sequencing, we may begin to identify milder cases, broadening the 
clinical spectrum of DNM1 DEE. 
  Initially, the Dnm1a isoform specific miRNA (miDnm1a) used for the fitful gene therapy 
was slated to be tested in the G359A model. However, preliminary early onset lethality of globally 
expressed (Sox2Cre) G359A, precluded this. Instead, we opted for the presumed “less” severe 
inhibitory neuron specific model (Gad2Cre).  Suffice it to say, the therapy was unsuccessful at 
curbing lethal seizures and growth deficits due to the presence of G359A on the Dnm1b isoform 
as well. The reason behind the difference in severity between global expression and inhibitory 
neuron specific expression may lie in the brain circuitry and the important role inhibitory neurons 
play in maintaining neuronal balance. Specifically, mutations in DNM1 or an absence of DNM1 in 
inhibitory neurons lead to more severe  phenotypes compared to excitatory neurons (Ferguson et 
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al. 2007; S. K. Asinof et al. 2015). Indeed, as previously seen in the fitful model, excitatory neuron 
specific expression of G359A did not lead to seizure associated lethality, but led to growth deficits, 
hyperactivity, postural abnormalities and repetitive behavior (S. K. Asinof et al. 2015). 
Additionally, asymmetric expression of G359A in inhibitory neurons alone possibly lead to more 
uncontrollable excitation than seen in mice globally expressing G359A. Hence, we see a clear 
seizure phenotype starting around PND 11 in mice expression G359A in inhibitory neurons but 
not those expressing G359A globally, or in excitatory neurons.   
 In this dissertation, we have further investigated the pathogenicity of DNM1 dominant 
negative DEE using two mouse models. However, there are more areas that need to be explored. 
Mice expressing G359A globally (Sox2Cre) do not show an overt seizure phenotype; even those 
surviving past PND 40 do not show handling or spontaneous seizures. Further assessing these mice 
physiologically will elucidate the presence of seizure activity. In fact, some mouse models of DEE 
do not show spontaneous seizures, but are typically reported to have a spike-wave discharge 
phenotype, or seizure susceptibility (Wang and Frankel 2021). Performing EEG in older mice 
would help ascertain the presence of seizure activity. There are already ongoing efforts to 
determine if G359A expression in excitatory neurons causes seizure activity through video 
electroencephalographic recordings. Supplementing the EEG study with more adult behavioral 
assessment could provide more insight into the contributions of neuronal subpopulations on 
disease phenotypes, as was previously done in the fitful model.    
 The Dnm1G359A mouse model, based on our knowledge, is the first mouse model of a human 
variant of DNM1 DEE. Thus, it serves as a powerful tool with which to further investigate the 
concept of a critical window as it pertains to future therapeutic prospects for patients currently 
suffering from DNM1 DEE. The critical window is a time period during development when 
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treatment interventions have the potential to be the most efficacious. Past the critical window, 
neuronal damages caused by pathogenic variants may become difficult to reverse, although 
treatment may still prevent further damage. While mice and human development vary, these 
models can nevertheless be informative in shaping our understanding of complex phenomena such 
as the critical window. Using a tamoxifen inducible system, or an AAV-Cre construct, expression 
of G359A can be “turned on” in neurons of mice at different developmental ages, and even into 
adulthood. This sort of experiment will not only inform on the critical window, it will also enable 
the understanding of how resistant the brain is post development to pathogenic mutations.  
 Additionally, this model also provides a means to explore more targeted therapeutic 
treatment for the first human DNM1 variant modelled in mice. Based on the failure of miDnm1a 
treatment to improve outcomes in mice expressing G359A in inhibitory neurons, it is unlikely that 
isoform specific therapy will be efficacious at addressing disease phenotypes in the G359A mouse 
model. Unlike fitful, which is isoform specific (Dnm1a), G359A, and indeed all human variants, 
are present in both isoforms. Both isoforms of DNM1 have important semi-redundant and 
compensatory functions (Boumil et al. 2010). Dnm1b is needed early in development and Dnm1a 
is the predominant isoform postnatally (Boumil et al. 2010). The expression of G359A in Dnm1b 
may account for the decreased weight observed in mice globally expressing G359A at PND 1. 
Thus, the best approach would be to create allele specific miRNA constructs to specifically target 
the mutated variant on both isoforms, however, this approach is costly.  Alternatively, one could 
use a knockdown and replace approach, where endogenous Dnm1 is knocked down, and vector 
delivered Dnm1 is reintroduced.  
 Overall, the Dnm1G359A mouse presents an opportunity to better understand the human 
condition, and to execute a gene therapy approach whose success brings the field closer to a more 
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effective treatment for patients with dominant negative or gain-of-function DEEs. The recent 
approval of various RNAi-based therapies for other rare genetic diseases further bolsters 
confidence that this group of therapies would make substantial differences in the lives of patients.  
 
KCNQ3 model for GOF DEE: Conclusions and future directions  
 Mutations in the voltage-gated potassium channel KCNQ3 cause electrical status 
epilepticus during sleep (ESES), lack of speech, and developmental delays. The KCNQ3R231H 
mouse model of KCNQ3 DEE showed significant seizure activity and susceptibility as well as 
behavioral and molecular abnormalities. Like most mouse models, these mice do not perfectly 
model all aspects of the human condition; however, we have been able to gain insight into the 
pathogenesis of gain-of-function mutations in KCNQ3 and have identified viable phenotypes with 
which to assess future therapeutic interventions. Over the last year, strong replicable phenotypes 
have been identified and initial therapeutic assessment is already underway. Because the R231H 
mutation is a gain-of-function mutation, a viable gene therapeutic treatment involves a knockdown 
strategy to eliminate the toxic variant. In the case of R231H, the initial strategy is to knockdown 
all KCNQ3 transcripts using a RNAi approach. Mouse studies showed that knockdown of KCNQ3 
was well tolerated. Additionally, in a similar approach, knockdown of  SCN8A in the SCN8A 
mouse model of DEE previously discussed, was shown to be beneficial in improving key disease 
phenotypes (Lenk et al. 2020; Nappi et al. 2020). Together, these studies further provide 
enthusiasm for the potential efficacy of this approach. However, it is important to keep in mind 
that KCNQ3 is needed for M-channel (a channel that plays an important role in regulating neuronal 
excitability) localization to the axon initial segment (AIS; the site of action potential initiation) 
which enables the M-channel to properly regulate neuronal excitability (Rasmussen et al. 2007).  
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Thus, knockdown needs to be properly regulated to ensure the availability of KCNQ3 for AIS 
localization.   
 Recently, the R231C variant of KCNQ3 DEE was acquired from a collaborator. Ongoing 
preliminary behavioral and electroencephalographic data suggests phenotypes similar to those 
observed in the R231H model. Future directions will further explore electrophysiological, 
electroencephalographic, molecular and behavioral phenotypes present in both models. Both of 
these models provide avenues through which to further model human DEE variants with the aim 
of identifying phenotypic readouts to assess the efficacy of gene therapies, a much-needed 
alternative treatment approach for patients suffering from severe DEEs.  
 
Final thoughts  
 There are various limitations in utilizing mouse models to study human diseases, 
specifically DEEs.  The major limitation is that these models do not fully recapitulate all human 
clinical phenotypes. Indeed, a simple explanation lies in the fact that mouse development is 
considerably quicker than human development. This difference in developmental speed between 
the species leads to a decrease in the amount of absolute time mice are exposed to the pathogenic 
variant, potentially decreasing the impact of the pathogenic variants in mice, compared to humans.  
An approach to address this and maximize impact of the pathogenic variant, may be to characterize 
such mouse models at an older age. Indeed, a recent study of the Cdkl5 haploinsufficiency model 
of DEE (previously discussed), reported the observation of spontaneous seizures in Cdkl5 mouse 
models for the first time. Importantly, these spontaneous seizures have only been observed in aged 
mice (Mulcahey et al. 2020). Although there is a desire to characterize mouse models of human 
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neurodevelopmental diseases during the corresponding mouse developmental period, for some 
models, this may not be the optimal time period.  
 Besides the inherent limitations of mouse models of DEEs, there are also limitations to 
gene therapies, and specifically to viral gene therapies. A big challenge when implementing viral 
therapies is the size of the construct. AAVs, the vectors most in use for CNS disorders, are quite 
small, precluding gene replacements of large genes for mutations that cause LOF effects (Steven 
J. Gray et al. 2011; Tornabene et al. 2019). To overcome this limitation, dual or triple AAV vectors 
can now be used, each containing a portion of the coding sequencing from the protein of interest 
and the genetic element inteins. Inteins enable trans-splicing and reconstitution of the gene product 
in vivo without leaving amino acid modification in the final gene product (Tornabene et al. 2019). 
Additionally, AAVs can be immunogenic, making initial treatment in a patient that has previously 
been exposed to wild-type AAV, or administering a booster treatment difficult (Naso et al. 2017; 
Verdera, Kuranda, and Mingozzi 2020). Fortunately, recent work has shown that Mycoplasma 
protein M, derived from bacteria, can effectively inactivate immunoglobulins interaction with viral 
antigens prior to viral administration (Herzog and Biswas 2020). Regardless of these  limitations, 
AAVs are the most effective vectors for gene therapies, they are long lasting (can last seven to ten 
years in humans), and recent technological advances allow more control over dosage, expression 
and tissue specificity through the use of various promoters, enhancers and viral pseudotypes 
(Steven J. Gray et al. 2011; Domenger and Grimm 2019). 
 In conclusion, although mouse models currently used to study DEE have apparent 
limitations, they have nonetheless provided valuable insight into the pathophysiological 
mechanisms of DEE-causing pathogenic variants. They also provide a preclinical model with 
which to assess the efficacy of targeted therapies. The success of the Dnm1Ftfl RNAi-based gene 
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therapy, and others like it in mouse models, are a testament to the potential of these models in 
pushing the boundaries and identifying viable treatment options that would immensely improve 
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